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The pituitary is a small gland that lies within the sella turcica, a recess in the 
sphenoid bone. Despite its small size, the pituitary gland is an important regulator 
of  hormone homeostasis. Under the control of  hypothalamic peptides, the anterior 
lobe, or adenohypophysis, synthesizes and secretes growth hormone (GH), prolactin, 
adreno-corticotroph hormone (ACTH), thyroid stimulating hormone (TSH), and the 
gonadotrophs LH and FSH. These hormones, in turn, stimulate their target glands, 
such as the adrenal cortex, thyroid, and ovaries/testicles to produce their respective 
end hormones: cortisol, thyroid hormone, estradiol/progesterone (in females) and 
testosterone (in males), respectively. The posterior lobe consists of  axons of  hypothalamic 
nerves expressing vasopressin and oxytocin. Vasopressin (also named anti-diuretic 
hormone ADH) is released in response to an increase in plasma osmolality resulting 
in increased renal water reabsorption. Oxytocin is released in large amounts during 
labour and causes contraction of  the smooth muscle cells of  the uterus. Furthermore 
it is responsible for the milk ejection reflex during lactation by contracting the smooth 
muscle cells of  the mammary glands to release the milk into the duct system. 
Disturbances in the secretion of  pituitary hormones rapidly affect the levels of  the 
hormones produced by their target glands. An increase in pituitary hormones leads to 
characteristic symptoms signs and phenotype, such as the Cushing phenotype in case 
of  ACTH-induced cortisol excess or acromegaly in case of  GH excess. Impairment in 
pituitary function is accompanied by non-specific complaints, such as tiredness, lack 
of  concentration, and decreased physical tolerance and amenorrhoea. Furthermore, 
impaired bone mass will develop with a consequent increased fracture risk. (1) 
Disturbances in pituitary function have been shown to decrease overall survival, to 
cause metabolic dysregulation, as well as impaired quality of  life. (2-4)
HYPOPITUITARISM
Hypopituitarism is the term used to describe insufficiency of  pituitary hormone secretion 
and may affect anterior- or posterior pituitary function, or both. The reported incidence 
of  hypopituitarism is around 12–42 new cases per million per year. The prevalence of  
hypopituitarism is 300–455 per million but this might be an underestimation as the 
disease is likely to be underreported since the clinical manifestations depend on the 
extent of  hormone deficiency and are largely non specific, with complaints like fatigue, 
general unwell-being and cold intolerance. (5) The diagnosis of  hypopituitarism relies on 
the measurement of  basal and stimulated pituitary- and end-organ hormone secretion, 
and is more complicated than establishing the diagnosis of  end organ deficiency.  






INSUFFICIENCY OF THE GH-IGF-1 AXIS: GROWTH HORMONE DEFICIENCY 
Growth Hormone (GH) plays an essential role in growth and maturation. Growth 
hormone is secreted in large amounts during childhood; and thereafter GH levels 
decline during aging. 
In adults, Growth Hormone Deficiency (GHD) has been associated with 
hypercholesterolaemia and hypertriglyceridaemia.(6) GHD is also associated with low 
muscle mass, a decrease in bone mass and diminished quality of  life (QoL). (1,7,8) It 
is generally accepted that 24-hour GH secretion poorly reflects GH status in adults. 
A number of  tests evaluating GH secretory reserve may be used to diagnose GH 
deficiency (GHD). (9) Figure 1
The standard for diagnosing GHD is the Insulin Tolerance Test, or alternatively when 
contra-indicated a Growth Hormone Releasing Hormone/Arginine-test (GHRH/Arg) 
(with BMI-adjusted GH cut-offs). (10) IGF-1 levels are not reliable to assess the GH/
IGF-1 axis because normal levels do not exclude severe GHD. However, when IGF-1 
levels are below -2 SD in the presence of  2 or more insufficient pituitary axes, severe 
GHD is present in almost all cases. (10)
Adult Growth Hormone Deficiency will be more extensively discussed in Section II. 
FIGURE 1. 
GH/IGF-1 secretion secretion
GH; Growth Hormone, GHRH: Growth Hormone Releasing Hormone, IGF-1: Insulin-like Growth Factor 1, GHRP: 
Growth Hormone Releasing hexaPeptide
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INSUFFICIENCY OF THE HYPOTHALAMUS-PITUITARY-ADRENAL AXIS (HPA-
AXIS): SECONDARY ADRENAL INSUFFICIENCY.
The HPA-axis controls together with the sympathetic nervous system the stress 
response, and therefore, is of  paramount importance for survival. Disruption or 
insufficient secretion of  CRH and/or ACTH impairs adrenal glucocorticoid synthesis 
and secretion, a condition that is potentially lethal. In general, symptoms of  secondary 
adrenal insufficiency are non-specific, but most patients with secondary adrenal 
insufficiency report fatigue and malaise (weight loss) characterized by abdominal 
discomfort and nausea. Blood pressure is usually normal or slightly decreased and 
since mineralocorticoid synthesis remains unaffected orthostatic hypotension will not 
occur until the maximal activation of  the renin-angiotensin-aldosterone system (RAAS) 
cannot further compensate for electrolyte and fluid loss. In that case, an Addisonian 
crisis may develop. 
The diagnosis of  secondary adrenal insufficiency involves the evaluation of  both basal 
(non-stimulated) cortisol concentrations as well as dynamic testing. Various dynamic 
tests have been developed to test the secretory capacity of  the pituitary gland and are 
currently used in daily clinical practice. A single morning cortisol measurement after 
an overnight fast will already provide some information. In case of  a fasting cortisol 
concentration > 500 -550 nmol/l, in the absence of  concurrent corticosteroid use 
or estrogen use, the chance of   HPA-axis insufficiency is considered very low. Also, 
when cortisol concentrations are  <80 nmol/l, the diagnosis of  AI is very likely  and 
dynamic testing is generally considered  not necessary. (11) However, since basal cortisol 
concentrations are in the range between 80-500  in most cases, additional dynamic testing 
is crucial for the evaluation of  corticotrope function. In the last decades several tests 
have been used to diagnose secondary hypocortisolism. To date, the insulin tolerance 
test (ITT) remains the golden standard for the evaluation of  the HPA-axis. (11,12) 
In case of  contraindications for the ITT, such as epilepsy or coronary artery disease, 
alternative dynamic tests such as the corticotrophin releasing hormone (CRH) test, the 
metyrapone test, or the ACTH stimulation test can be used to assess adrenal function. 
(13-15) The choice of  test is made by the treating physician based on the patient’s clinical 
condition and one’s centers experience. Once diagnosed, hypocortisolism is treated 
with hydrocortisone replacement. Hydrocortisone therapy for hypopituitarism was 
associated with supraphysiological cortisol levels in the past, leading to adverse effects 
such as increased glucose intolerance, decline in bone mass and increased cardiovascular 
risk factors, such as hypertension and increased abdominal fat distribution. Decreasing 
the glucocorticoid dose from 20-30mg/day to 15mg/day was associated with beneficial 
effects in terms of  body composition, lipid profile, and QoL. (16) Current replacement 
doses are 20 mg divided in three doses. Unfortunately, to date there are no adequate 
methods to monitor over-replacement of  hydrocortisone in routine clinical practice.






INSUFFICIENCY OF THE HYPOTHALAMUS-PITUITARY-GONADAL AXIS: 
SECONDARY- OR HYPOGONADOTROPIC HYPOGONADISM. 
Hypogonadotropic hypogonadism is defined as the presence of  low or normal 
gonadotropin levels, (luteinizing hormone (LH) and follicle stimulating hormone (FSH)) 
in the presence of  low testosterone in males or estrogen levels/cyclic disturbances 
in pre-menopausal women. In pre-menopausal women, secondary hypogonadism 
manifests with (oligo-) amenorrhea, decreased libido as well as fertility and 
psychological disturbances. In post-menopausal women, hypogonadism might often be 
a-symptomatic and the absence of  high serum LH/FSH values confirms the diagnosis. 
In males, hypogonadism presents with decreased libido, potency and fertility, and with 
increased prevalence of  depressive like symptoms and other mood disturbances and 
osteoporosis. In males, testosterone replacement therapy is administered in the form of  
transdermal testosterone preparations allowing stable physiological serum testosterone 
levels whereas in pre-menopausal women, replacement therapy with oral estrogens 
alone or in combination with progestagens is administered. 
INSUFFICIENCY OF THE HYPOTHALAMUS-PITUITARY-THYROID AXIS: 
SECONDARY HYPOTHYROIDISM
Symptoms of  hypothyroidism are associated with complaints of  tiredness, edema 
(especially periorbital), constipation, weight gain and depression. The symptomatology 
of  secondary hypothyroidism does not differ from primary hypothyroidism, but may 
be masked by other concomitant pituitary insufficiencies. A diagnosis of  secondary 
hypothyroidism is confirmed by the presence of  a low serum FT4 levels and 
inappropriately normal or low TSH levels. TSH levels are non-diagnostic in secondary 
hypothyroidism.  In case of  multiple pituitary hormone deficiencies, secondary 
hypothyroidism should also be suspected when FT4 levels are within the lower tertile 
of  the reference ranges. L-thyroxine is the treatment of  choice but under-replacement 
is often the case resulting in a negative cardiovascular profile, although the awareness 
for the risks of  chronic under-replacement is rising. (17)
Concomitant corticotropin deficiency should be excluded in order to avoid acute adrenal 
insufficiency before starting replacement therapy and retesting of  the HPA-axis should 
be considered after re-institution of  normal thyroid hormone values. 
With the exception of  congenital forms hypopituitarism is largely caused by pituitary 
tumours, or by the consequent treatment of  those tumours with surgery or radiotherapy. 
Hypopituitarism may also arise after traumatic brain injury or vascular insult and after 
radiotherapy for non-pituitary tumours. In the course of  treatment in various tumours 
like for instance nasopharyngeal carcinoma (NPC) the pituitary is within the radiation 
field of  the primary tumour resulting in a high dose to the pituitary and the risk of  
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hypopituitarism. The aim of  this thesis was, first of  all, to critically evaluate the available 
literature on the long-term consequences of  cranial irradiation, and subsequently to 
evaluate the prevalence of  pituitary insufficiency in our tertiary referral center using 
state of  the art endocrine evaluation (Section I). In addition, we aimed to investigate 
the metabolic phenotype of  the adult GHD patient in more detail after long-term rGH 
replacement given the unknown contribution of  growth hormone replacement therapy.
Section I: Radiation Induced Hypopituitarism
Irradiation of  the hypothalamic-pituitary region is thought to result in a characteristic 
pattern of  decline of  pituitary function, explained by the cell content in the pituitary with 
growth hormone (GH) secretion declining first, followed by ACTH, gonadotrophins 
and TSH. (18) 
Radiation-induced pituitary insufficiency is a dose-dependent late sequel of  radiotherapy 
for pituitary tumours with prevalence rates for one or more pituitary insufficiencies of  
around 50% after 5 years, arising up to 75 % after 10 years, following a total dose of  
40-45Gy Figure 2. (19-21) The prevalence of  insufficiencies is correlated with the total 
radiation dose to the hypothalamic/pituitary region.
FIGURE 2.
Probability of  normal pituitary function after irradiation for pituitary tumours with 40 Gy adapted from Littley et all.18 






Data from historical cohorts indicate that a total dose of  7- 24 Gy delivered to the 
pituitary/hypothalamus may cause growth hormone deficiency only whereas dosages 
as high as 50-60 Gy will most certainly cause multiple pituitary hormone deficiencies. 
(22) The incidence of  multiple pituitary deficiencies thus increases both in time and 
with higher doses. (18, 23) The hypothalamic region is suggested to be more radiation 
sensitive causing elevated prolactin levels after irradiation in the presence of  still 
intact pituitary function. This is indicative of  a decreased dopaminergic inhibition by 
the hypothalamus and thus prolactin release, however hypothalamic dysfunction is 
difficult to observe since its hormones (GnRH, TRH, CRH, GHRH) are difficult to 
measure.  The pathophysiological basis of  the effect of  irradiation is DNA damage, 
strand breaks, both in healthy- as well as in tumour tissue. This damage is generated by 
direct 3-dimensional dysfunctional changes in DNA as well as by the indirect negative 
effect of  production of  free radicals from water molecules in the cell. (24) These strand 
breaks   may have direct lethal effects or will have accumulating sub-lethal effects that 
eventually will restrict potential cell replication. After radiation cell death occurs in the 
mitotic phase of  the cell cycle (late G2-earleS phase) providing a partial explanation for 
the delayed onset of  hormonal failure in slowly replicating tissue, such as that of  the 
neuroendocrine tissue of  the hypothalamus and pituitary. (25) Figure 3
  


























Ionising irradiation also induces degenerative changes in surrounding glia cells, causing 
decreased trophic support and demyelinisation resulting in chronic neuronal damage. 
The vascular system is also compromised by the release of  pro-inflammatory cytokines 
such as Necrosis Factor-kappa beta (NF-κB). Due to radiation induced oxidative stress 
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NF-κB causes endothelial proliferation by promoting the release of  anti-inflammatory 
cytokines and adhesion molecules. Inflammatory cells are subsequently recruited, 
promoting foam cell formation which results in increased collagen synthesis, and 
thus of  atherosclerosis. (26) Clinical studies performed in patients previously treated 
for e.g. lymphoma, breast cancer or head and neck cancer have demonstrated an 
increase in cardiovascular risk, also after adjustment for classic cardiovascular risk 
factors. Depending on the study, the relative risk of  a clinical cardiovascular event (i.e., 
myocardial infarction, stroke) to be related to irradiation ranged from 1.5- to 4.0-fold, 
and this risk was even higher in the presence of  traditional cardiovascular risk factors. 
(27,28)
Other reported late effects of  cranial radiotherapy include a decline in neurocognitive 
function resulting in a decreased quality of  life (29-31). In larger studies however the 
contributory role of  cranial radiotherapy to the risk of  cerebrovascular incidents was 
not higher than that of  surgical trauma or glucocorticoid over-replacement or of  
undiagnosed hypopituitarism. (32)
Pituitary insufficiency is a well known late onset complication of  cranial irradiation in 
children treated for cerebral tumours or after total body radiotherapy.(33-41) In the 
Childhood Cancer Survivor Study (CCSS) 43% of  children treated for cerebral tumours 
had one or more endocrinopathies. Consequently, virtually all follow-up protocols 
for childhood cancer survivors include endocrine assessments as the development of  
hypopituitarism can still occur years after the initial treatment, especially in the doses < 
45 Gy.  Over the past decades, survival rates of  patients treated with cranial radiotherapy 
for malignant or benign tumours have substantially improved by the introduction of  
new surgical, radiotherapy, and chemotherapy options. In contrast to the long-term 
survivors of  cranial radiotherapy in childhood, endocrine surveillance programs 
have not been routinely incorporated in adults treated with cranial radiotherapy. The 
prevalence of  hypopituitarism after cranial radiotherapy is influenced by a number of  
factors. First, the time interval between radiotherapy and the assessment of  pituitary 
function is important, since the development of  pituitary failure is likely to increase in 
time after radiotherapy. (42-44) Second, hypothalamic and pituitary insufficiencies are 
more likely to develop with increasing radiation exposure. 
Furthermore, studies in survivors of  childhood acute lymphoblastic leukaemia as 
well as in childhood brain cancer demonstrated an increased risk of  metabolic and 
cardiovascular late effects after cranial irradiation, including effects on body composition, 
insulin resistance and hyperleptinaemia. Patients treated with radiotherapy for pituitary 
tumours had higher visceral to subcutaneous fat ratios when compared with controls 
who did not receive radiotherapy.(47) Further studies are needed to determine the clinical 
significance of  these findings and, where clinically relevant, whether cardiovascular 
outcomes may be modulated by additional therapy. 






A number of  non-pituitary tumours, such as nasopharyngeal carcinomas, meningiomas 
or primary cerebral tumours are treated with high dose radiotherapy. Most often 
treatment schedules comprise multiple fractions of  2Gy, with a boost sometimes 
additionally delivered to the primary tumour. Depending on the tumour localisation, the 
pituitary/hypothalamic region will receive some dose despite improved radiotherapeutic 
techniques. Figure 4. In nasopharyngeal carcinoma, the total dose on the primary tumour 
area will be at least 6-70 Gy in fractions of  2 Gy. Depending on the location of  the 
primary tumour this might result in an estimated dose of   > 40 Gy to the pituitary 
gland, predicting a very high probability of  pituitary insufficiency, as depicted in Figure 
2.  Structured follow up for pituitary function is not routinely incorporated in the long 
term monitoring of  these patients. Since the overall survival of  stage I and II NPC 
patients has improved throughout the years to a total of   > 80% 5 year survival rate, 
structured monitoring of  pituitary function is advisable. (48,49)
FIGURE 4.
Figure 4A and 4B show the position of  the primary tumour (yellow line), the radiation field (red line) and the pituitary 
region (green line). Figure 4C shows the isodose lines of  66.5 Gy (purple), 57.75 Gy (Cyan) and 30 Gy (blue) in the same 
patient, notice the position of  the pituitary region (green) within the radiation field.  
  
                                 
  
Figure  4.	  
Figure	  4A	  and	  4B	  show	  the	  position	  of	  the	  primary	  tumour	  (yellow	  line),	  the	  radiation	  field	  (red	  line)	  
and	  the	  pituitary	  region	  (green	  line).	  Figure	  4C	  shows	  the	  isodose	  lines	  of	  66.5	  Gy	  (purple),	  57.75	  Gy	  
(Cyan)	  and	  30	  Gy	  (blue)	  in	  the	  same	  patient,	  notice	  the	  position	  of	  the	  pituitary	  region	  (green)	  within	  






When hypopituitarism develops in the course of  treatment for an underlying disease, such 
as nasopharyngeal carcinoma, the symptoms of  hypopituitarism may mimic those of  
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residual symptoms after chemotherapy, surgery or cranial irradiation and may therefore 
be easily overlooked. Cranial radiotherapy may also induce cognitive impairments, 
which may mask symptoms of  hypopituitarism. Diagnosing hypopituitarism can be very 
difficult especially for physicians not familiar with endocrine pathology such as radiation 
oncologists and Ear-Nose-and Throat specialists. Even a trained endocrinologist 
cannot diagnose pituitary failure only on the basis of  clinical signs and symptoms. 
Since hypopituitarism will develop several years after radiotherapy most patients will 
not consult an internist, and therefore the diagnosis may be easily overlooked.  Despite 
the fact that there are many ways to screen for pituitary dysfunction, the evaluation of  
the effects of  radiotherapy on pituitary or hypothalamic function in adult patients who 
were treated with cranial irradiation for different causes has not been incorporated 
into standard patient care. In addition, there are no protocols for standardizing the 
endocrinological evaluation or follow up for these patients.  
In Chapter 2 and appendix 1 of  this thesis a review and meta-analysis of  the published 
English literature is presented, whereas Chapter 3 and the appendix 1 address the 
prevalence and time frame of  onset of  pituitary insufficiency after irradiation for head 
and nasopharyngeal tumours, including a proposed algorithm for standardized follow 
up. 
Section II: Growth hormone secretion and growth hormone deficiency
The regulation of  GH secretion is controlled by the net balance between stimulatory 
hypothalamic peptides such as GHRH and GHrelin, and on the other hand the 
inhibitory tone of  somatostatin. The net result is a pulsatile secretion of  GH, which is 
important because most of  the secretion occurs in bursts. The magnitude of  GH bursts 
correlates with somatic growth and with the hepatic actions of  GH. Activation of  the 
GH-receptor in the liver induces key intracellular signaling pathways such as PI3Kinase, 
MAP Kinase, and STAT5b, the latter resulting in the transcriptional activation of  the 
IGF-1 gene. Together with IGF-1, GH exerts its anabolic effects on target tissues. (52) 
GH, as well as sex hormones, are thus extremely important for skeletal growth and 
maturation throughout puberty.  
The largest amount of  growth hormone is secreted during adolescence; with a further 
progressive decline in GH secretion throughout life. 
Growth Hormone Deficiency (GHD) has been associated with an adverse metabolic 
profile and with an increased cardiovascular mortality due to abdominal obesity, 
hypercholesterolaemia and hypertriglyceridaemia in adults. (1-3) Untreated GHD is 
also characterized by a decrease in muscle bone mass, decreased bone turnover and 
increased fracture risk. (7,8) GHD is also associated with an overall decrease in quality 
of  life. (51-53) 






In 1990, Rosen et al reported increased mortality in patients with hypopituitarism, 
due to cardiovascular disease (CVD), particularly cerebrovascular disease, which was 
attributed, at least in part, to GHD. (2,54) Over the following decades a number of  
studies from 4 different cohorts compounding approximately 2000 patients with 
hypopituitarism, have reported increased mortality in these patients treated historically 
with conventional hormone replacement therapy,none of  these patients were treated 
with recombinant GH (rGH) replacement. These studies only included patients with 
surgically resected non-secreting pituitary adenomas and craniopharyngiomas and 
excluded patients with Acromegaly and Cushing’s disease, since it was assumed already 
that these specific diseases would increase mortality risk, as demonstrated by Dekkers 
et al in 2006 and 2008. (3,55-58) A significant number of  these patients also received 
additional cranial irradiation, and the majority of  pre-menopausal women were not 
treated for gonadotropin deficiency.
The classical clinical features of  the adult patient with GHD is that of  a patient 
suffering from overweight, with predominantly abdominal obesity, decreased muscle 
strength, reduced exercise intolerance and depressed mood. Additional investigations 
would reveal elevated serum lipids, particularly LDL cholesterol, reduced lean body/
increased fat mass and reduced bone mineral density.  In the mid 1990’s, human 
recombinant growth hormone (rGH) became available for the treatment of  adults with 
severe GHD. Since then, consistent beneficial effects of  replacement therapy with rGH 
have been reported on body composition and lipid profile, resulting in reduction of  fat 
mass combined with an increase in lean body mass, and a reduction in total cholesterol 
(TC) levels, as meta-analysed and summarized by Maison et al. (6) Favourable effects 
were also reported on bone turnover, bone mineral density (BMD), muscle strength, 
cognitive function and QoL.(6, 59, 60) 
In cross-sectional studies, beneficial effects of  rGH replacement have been reported 
to sustain for at least 5 years of  treatment; data with a longer follow-up duration are 
scarce. With respect to cardiovascular risk profile, a direct improvement of  several 
cardiovascular risk factors was noted within the first year of  treatment, which persisted 
during long-term rGH treatment. (61,62) A sustained improvement of  lipid spectrum 
and diastolic blood pressure (DBP) was reported in a small study over 7 and 10 years of  
treatment, suggesting on-going beneficial effects of  rGH even beyond 5 years. However 
whether rGH replacement has favourable effects on the incidence of  cardiovascular 
events, including cardiovascular death is yet to be established.
GROWTH HORMONE AND THE SKELETON
The skeleton consists of  cortical bone and trabecular (cancellous) bone. Cortical bone, 
which comprises 80% of  the skeleton, is designed to provide rigidly and strength and 
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is predominantly found in the long bones, e.g. at the femur. Cancellous bone has a 
more flexible design with interconnecting trabecles, and is metabolically more active 
then cortical bone. There are three types of  bone cells: osteoclasts, responsible for 
bone resorption, osteoblasts, responsible for bone formation and osteocytes that are 
the mechano-sensors of  the skeleton. The three types of  bone cells form the main 
components of  the so-called basic multicellular unit (BMU).  In a healthy adult there 
are more then 1 million BMU’s, which are mostly active in cancellous bone. In a BMU 
bone resorption takes 3 weeks to be completed whereas bone formation may last up to 
9 months. The balance between formation and resorption is essential for maintaining 
a normal bone mass and skeletal integrity. Disruptions in the ratio of  bone formation 
and resorption in favour of  resorption will ultimately lead to progressive bone loss and 
increased bone fragility. 
GH and IGF-1 play an important role in bone growth and metabolism throughout the life 
span of  an individual.(63) IGF-1 mediates skeletal growth by promoting endochondrial 
ossification in cartilage and by enhancing osteoblast formation and differentiation of  
both osteoblasts as osteoclasts, GH also exerts direct effects on bone.(64, 65)  Both 
GH and IGF-1 act as anabolic hormones on bone by stimulating proliferation, and to 
some extent, differentiation of  osteoblasts.  IGF-1 promotes osteoblast differentiation 
through the mTOR pathway. This has been demonstrated in an IGF-1 knock-out mouse 
model in which decreased bone formation and subsequent decreased bone mass has 
been observed. (66)  Up-regulation of  IGF-1 mediated pathways in osteoblasts results 
in widening of  the cortex and in an increase in the length of  the long bones, whereas 
trabecular bone is hardly affected by these pathways. In osteocytes, knocking out IGF-
1 results in a decrease in calvarial bone growth rate. (67) IGF-1 is also a co-regulator 
in osteoclast differentiation by induction of  Receptor Activator of  Nuclear factor kB 
Ligand (RANK-L) expression. RANK-L is a stimulator of  osteoclast differentiation, 
proliferation and activation and thus prolongs the lifespan of  the osteoclast resulting in 
an overall increase in bone remodelling. (68) Figure 5
In contrast GH promotes the production of  osteoprotegerin (OPG) which binds to 
RANK-L and inhibits osteoclast formation and differentiation. (69) The ratio between 
RANK-L and OPG is critical for optimal balance between bone formation and 
resorption. After the menopause for example, OPG levels drop tremendously due to 
estrogen deficiency, the most important stimulator of  OPG formation, leading to a 
marked increase in bone loss particularly within the first year after the menopause. 
IGF-1 knockout models have also shown that IGF-1 is required for adequate function 
of  parathyroid hormone (PTH). In the absence of  IGF-1, PTH does not longer have 
a stimulating effect on bone formation rates. IGF-1/GH plays a key role in bone cell 
growth and differentiation.  






In humans with growth hormone insensitivity due to inactivating mutations in the gene 
encoding the GH receptor (Laron syndrome) GH levels are very high and IGF-1 levels 
are reduced by more than 80%. These individuals are extremely short of  stature due to 
short long-bones. In patients with Laron syndrome the cortex is of  normal thickness and 
there is no increased incidence of  osteoporosis or fractures. (70) In contrast, untreated 
GHD is characterized by low bone turnover, decreased bone mineral density (BMD) 
and increased fracture risk (1,7). Recombinant human GH (rGH) replacement therapy 
has been shown to increase bone turnover as reflected by an increase in bone formation 
and bone resorption markers, resulting in an initial decline in (or unchanged) BMD, 
followed by a small increase of  about 1-2% in the first 2 years of  rGH replacement due 
to a positive balance in favor of  bone formation. (71,72) 
Data on the effects of  long-term rGH replacement on BMD are, however, scarce. 
Previous studies reported that rGH replacement induces a progressive increase in BMD 
and BMC up to 5-7 years of  treatment, followed thereafter by a maintenance of  BMD 
up to 7 years of  treatment.(72-74) Götherström et al. found an increase in total body 
and lumbar spine BMD and BMC up to 10 years of  rGH replacement, whereas femoral 
neck BMD and BMC reached a peak value after 5-7 years. Only one study has reported 
the effects of  15 years of  rGH supplementation. This study reported a sustained 
increase in total body and lumbar BMD and BMC over 15 years, whereas femoral neck 
BMD and BMC returned towards baseline values after 7 years. (59)
FIGURE 5. 
Growth Hormone/IGF-1 and bone metabolism
GH: Growth Hormone, PTH: Parathyroid Hormone, FGF: Fibroblast Growth Factor, PDGF: Platelet Derived Growth 
Factor, E2: Estrogen, T3:thyroid hormone, IGFBP2-5: Insulin Growth Factor-like Binding Peptide 2-5, RANKL: 
Receptor activator of  nuclear factor kappa-B ligand, OPG: Osteoprotegerin
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Another important issue regarding long-term rGH replacement therapy in adults is 
the potential association between growth hormone/IGF-1 and cancer risk, which is 
an on going topic of  debate. A number of  animal studies as well as epidemiological 
studies in humans examined the relationship between low IGF-1 as well as reduced 
cancer risk and cardiovascular risk. The activity of  the GH/IGF-1 axis decreases with 
ageing, yet smaller individuals within a species usually live longer (including ponies and 
small dogs). (75) Life span is also longer in mice lacking GHR, resulting in low IGF-1 
levels. Although some of  these mutant mice were also deficient in other hormones, 
such as TSH, their longevity is thought to be primarily due to their Growth Hormone 
Deficiency (GHD), since restoration of  GH levels reverted their longevity to match 
that of  non-mutants.(76,77)
Reduced IGF-1 levels as well as reduced IGF-1 signalling has been associated with 
reduced cancer risk in humans. For instance, cancer was virtually absent in a Ecuadorian 
cohort of  patients with severe GHD due to GHR gene mutations). (78) Another cohort 
of  patients with Laron syndrome showed a general identical clinical picture. (79) To 
date, only one case of  (non-lethal) cancer has been reported in both Laron cohorts. 
Whether IGF-1 per se alters longevity in humans remains questionable. Among others, 
the Leiden Longevity study showed that the relation between longevity and IGF-1 may 
be through insulin sensitivity. Rozing et al. showed a lower prevalence of  diabetes, and 
non-fasted serum glucose levels in the offspring of  familial nonagenarians compared to 
their partners although IGF-1 and IGFBP3 did not differ between both groups (80). It 
was already shown in the 90’s that sporadic long-lived centenarians were very sensitive 
to insulin compared to young adults and that insulin sensitivity decreases with age. 
(81) A recent meta-analyses of  IGF-1 in the general population showed an increase in 
mortality in both high as well as in the population with low IGF-1 levels, hazard ratio 
(HR) 1.18, (95%CI 1.04-1.34). (82) This U-shape relationship was present for both 
cancer and cardiovascular mortality. In addition, several other epidemiological reports 
showed an association of  both low and high IGF-1 levels with DM2, sarcopenia, 
osteoporosis and cardiovascular disease. (75,83) However, this by no means proves that 
low and high IGF-1 levels are related to increased specific morbidity or mortality. 
Taken together, these data do suggest that optimizing the activity of  the GH/IGF-1 
axis to promote healthy aging in humans is more complex than originally appreciated, 
and requires a greater understanding of  its array of  interactions and tissue specificity. 
Chapter 4 describes the results of  an extended literature search on long-term growth 
hormone replacement in adults beyond 5 years of  treatment. In Chapter 5 the changes 
in metabolic profile after initiation of  growth hormone replacement within a group of  
long-term recombinant GH therapy users are presented and discussed. In Chapter 6, 
the difference in metabolic profile of  GHD patients on stable, defined as > 5 years, 
rGH replacement therapy to the metabolic profile of  the general population will be 






addressed. Chapter 7 discusses whether long-term rGH replacement has any beneficial 
effect on bone metabolism. Finally, in Chapter 8, a systematic literature search and 
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Pituitary Dysfunction in Adult Patients after Cranial 




Cranial radiotherapy is an important cause of  hypopituitarism. The prevalence of  
hypopituitarism varies considerably between studies. We conducted a systematic review 
and meta-analysis of  reported prevalences of  hypopituitarism in adults radiated for 
nonpituitary tumours.
We searched PubMed, EMBASE,Webof  Science, and the Cochrane Library to identify
potentially relevant studies. Studies were eligible for inclusion with the following 
criteria: 1) cranial radiotherapy for nonpituitary tumours and/or total body irradiation 
for hematological malignancies; 2) adult population (>18 yr old); and 3) report on 
endocrine evaluation.
Data review was done by two independent reviewers. Besides extraction of  baseline 
andtreatment characteristics, also endocrine tests, definitions,andcutoff  values used to 
define pituitary insufficiency were extracted.
Eighteen studies with a total of  813 patients were included. These included 608 patients
treated for nasopharyngeal cancer (75%)and 205 for intracerebral tumours.The 
total radiation dose ranged from 14 to 83 and 40 to 97 Gy for nasopharyngeal and 
intracerebral tumours, respectively.
The point prevalence of  any degree of  hypopituitarism was 0.66 [95% confidence interval 
(CI),0.55–0.76]. The prevalence of  GH deficiency was 0.45 (95% CI, 0.33–0.57); of  LH 
and FSH, 0.3 (95%CI, 0.23–0.37); of  TSH, 0.25 (95% CI, 0.16–0.37); and of  ACTH, 
0.22 (95% CI, 0.15–0.3), respectively. The prevalence of  hyperprolactinemia was 0.34 
(95% CI, 0.15–0.6). There were no differences between the effects of  radiotherapy for 
nasopharyngeal vs. for intracerebral tumours.
Hypopituitarism is prevalent in adult patients after cranial radiotherapy for nonpituitary
tumours. Therefore, all patients treated by cranial radiotherapy should have structured 
periodical assessment of  pituitary functions. 







Pituitary insufficiency is a late onset sequel of  cranial irradiation for intracerebral and 
nasopharyngeal tumours or total body radiotherapy for haematological malignancies in 
children (1-9). In the Childhood Cancer Survivor Study (CCSS) 43% of  children treated 
for cerebral tumours had one or more endocrinopathies (10). Consequently, structured 
follow-up programs for childhood cancer survivors include endocrine assessments. 
In the last decades, survival rates of  patients treated with cranial radiotherapy for 
various malignancies as well as for benign tumours have improved substantially by 
introduction of  new surgical, radiotherapeutical, and chemotherapeutical options. In 
contrast to the long-term survivors of  cranial radiotherapy in childhood, endocrine 
surveillance programs have not been routinely incorporated in adults treated with cranial 
radiotherapy. The prevalence of  hypopituitarism after cranial radiotherapy is affected 
by several factors. First, the time interval between radiotherapy and the assessment 
of  pituitary function is important, since the development of  pituitary failure is likely 
to increase in time after radiotherapy (11-13). Second, hypothalamic and pituitary 
insufficiencies are more likely to develop with increasing radiation exposure (10;14). 
Finally, methodological differences between the studies with respect to endocrine 
evaluation, like the use of  different endocrine tests with different criteria for pituitary 
insufficiency, will also affect the prevalence of  hypopituitarism. 
The aim of  this study was to systematically assess the reported prevalence of  pituitary 
insufficiency after cranial or total body radiotherapy for intracerebral tumours, 
nasopharyngeal tumours or haematological malignancies at the adult age. 
DESIGN
Search strategy and eligibility criteria
We searched the following databases for studies on cranial radiotherapy and pituitary 
failure: PubMed, Cochrane Library, Web of  Science, EMBASE, CINAHL database, 
Academic Search Premier, and Science Direct. The search was performed on August 
14th, 2010.
In collaboration with a trained clinical librarian, we composed a search strategy for 
the above mentioned databases, focussing on radiotherapy, pituitary function, cerebral 
tumours and nasopharyngeal tumours.  We used all relevant keyword variations, including 
free text words. The complete strategy is provided in appendix 1 (see supplemental data). 
Furthermore, the references of  relevant articles were checked for additional articles. 
Only original articles in English were included. Studies were eligible for inclusion in this 
review if  they fulfilled the following criteria: 1) cranial radiotherapy for non-pituitary 
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tumours and/or total body irradiation for haematological malignancies 2) > 18 years at 
the time of  radiotherapy 3) report on endocrine evaluation. 
In case of  mixed cohorts (i.e. including both paediatric and adult patients), patients 
<18 years were filtered from the results. In case of  duplication of  reports involving the 
same patient cohort the results on the different axes were combined in the analyses and 
tables, and only the paper with the longest duration of  follow-up was included. 
Data review and analysis
Initial selection of  studies by title and abstract was performed by two reviewers (N.A 
en N.K.). These studies were retrieved for full assessment. All studies were evaluated 
by the two reviewers independently. Disagreements were resolved by consensus. Data 
extraction was based on data from each study provided at the population level. The 
definition of  hypopituitarism had to be stated in the paper, including the endocrine 
tests used for the evaluation, definitions and cut-off  values used to define pituitary 
insufficiency for each axis, hormone assays and reference values provided by the authors.
Statistical analysis
The main outcome of  the present meta-analysis was the pooled proportion of  patients 
with pituitary insufficiency after cranial radiotherapy. For all studies, the proportion 
of  patients with hypopituitarism was calculated as the number of  patients with the 
pituitary insufficiency divided by the total number of  tested patients. 
Meta-analysis was performed using an exact likelihood approach. The method used was 
a logistic regression with a random effect at the study level (15). Given the expected 
clinical heterogeneity a random effects model was performed by default and no fixed 
effects analyses were performed. For meta-analysis of  proportions the exact likelihood 
approach based on a binomial distribution has advantages compared to a standard 
(DerSimonian and Laird) random effects model that is based on a normal distribution. 
Firstly, estimates from a binomial model are less biased than estimates from models 
based on a normal approximation (15;16). This is especially the case for proportions that 
are close to 0 or 1. Secondly, no assumptions are needed for the exact approximation 
when dealing with zero-cells, whereas the standard approach needs to add an arbitrary 
value (often 0.5) when dealing with zero-cells. Adding values to zero-cells is known to 
contribute to the biased estimate of  the model (17;18). 
Meta-regression analyses were also performed with an exact likelihood approach. A 
random effects meta-regression was performed to address the question whether the 
tumor site (nasopharyngeal vs intracerebral) influences the prevalence of  pituitary 
insufficiency. All analyses were performed with STATA 10.0 (Stata Corp, Texas, USA).






Risk of Bias assessment
An additional evaluation of  the risk of  bias was performed in order to identify 
components that could potentially bias an association between cranial radiotherapy 
and hypopituitarism. The following study characteristics were evaluated: 1) adequacy 
of  exposure determination, 2) adequacy of  inclusion and follow-up, and 3) adequacy of  
outcome determination. For exposure determination 1 point was given if   it was stated 
clearly that the pituitary was involved in the radiation field and 1 point if  the estimated 
dose at the pituitary was reported. For the evaluation of  inclusion of  patients, 1 point 
was given for each study that included (consecutive) non-selected patients. For outcome 
determination, 1 point was given when the hormonal evaluation also included dynamic 
tests and 1 point if  all patients in the study were tested. Consequently, each study could 
attain a maximum score of  5 points. Studies that scored 0-2 points were considered to 
have a high risk of  bias, studies with 2-3 points as intermediate risk, and studies with 
4-5 points as studies with a low risk of  bias. 
RESULTS
Systematic literature search (Figure 1)
The initial search resulted in a total of  849 articles (301 in PubMed, 4 in Cochrane 
Library, 131 in Web of  Science, 353 in EMBASE, 16 in CINAHL database, 27 in 
Academic Search Premier, and 17 in Science Direct). Of  these articles, 616 were unique 
without duplications. We excluded 378 papers based on title and abstract or language, 
157 studies which evaluated patients aged <16 years and 7 papers which were not 
available for evaluation. Consequently, a total of  74 potentially relevant papers were 
retrieved for full assessment. Of  these 74 publications, 51 papers were excluded from 
further analysis because the studies did not fulfil one or more of  the eligibility criteria.
Therefore, ultimately, our search strategy resulted in 23 manuscripts meeting the 
inclusion criteria. However, some reports described data from the same patient cohort 
(19-26).In these cases the results were combined as one study in the analysis or the 
study with the longest follow-up was included. Consequently, a total of  18 studies 
were included in the present review, comprising 813 patients. The number of  included 
patients per study ranged from only 6 (27) to 312 (20). Five studies included patients 
< 18 yrs (26-30). However, in only three of  these five studies (27;28;30) it was possible 
to obtain the numbers of  patients treated after the age of  18 yrs. The remaining two 
were included because of  the low number of  patients<18 years or sub-analysis on the 




616 potentially relevant papers 
identified and screened 
 
 
  378 excluded based on title and abstract                                        
157 excluded because of pediatric literature 
7 papers not possible to obtain 
 
74 potentially relevant papers 
retrieved for more detailed 
assessment 
  
25 papers included in the study 
  
49 papers did not meet inclusion criteria 
1 paper excluded due to overlap in patientgroups 
24 papers included for analyses 
  
Study characteristics (Table 1&2)
Details of  the 18 included studies are summarized in Table 1 and 2. The studies were 
published between 1975 and 2009. Seventy-five percent of  the patients (608/813) 
were treated for nasopharyngeal cancer (Table 1). The remaining 25% were treated for 
intra-cerebral tumours (table 2). The majority of  studies were cross-sectional studies 
with time after irradiation ranging from 4 months to 30 years. However the time after 
radiation varied considerable between individuals, even within one single study. Two 
studies did not report the time interval between irradiation and endocrine evaluation 
(28;31). None of  the included papers evaluated patients treated with prophylactic body 
irradiation in the course of  stem cell transplantation for haematological malignancies.
In three reports patient selection criteria were not stated (20;28;31) whereas four studies 
selected symptomatic patients by recruiting from a radiotherapy complication outpatient 
clinic or by inclusion of   only patients suspected for any degree of  hypopituitarism 
(21;30;32;33). For example, two studies used questionnaires on fatigue or diminished 
libido in combination with basal hormone samples to select patients for further 
endocrinological evaluation (22;28).
FIGURE 1.
Flowchart of  study assessment and exclusion stages.
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Risk of bias assessment
One study was classified as high risk (received 1 point) (28), eight studies as intermediate 
risk (20;22;29-31;33-35), and 9 studies as low risk for selection bias (21;23;26;27;32;36-
39).
Radiotherapy
The radiation dose was reported in all, but one, study (31), and ranged from 14-83 Gy, and 
40-97 Gy in patients treated for nasopharyngeal carcinomas and intra-cerebral tumours, 
respectively. A total of  nine studies (6 involving patients treated for nasopharyngeal 
tumours and 3 for intracerebral tumours) also calculated the estimated dose delivered 
to the pituitary, ranging from 46-83 Gy (in patients treated for nasopharyngeal tumours) 
and 25-97 Gy (in patients with intra-cerebral tumours) (21;23;26;29;30;36-39). 
Endocrine assessment (Table 1 &2)
The overall prevalence of  any degree of  hypopituitarism differed considerably between 
the studies, ranging from 25% (22) to 100% (21;37) in studies involving patients treated 
for nasopharyngeal tumours, and from 37% (31) to 77% (39) in patients treated for 
intra-cerebral tumours.
Growth hormone (GH)-IGF-I axis (n=724):  
Fourteen studies evaluated the GH-IGF-I axis. However, in only 61% (440/724) of  the 
patients the axis was evaluated using either basal serum IGF-I and/or GH levels and/
or a stimulation test (glucagon stimulation test, insulin tolerance test (ITT), arginine test, 
and combined growth hormone releasing hormone plus arginine test) (20-23;26;27;30-
32;35-40). The prevalence of  GH deficiency (GHD) varied between 24-100%. The 
prevalence of  100% was assessed in one study of  6 patients that evaluated only 2 
patients using ITT (35). 
Hypothalamic-pituitary-adrenal (HPA)-axis (n=751): 
The HPA-axis was evaluated in 14 studies. In only 61% (460/751) of  the patients the axis 
was tested by either basal serum cortisol levels and/or a stimulation test (corticotropin 
releasing hormone test, ITT, Glucagon- or ACTH-test). Adrenal insufficiency was 
diagnosed in 0-50% of  patients with nasopharyngeal tumours and in 3-62% of  the 
patients with intra-cerebral tumours.
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Hypothalamic-pituitary-thyroidal-axis (n=488):  
Sixteen studies evaluated thyroid function using either basal serum hormone levels or 
a TRH-stimulation test. Thyrotropin deficiency was diagnosed in 26% of  the patients 
(126/488). The prevalence rates ranged between 0-67% and 13-25% in patients with 
nasopharyngeal cancers and intracerebral tumours, respectively.
Hypothalamic-pituitary-gonadal axis (n=469)
The pituitary-gonadal axis was assessed in 14 studies. Hypogonadotropic hypogonadism 
was present in 30% (143/469): in 30-82% of  cases treated for nasopharyngeal cancer 
and in 38-61% of  cases treated for intracerebral tumours. 
Hyperprolactenemia (n=515): 
Prolactin levels were measured in 15 studies, documenting hyperprolactinemia in 147 of  
515 patients (29%, 2-100% in patients treated for nasopharyngeal cancers, and 7-100% 
in patients treated for intra-cerebral tumours).
Meta-analysis
The pooled prevalence of  any degree of  hypopituitarism was 0.66 (95% CI 0.55-
0.76). Growth hormone deficiency was the most prevalent pituitary deficiency, with a 
prevalence of  0.45 (95% CI 0.33-0.57), followed by LH/FSH deficiency 0.3 (95% CI 
0.23-0.37) and TSH deficiency 0.25 (95% CI 0.16-0.37), respectively. The prevalence of  
hyperprolactinemia was 0.33 (95% CI 0.16-0.56) and ACTH deficiency had the lowest 
prevalence 0.22 (95% CI 0.15-0.3). 
In a random effects meta-regression, the effect of  tumor localization (nasopharyngeal 
vs cerebral) on the prevalence of  deficiencies was assessed. No statistically significant 
association between the probability of  any pituitary deficiency (p=0.14), GH deficiency 
(p=0.36), ACTH deficiency (p=0.75), TSH deficiency (p=0.11) LH/FSH deficiency 
(p=0.21) as well as hyperprolactenemia (p=0.44) and the indication for radiotherapy 
(nasopharyngeal cancer vs. intra-cerebral tumours).
A sensitivity analysis with four studies explicitly mentioning the inclusion of  consecutive 
unselected patients was performed (23;29;36). The pooled prevalence of  any pituitary 
deficiency was 0.62 (95% CI 0.45, 0.77), which is similar to the pooled prevalence of  




Random effects meta-analysis of  prevalence of  pituitary insufficiency after cranial radiotherapy.
FIGURE 3.
Random effects meta-analysis of  prevalence of  pituitary insufficiency according to tumor site.






Pituitary insufficiency related to duration of follow-up after radiotherapy
Two studies reported on the occurrence in time of  hypopituitarism (23;26).The 
prevalence of  pituitary failure in patients treated for nasopharyngeal tumours was 6% 
after 1 year, 35% after 2 years, 56% after 3 years and 62% after 4 and 5 years (23). 
Samaan, and colleagues (26), reported on the classical sequential order of  failure of  
individual pituitary functions in time. GH deficiency occurred after a mean of  2.6 
years, followed by failure of  the pituitary-gonadal axis and hyperprolactinemia after 
approximately 3.8 years, ACTH insufficiency after 6 years, and finally TSH insufficiency 
after a mean of  11 years. 
DISCUSSION
This systematic review and meta-analysis demonstrated that pituitary insufficiency is a 
highly prevalent condition in adult patients after cranial radiotherapy for nasopharyngeal 
and intra-cerebral tumours. The prevalence of  any form of  hypopituitarism was 
0.66(CI 0.55-0.76). There were considerable variations in the reported prevalence 
rates of  hypopituitarism after cranial radiotherapy, ranging from hardly any effect on 
pituitary function to almost 100% of  the patients being affected. These variations were 
associated with differences in the number of  patients included in the study and manner 
of  endocrine evaluation. 
The risk of  development of  hypopituitarism after cranial radiotherapy is a well recognized 
phenomenon in children. The likelihood to develop hypothalamic-pituitary insufficiency 
increases with increasing radiation exposure and with prolonged duration of  follow-up 
up after radiotherapy (11;12). In the Childhood Cancer Survivor study (CCSS) 43% 
of  paediatric patients treated for cerebral tumours had one or more endocrinopathies 
(10). Our meta-analysis showed that hypopituitarism is present in approximately two 
third of  all adult patients previously treated with cranial irradiation. The prevalence 
of  hypopituitarism after cranial radiotherapy is affected by several factors including 
radiation dose and techniques. Furthermore, the time interval between radiotherapy and 
the assessment of  pituitary functions is important, since the development of  pituitary 
failure is likely to increase during prolongation of  follow-up after radiotherapy (11;12). 
A random effects meta-regression revealed no significant different effects of  underlying 
disease on pituitary function between the two groups of  adult patients reported in 
literature: those treated for nasopharyngeal cancer vs intra-cerebral tumours. In addition, 
the overall difference in radiation dosage did not differ between groups: 40-83 Gy for 
the patients treated for nasopharyngeal carcinoma and 40-97 Gy for the patients with 
cerebral tumours. The use of  different radiotherapeutical techniques however will 
most likely affect the rate of  subsequent hypopituitarism, because higher cumulative 
radiation doses are associated with increasing incidence rates of  pituitary failure (11;12). 
Chapter 2
42
Patients treated for nasopharyngeal tumours are usually treated with a higher average 
dosage and additive high dose single tumour boost. Therefore, a separate analysis of  the 
studies concerning nasopharyngeal tumours vs. the other studies was performed (Fig. 
3). However, there were no significant differences in the prevalence of  any pituitary 
insufficiency between both groups. There are various possible explanations for this 
lack of  significant differences between the two patient groups despite differences 
in irradiation dose. In nine studies from which the estimated doses delivered to the 
pituitary could be extracted (six involving patients treated for nasopharyngeal tumours 
and three for intracerebral tumours), the dose ranges were wide in both patient groups 
and showed a considerable overlap. In patients treated for nasopharyngeal tumours, 
the dose ranged from 46–83 Gy, and in patients with intracerebral tumours the dose 
ranged from 25–97 Gy. Duration of  follow-up since radiotherapy varied from 11–253 
months in the patient group treated for nasopharyngeal tumours and from 12–156 
months in the group treated for intracerebral tumours. Finally, the overall prevalence of  
pituitary insufficiency is already high in both groups, with 0.54 (95% CI, 0.42– 0.66) for 
intracerebral tumours vs. 0.74 (95% CI, 0.57– 0.86) for nasopharyngeal tumours. This 
0.2 difference in prevalence, however, did not result in significant differences between 
groups (P = 0.14). According to our risk of  bias stratification, nine studies were 
considered as being at low risk of  bias. The majority of  studies used cross-sectional 
study designs with large differences in the time of  evaluation in relation to previous 
radiotherapy. The selection of  patient groups differed largely between the studies. 
Patient selection criteria were not stated in some of  the reports (19, 27, 30), whereas 
the description of  the selection procedures in other studies suggests preselection of  
patients, like recruitment from a radiotherapy complication outpatient clinic or by 
including only symptomatic patients suspected for any degree of  hypopituitarism (20, 
29, 31, 32). Two studies (n=186) used a prospective design; the reasons for loss to 
follow-up were not mentioned in any of  the studies, precluding definite answers after 5 
years of  follow-up (22, 25). We additionally performed a sensitivity analysis of  studies 
that qualified as a potential low–intermediate risk of  bias (22, 28, 35, 37). This analysis 
revealed a pooled proportion of  any pituitary deficiency of  0.62 (95% CI, 0.45–0.77), 
which is remarkably close to the overall found prevalence of  0.66 (95% CI, 0.55–
0.76) calculated for all studies. This outcome illustrates that signs and symptoms of  
hypopituitarism after cranial irradiation apparently are not predictive of  hypopituitarism 
in individual patients with their condition. Differences in endocrine evaluation may 
also affect the reported prevalence. The majority of  patients were not evaluated by 
proper stimulation tests. Therefore, it is likely that the estimates of  hypopituitarism after 
cranial radiotherapy represent a rather conservative estimation of  the true prevalence 
of  hypopituitarism. In addition, studies that did perform stimulation tests used different 
tests and cut-off  values, and only 10 of  18 studies assessed all pituitary axes (but even 
then, not all patients were tested for each axis). Moreover, the hypothalamic-pituitary-






thyroidal axis and the hypothalamic-pituitary-gonadal axis can also be influenced by the 
use of  alkylating chemotherapeutics and exposure of  the thyroid gland and gonads to 
irradiation (18, 39–42). Primary hypothyroidism in patients treated for nasopharyngeal 
carcinoma occurs up to 20–30% within the first year after treatment (42). In the random 
effects regression model, the prevalence of  TSH deficiency was 0.33 (95% CI, 0.19–0.5) 
and 0.16 (95% CI, 0.08–0.32) for the patients treated for intracerebral tumours. These 
differences were not significant, with p= 0.11. Hypogonadism after cranial radiotherapy 
was difficult to quantify because some studies reported testosterone or estrogen levels, 
whereas others used delayed or insufficient LH/FSH responses to GnRH as a criterion 
for hypogonadism. In addition, primary gonadal failure is highly prevalent in patients 
treated with chemotherapy, especially when treated with alkylating agents that could 
overestimate the results (39). Patients treated for nasopharyngeal tumours were more 
likely to receive chemotherapy, but again, no significant differences between groups 
were found. Prolactin might be another possible tool to estimate the likelihood of  
radiation-induced damage of  the hypothalamic area. Because hyperprolactinemia might 
be a consequence of  decreased hypothalamic dopamine secretion, hyperprolactinemia is 
variable in severity and often subclinical; it diminishes and might even normalize in time 
due to slowly evolving radiation-induced damage of  lactotrophs. If  hyperprolactinemia 
is to be considered as an indicator of  disturbed hypothalamic dopamine secretion, one 
could expect the prolactin level to be high in the first years after radiation and normal 
after several years when lactrotroph function has declined. Unfortunately, none of  the 
studies provided information on prolactin levels in relation to the time interval since 
radiotherapy. Considering the high prevalence of  hypopituitarism found, 0.66 (95% CI, 
0.55–0.76), and that there was no significant difference between groups, assessment 
of  pituitary function should be included in the long-term follow-up of  all cranially 
irradiated patients. Current literature does not provide a timeline or a sequence of  axis 
failure. Hypopituitarism can occur as soon as the first year after treatment, but it can 
also occur 11 years after treatment (22, 25). Taking into consideration the improved 
survival of  patients, duration of  follow-up for at least 15 years should be advisable. 
This follow-up period should include a basal morning hormone sample and dynamic 
testing of  the HPA axis in every patient not on corticosteroids. Dynamic testing of  
the somatotrope axis should be defined per patient because GH failure will not have 
therapeutical consequences, although it might be an indicator for radiation induced 
pituitary damage. This systematic review underscores the need for structured periodical 
endocrine assessments of  all patients who survive after cranial radiotherapy for all kinds 
of  diagnoses. Therefore, an increasing number of  patients will require a structured, 
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Chapter 3
Pituitary dysfunction in adult patients after cranial 




Background: Pituitary insufficiency after radiotherapy in the hypothalamic pituitary region 
is a well-known complication. However, endocrine assessments are not incorporated in 
the follow-up after cranial irradiation for head and neck tumours.
Aim of  the study: to evaluate pituitary function in patients cranially irradiated for non-
pituitary tumours.
Patients and Methods: Evaluation of  pituitary function in all available patients treated at 
our center with cranial radiotherapy for head and neck tumours.
Results: We included 80 patients. Forty patients were treated for cerebral tumours, 15 
for nasopharyngeal tumours, and 25 for different tumours like meningioma or cerebral 
metastasis. Mean age was 47.5 (18.6-89.7) years. Mean radiation dose delivered at the 
pituitary region was 56.27 Gy (40.0-70.0). Pituitary insufficiency was present in 16 
patients within 2 years after irradiation within 2 years after irradiation. 23/49 patients 
(47%) after 5 years and 27/45 (60%) after 10 years and 31/35 patients (89%) after 15 
years, respectively.
Conclusion: Pituitary insufficiency is highly prevalent in adult patients treated with 
cranial radiotherapy for head and nasopharyngeal tumours. These prevalence rates 
are comparable to those observed after radiotherapy for pituitary tumours. Because 
hormone replacement of  endocrine deficits improves quality of  life and prevents 
potential severe complications, such as Addisonian crises, periodical evaluation of  
pituitary function is advocated. 







Radiation-induced pituitary insufficiency is a well-known dose-dependent late sequel 
of  pituitary irradiation for pituitary tumours with prevalence rates of  any pituitary 
insufficiency of  approximately 50% after 5 years, and up to 75 % after 10 years following 
a total dose of  40-45Gy (1-3). In accordance, when the hypothalamic-pituitary region is 
within the radiation field, cranial irradiation for non-pituitary tumours may also induce 
pituitary insufficiency (4). In children, the high incidence of  pituitary insufficiency 
after cranial irradiation for cerebral or nasopharyngeal tumours, including total 
body irradiation (TBI) for hematological malignancies, is well established (5-9). The 
Childhood Cancer Survivor Study (CCSS) reported one or more endocrinopathies to be 
present in 43% of  children treated for cerebral tumours. Consequently, these children 
are subjected to structural endocrine surveillance also when reaching adulthood (10).  
Currently, guidelines on endocrine surveillance in adult patients are not available. 
Survival rates for e.g. cerebral and nasopharyngeal tumours have improved substantially 
by new treatment modalities (11,12). Therefore, it is likely that an increasing number 
of  adult patients will also be affected by endocrine complications of  cranial irradiation. 
Since complaints of  hypopituitarism are generally non-specific, endocrine tests are 
required for an accurate diagnose of  pituitary failure. Endocrine function tests are 
necessary for diagnosing hypocortisolism or growth hormone deficiency. Growth 
hormone deficiency however might not be clinically relevant for a patient treated for 
a malignant tumour since cancer patients generally will not be substituted with growth 
hormone, although in childhood cancer survivors no there was no statistically significant 
increased overall risk of  the occurrence of  neoplasms associated with rh-GH exposure 
(13). But diagnosing growth hormone deficiency will still be useful since it may serve 
as an indicator of  radiation induced hypothalamic/pituitary damage. In a recent meta-
analysis, we have concluded that the low number of  adult patient cohorts followed 
after cranial radiotherapy for non-pituitary tumours with sufficient long-term data and 
proper dynamic endocrine evaluation precludes strong conclusions on the incidence 
and prevalence rates of  pituitary insufficiency. However, the meta-analysis suggested 
a high prevalence of  any form of  pituitary insufficiency, like in children, of  0.66 (95% 
CI, 0.55–0.76) after cranial radiotherapy for both nasopharyngeal and cerebral tumours 
(14). In addition, the time of  onset of  pituitary failure was documented in only 3 studies 
(15-17). The aim of  this cohort study was to evaluate the prevalence, and the time 
of  onset, of  pituitary insufficiency in adult patients after cranial irradiation for non-




The patient registry of  the department of  Radiotherapy was checked for patients who 
underwent cranial radiotherapy for non-pituitary tumours from 1990-2010 with the 
hypothalamus and/or the pituitary within the radiation field and whom received >20Gy 
to the hypothalamus-pituitary region (n=1504). We selected a threshold of  20 Gy based 
on data from historical cohorts indicating that a total dose of  7-24 Gy delivered to the 
pituitary/hypothalamus region, may cause growth hormone deficiency only, whereas 
dosages as high as 50-60 Gy will most certainly cause multiple pituitary hormone 
deficiencies (18). When alive and not already known to the outpatient clinic of  the 
department of  Endocrinology, patients were invited for endocrine testing. Patients were 
excluded if: 1) radiotherapy was given for pituitary or parasellar tumours 2) radiotherapy 
was applied as TBI, 3) pituitary insufficiency was already present before radiotherapy 4) 
was a life expectancy of  less then 12 months at time of  screening. Pituitary functions 
were checked at first outpatient clinic visit with basal hormone samples and endocrine 
function tests, afterwards patients were monitored by a standardized protocol (vide 
infra). In addition we used clinical and amnestic information on their condition prior to 
radiation.  In case of  pituitary insufficiency medication was started at the discretion of  
the treating physician. This study represents a combined analysis of  the patients already 
known at the department of  endocrinology and patients from the screening of  records 
of  radiotherapy. 
Mean applied radiation dose:
All files were screened for a calculated/estimated dose to the pituitary/hypothalamic 
region. For patients irradiated before 2004, the isodose lines plotted on 2D images 
and on plain x-rays of  the skull were used to estimate the pituitary dose. After the 
introduction of  CT based treatment planning in our department CT images where used 
to read the plotted dose. Since 2007 the planning software gives a calculated dose to the 
hypothalamic/pituitary region, and mean doses to the pituitary were collected.
Parameters
At baseline disease specific information was extracted from the medical files. 
The following parameters were assessed:
Anthropometric parameters: body weight and height were measured. Body weight was 
measured to the nearest 0.1 kg, and body height was measured barefoot to the nearest 
0.001 m. Additional information on medication use, Karnofsky score, IADL score, and 
co-morbidity was gathered.







Biochemical parameters: IGF-1, GH, TSH, fT4, ACTH, cortisol, LH, FSH, estradiol, 
testosterone, Sex Hormone Binding Globulin (SHBG), and prolactin concentrations 
were measured, furthermore general laboratory parameters including renal and liver 
function and cardiovascular parameters where obtained. Blood samples were taken for 
laboratory measurements after an overnight fast. 
For diagnosing cortisol deficiency we used the following stepwise approach. First a basal 
cortisol level was performed. When basal cortisol concentrations were  <80 nmol/l, in 
the absence of  glucocorticoid use, the diagnosis of  hypocortisolism was considered 
evident and no additional tests were performed (19). To date, the insulin tolerance test 
(ITT) remains the golden standard for the evaluation of  the HPA-axis (19).  In case of  
contraindications for the ITT, such as epilepsy or coronary artery disease, alternative 
dynamic tests such as the corticotrophin releasing hormone (CRH) test (n=10), the 
metyrapone test (n=4), or the ACTH stimulation test were used as to assess adrenal 
function (19-23). The choice for a specific test was made by the treating physician on 
an individual basis depending on the patient’s clinical condition. Cortisol deficiency was 
defined by a peak cortisol below 0.55 µmol/L, either after insulin-induced hypoglycemia 
(glucose nadir <2.2mmol/l) or after stimulation with 100 mcg CRH. A limited number 
of  patients were tested using meytrapone (n=4) since in the past CRH was not available 
for some time, two of  them were retested with the insulin tolerance test when possible. 
Metyrapone (30 mg/kg, Metopiron, Novartis Pharma B.V., Arnhem, the Netherlands) 
was administered orally at midnight. The next morning post absorptive blood samples 
were obtained for measurement of  11-deoxycortisol, cortisol and ACTH levels. A 
cut-off  value for 11-deoxycortisol of  200 nmol/L was used to define normal adrenal 
function (20-22). Growth hormone deficiency was defined by a GH peak response 
to the insulin induced hypoglycemia of  <3µg/l or by a GH peak after combined 
Growth Hormone Releasing Hormone +Arginine-test (GHRH/Arg test) using BMI-
adjusted GH cut-offs. (24,25). When secondary amenorrhea was present for >1 year 
in the presence of  a low serum estradiol (estradiol 0-200 pmol/L) with normal or low 
serum levels of  FSH and LH, premenopausal women were classified as gonadotropin-
deficient. In men, gonadotropin deficiency was defined as a testosterone level <8.0/l 
with and normal or low serum levels of  FSH and LH  (FSH 1.5-12.5 U/L; LH 2.0-
9.0 U/L). Thyroid-stimulating hormone (TSH) deficiency was defined as free T4 level 
below the reference range (<12 pmol/L). Hyperprolactinemia was defined by a basal 





In patients, serum IGF-1 concentrations were measured. From 1986 to 2005, serum 
IGF-1 concentrations were determined by RIA (Incstar, Stillwater, MN) with a detection 
limit of  1.5 nmol/l and an interassay CV less than 11%. IGF-1 was expressed as SD 
score for age- and gender-related normal levels determined in the same laboratory. Since 
2005, serum IGF-1 concentrations (nmol/l) were measured using an immunometric 
technique on an Immulite 2500 system (Siemens Healthcare Diagnostics, Deerfield, 
IL, USA). The intra-assay variations at mean plasma levels of  8 and 75nmol/l were 5.0 
and 7.5%, respectively. IGF-1 levels were expressed as SDS, using lambda-mu-sigma 
smoothed reference curves based on 906 controls  (26,27).
FT4, TSH, LH, FSH, and PRL concentrations were measured by 
electrochemiluminescence immunoassay (ECLIA),using a Modular E170 (Roche 
Diagnostics). The maximal inter-assay CV was 5.0%. ACTH was determined by 
immunoluminometric assay using an Immulite 2500 (Siemens Healthcare Diagnostics, 
Deerfield, IL, USA). The maximal inter-assay CV was between 5.0 and 10.0%. For the 
measurement of  estradiol, a RIA (Orion Diagnostica, Espoo, Finland) was used (CV 
was 6% at 70 pmol/l) with a detection limit of  20 pmol/l. Testosterone was measured 
using an RIA (Siemens Healthcare Diagnostics; CV was 20% at 1.0 nmol/l and 12% at 
14 nmol/l). The detection limit was 0.2 nmol/l.
Statistical analysis
SPSS for Windows, Version 17.0 (SPSS, Inc.,Chicago, IL, USA) was used for statistical 
analysis. Results are presented as mean, age and follow up are stated as median, unless 
stated otherwise. 
RESULTS
We identified 1504 patients from the records of  the radiotherapy department. We 
excluded 426 patients treated with TBI for hematological malignancies. Of  the 1078 
remaining patients, 243 patients were still alive at screening (23%). Another 130 patients 
did not fulfill inclusion criteria: 102 patients (9%) had progressive disease at the time of  
the study, 28 had other exclusion criteria. Finally, 8 patients were lost to follow up. 105 
patients were enrolled in the current study. 
Of  this total of  105 patients, 59 patients had been assessed at the endocrine department 
since the beginning of  their follow up period. The remaining 45 patients were invited for 
endocrine evaluation, of  whom 24 declined, and therefore 21 new patients underwent 
a complete endocrine work-up (Figure 1).







A total of  80 patients were enrolled in the study. Forty were treated for cerebral 
tumours, 15 for nasopharyngeal tumours, 25 for different tumours like meningioma, or 
metastasis. Median age was 47.5 years and median time of  follow-up was 6 years (range 
0.5-35) (Table 1.)
General assessment of  Karnofsky score and ADL in general showed a normal score, in 
agreement with the inclusion criteria and outpatient clinic setting of  this study.
For 39 patients, treated after 2007, the planning software calculated a estimated dose 
to the pituitary, from all other patients, if  possible, retrospective dose calculations were 
made from the the isodose lines plotted on 2D images and on plain x-rays of  the skull 
or from 2004 onwards CT images were used.  Mean radiation dose was 56.27 Gy (range 
40-70). 
For 39 patients, treated after 2007, the planning software calculated an estimated dose to 
the pituitary, mean 31.7 Gy. Stereotactic radiotherapy was fractionated and performed 
elsewhere, it was not possible to retrieve the radiation plans.
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Flowchart patient selection




No adverse events occurred during the insulin tolerance test.
Of  the total of  80 patients, fifty patients (62%) were diagnosed with any form of  
hypothalamic-pituitary insufficiency. When patients with isolated hyperprolactinemia 
(n=9) were excluded, the prevalence of  any pituitary insufficiency was 51%.  Pituitary 
insufficiency was present in 16 patients within 2 years after irradiation. This number 
increased to 23/49 patients (47%) after 5 years and 27/45 (60%) after 10 years. Pituitary 
insufficiency was present in 31/35 patients (89%) with a follow-up duration of  at least 
15 years. 
Of  the 21 patients first tested during this cross-sectional study, 9 (43%) were found to 
have any form of  pituitary insufficiency; including previously undiagnosed symptomatic 
pituitary insufficiency. 
Growth hormone- IGF-1 axis:
Severe GH deficiency (GHD) was documented in 27 patients (33%). 
In 70% ITT was performed, 18 patients did not undergo dynamic testing and were 
diagnosed with GHD using serum IGF-1 followed by calculating the standard deviation 
TABLE 1 Patient characteristics 













Mean Dose Rtx (Gy) 56.3 (40.0-70.0)




Other tumours: Chondrosarcoma n=2, Ethmoidcarcinoma n=1, Arachnoidsarcoma n=1, Osteosarcoma n=1, 
Parachordoma n=1, Haemangiopericytoma n=1, Non-Hodgkin Lymphoma n=1. Gy; Grey, Rtx; Radiotherapy






of  the value in the age- and sex-specific reference range <-2SD in addition of  2 other 
failing pituitary hormones. Duration of  follow up before diagnosing GHD was 4,5 
years after irradiation (0,5-35 years) in the 59 patients known on the outpatient clinic of  
the endocrinology department
Hypothalamic-Pituitary-Adrenal-axis: 
Secondary adrenal insufficiency was diagnosed in 25 patients (31%). In 73% (n=59) 
of  the patients tested for HPA-axis ITT was performed, 7 (12%) were diagnosed with 
secondary hypocortisolism with ITT. Secondary adrenal insufficiency was diagnosed 
in the other patients with the ACTH test (n=4), the CRH test (2), the Metyrapon test 
(n=4). Duration of  follow up before diagnosing cortisol deficiency was after 6 years 
(range 0.5- 24 yrs) in the 59 patients known on the outpatient clinic of  the endocrinology 
department.
Gonadal axis
Hypogonadotropic hypogonadism was present in 20 patients (25%) of  the 59 patients 
known and the duration of  follow up before diagnosis was 7 years (range 0,5-16). 
Hypogonadotropic hypogonadism in the presence of  hyperprolactinemia was transient 
and resolved after initiation of  anti-dopaminergic treatment and these patients were not 
classified as having gonadal deficiency.
Pituitary-Thyroid axis
Central hypothyroidism was observed in 11 patients (14%), as defined by a low  Ft4 and 
and inappropriate TSH. TSH deficiency was seen after a duration of  follow up of  5.1 
(1.5-10.3) years after irradiation in the 59 patients known on the outpatient clinic of  the 
endocrinology department. 
Prolactin
Hyperprolactinemia was seen in 17 patients (21%) of  the patients known to the 
outpatient clinic after a follow up of   2,5 (0,5-21) years, but was symptomatic in only 2 
patients (females).
Disease specific pituitary insufficiency.
Cerebral tumours
40 patients (22 males) were treated for primary cerebral tumours with a mean dose of  
55.8 Gy ±4.4 Gy, range 46-61 Gy. Eleven patients (28%) were GHD, 9 (27%) suffered 
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from hypocortisolism, 13% were TSH deficient, and 13% had hypogonadotropic 
hypogonadism.  Hyperprolactinemia was seen in 27% of  patients, none were 
symptomatic. 
Nasopharyngeal carcinoma
Fifteen patients (11 males) were treated for nasopharyngeal carcinoma. Mean radiation 
dose was 63 Gy ±9.8 range 40-70 Gy. 2 patients from the group never tested prior to 
this study turned out to have symptomatic pituitary insufficiency. In the total of  15 
patients treated for nasopharyngeal carcinoma 3 (21%) were GHD, 5 (33%) were HPA 
deficient. TSH deficiency was seen in 20%, whereas 40% of  patients were hypogonadal 
and 40% suffered from hyperprolactinemia. Two patients (females) were symptomatic 
and were subsequently treated with cabergoline with reinstatement of  the gonadotroph 
function. 
Other tumours
Twenty-five patients were treated for various other tumours with a mean dose of  53 Gy 
±7 with a range of  40-69 Gy. In patients treated for cerebral metastases or other tumours 
52% were GHD, 40% HPA deficient, 28% TSH deficient, 36% were hypogonadal and 
28% of  patients had hyperprolactinemia.
DISCUSSION
This study, using optimal endocrine testing to evaluate pituitary function in a group of  
adult patients after cranial radiotherapy for head and neck tumours with the pituitary 
within the radiation field, showed that pituitary insufficiency was highly prevalent, since 
62% of  the patients were diagnosed with any form of  hormone deficiency. These 
findings add up to the presently available reports (14,17,28). The additional value of  
the present study is the standardized approach of  stringent endocrine testing and long-
term follow up in the majority of  patients. In addition, the long-term follow-up enabled 
to produce an overall timeframe showing that pituitary insufficiency of  any form was 
present in 55% of  the cases within 5 years after radiotherapy, and amounted to 75% 
and 90% of  the patients after 10 and 15 years, respectively. Another study following 
the same testing protocol reported a slightly lower rate of  pituitary deficiencies in 
patients irradiated for non-pituitary brain tumours in adulthood (28). The lower rate of  
deficiencies was mainly driven by the approximately 20% of  patients with diagnosed as 
adrenal insufficient, which can be explained, at least in part, by the use of  different cut 
of  values for the ITT (500 nmol/L vs 550 nmol/L in our hospital). A similar pattern of  






radiation-induced pituitary insufficiency with a prevalence of  38% within 32 months of  
cranial irradiation was reported by Madaschi and colleagues (17). 
This retrospective study, as others, suffers from several limitations. We fully acknowledge 
the fact that the patients from the Endocrinology department (n=59) studied in the 
present study reflect a very selected cohort since they were actively referred. A large 
number of  patients from our registry were deceased, due to their malignancies or had 
progressive disease and were not tested at time of  the study, which largely influences the 
population at risk to develop pituitary insufficiency. In addition, concurrent medication 
use like corticosteroids for the treatment of  cerebral edema or already diagnosed and 
treated primary thyroidal or gonadal failure precludes complete testing of  pituitary 
function in a significant number of  cases (29). We acknowledge the fact that the patients 
studied in the long-term in the present study reflect a selected cohort since they were 
actively referred. Although we screened the files of  all eligible patients treated with 
cranial radiation (Figure 1) and invited all patients alive with reasonable life expectancy, 
we were only able to study a minority of  all irradiated patients (n=80). Of  note, 59 
patients treated with cranial radiotherapy at our center was actively referred for endocrine 
testing. However these patients did not differ from the patients actively recruited in 
terms of  pituitary deficiencies, since pituitary insufficiency was present in 43% of  cases 
after a mean follow up of  4.8 ±3.2 years after radiotherapy (range 1-10 years). However, 
despite the high level of  heterogeneity in this study, as in the other available studies on 
this subject, and the methodological flaws, the prevalence of  pituitary insufficiencies is 
significant and clinically relevant. Despite the lack of  prospective data, this condition 
merits a much greater awareness of  all health care providers involved, including the 
development of  recommendations or guidelines. 
Lastly, the use of  different radiation schemes and patient cohorts, creating a very divers 
cohort. The degree of  pituitary deficiencies depends on the radiation dose delivered to 
the hypothalamic/pituitary region. Previous studies have shown that 7- 24 Gy as used for 
the treatment of  haematological malignancies result in growth hormone deficiency only 
(18,30). The incidence of  multiple deficiencies increases in time and with higher dosages 
due to the radiation induced changes to the DNA as well as indirectly by production 
of  free radicals from intracellular water molecules (31,32). These radiation-induced 
changes can cause direct lethal effects or will accumulate to sublethal effects that will 
restrict potential cell replication. Cell death after radiation occurs in de mitotic phase 
of  the cell cycle providing the explanation for the delayed onset of  hormonal failure in 
slowly replicating tissue, like neuroendocrine tissues of  the hypothalamic and pituitary 
(33). Furthermore, radiation may also induce tissue damage and dysfunction through 
chronic inflammation and release of  pro-inflammatory cytokines, compromising 
endothelial function by increasing endothelial proliferation and collagen synthesis (31-
34). We selected a threshold of  20 Gy based on data from historical cohorts indicating 
that a total dose of  7- 24 Gy delivered to the pituitary/hypothalamus region, may 
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cause growth hormone deficiency only, whereas dosages as high as 50-60 Gy will most 
certainly cause multiple pituitary hormone deficiencies (30). On the basis of  the current 
data and other studies we consider the chance of  developing hypopituitarism with 
pituitary doses > 20 Gy high enough to justify endocrine follow-up.
The presence of  pituitary insufficiency per se is associated with a decrease in quality of  
life as well as an increase in morbidity and mortality (35,36). Although available studies 
have some limitations, because studies are small sized, retrospective nature and use 
different diagnostic criteria to study pituitary function, it is clear that patients treated 
with cranial irradiation are at increased risk to develop pituitary insufficiency and that 
this easily treatable side effect can not be neglected. Therefore, although we advocate 
routine endocrine testing in every patient after cranial radiotherapy, the decision to 
proceed to pituitary testing with stimulation tests should be individually based. 
Diagnosing hypopituitarism can be challenging since it might be difficult to distinguish 
between symptoms of  hypopituitarism or radiation/chemotherapy induced changes. 
Furthermore biochemical findings might not be that clear e.g the finding of  low FT4 
combined with an abnormally low TSH makes a diagnosis of  central hypothyroidism 
obvious. However milder defects, characterized by FT4 levels still within the normal 
range, but decreasing following radiotherapy may be also clinically relevant and 
remain undiagnosed (37). Rose et al. reported on the fact that in childhood cancer 
survivors many patients with mild thyrotrope insufficiency were not diagnosed on the 
basis of  basal thyroid function screening (38). Patients treated for malignancies often 
complain of  irritability, anxiety and depression as well as fatigue (39-41). In patients 
with hypopituitarism, for example with growth hormone deficiency, the psychological 
symptoms include decreased energy levels, social isolation, and lack of  positive well 
being, depressed mood and increased anxiety (42). Whereas physical complaints like 
fatigue and decreased libido can be seen due to hormonal dysfunction as well. Even 
for endocrinologists, it remains very difficult to distinguish between hypopituitarism 
and general complaints after radiation or chemotherapy. Nevertheless, endocrine 
replacement is able to improve complaints caused by hypopituitarism. For example 2 
of  the 21 patients who were invited for endocrinological screening were already under 
long-term treatment for depression and their decrease libido was considered secondary 
to depression instead of  hypogonadism and 2 patients cured from nasopharyngeal 
carcinoma even presented in the past with unexplained hypotension before the diagnosis 
of  panhypopituitarism was made. This exemplifies the need for endocrine testing in any 
of  these patients since detection purely based on anamnesis will not be sufficient. 
We propose a follow up schedule according to both the total radiation dosage delivered 
to the pituitary and the expected life expectancy that is currently incorporated in our 
standard protocols in the follow up postcranial radiation (Figure 2). For all patients 
treated by cranial radiotherapy an estimated dose to the pituitary should be calculated. 
If  this estimated dose to the pituitary is  > 20 Gy, depending on the physical condition 






of  the patient endocrine follow up ip mandatory. How to proceed within the first years 
after radiation has to be tailored for each patient personally, since this is a very complex 
and fragile patient cohort. A follow up protocol as proposed needs to be validated 
prospectively, but this matter should be addressed since pituitary insufficiency is highly 
prevalent in adult patients treated with cranial radiotherapy with the pituitary within the 
radiation field. Replacement of  endocrine deficits is associated with improvement of  
quality of  life and prevents severe complications such as Addisonian crises. Therefore, 
we advocate that all patients with a life expectancy of  more than 1 year should be 
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Chapter 4
Long-term effects of recombinant human Growth 
Hormone (rGH) replacement in adults with Growth 




Background: The beneficial effects of  recombinant human growth hormone (rGH) 
therapy in growth hormone deficient (GHD) adults are well-established in the short-
term. However, data documenting the effects during prolonged follow-up are relatively 
scarce. 
Objective: To evaluate the reported effects of  rGH replacement (≥5 years) in GHD 
adults on biochemical and anthropometric parameters, quality of  life (QoL), bone 
metabolism, muscle strength, serious adverse events (SAEs), and mortality. 
Methods: We conducted a systematic literature search. Quality assessment of  retrieved 
papers was performed using a quality assessment based on the modified STROBE 
statement.
Results: We included 23 prospective studies with a rGH treatment duration ranging from 
5 to 15 years. Overall, beneficial effects were reported on QoL, body composition, lipid 
profile, carotid IMT and BMD. In contrast, the prevalence of  the metabolic syndrome, 
glucose levels, BMI and muscle strength were not, or negatively influenced. Most of  
the studies were uncontrolled, lacked the presence of  a control group (of  non-treated 
GHD patients), and reported no data on lipid-lowering and anti-diabetic medication. 
Overall mortality was not increased.
Conclusion: RGH treatment in adult GHD patients is well-tolerated and positively affects 
QoL in the long-term. However, the metabolic and cardiovascular effects during long-
term treatment are variable. The low numbers of  long-term studies and studied patients 
and lack of  control data hamper definite statements on the efficacy of  prolonged 
treatment. Therefore, continuous monitoring of  the effects of  rGH replacement to 
enable an adequate risk-benefit analysis that may justify prolonged, potentially life-long, 
treatment is advisable. 







Growth hormone deficiency (GHD) in adults has been associated with an adverse 
metabolic profile and increased cardiovascular mortality by inducing abdominal obesity, 
hypercholesterolaemia and hypertriglyceridaemia (1;2). Consistent beneficial effects of  
treatment with recombinant human growth hormone (rGH) were reported on body 
composition and lipid profile, resulting in reduction of  fat mass combined with an 
increase in lean body mass and a reduction in total cholesterol (TC) levels (3). In addition, 
favorable effects were reported on bone turnover, bone mineral density (BMD), muscle 
strength, cognitive function and quality of  life (QoL) (3-5). Most of  these effects have 
been documented in short-term studies, sometimes placebo-controlled, with a follow-
up duration ranging from 6 to 18 months. 
 The beneficial effects of  rGH therapy have been reported to sustain for at 
least 5 years on treatment; however data with a longer follow-up duration are scarce. 
With respect to cardiovascular disease, a direct improvement of  several cardiovascular 
risk factors was noted within the first treatment year, which was reported to sustain 
during prolonged rGH treatment (6;7). In a small study, sustained improvement of  
lipid spectrum and diastolic blood pressure (DBP) was reported over 7 and 10 years, 
suggesting ongoing beneficial effects even beyond 5 years (6;7). However, it is presently 
unknown whether rGH therapy has favorable effects on the incidence of  cardiovascular 
events, including cardiovascular death. With respect to bone, rGH replacement therapy 
increases bone remodeling, indicated by an increase of  biochemical markers of  both 
bone formation and resorption. This results in an initial decline in BMD, followed by 
a significant increase in BMD, reaching a plateau phase after 5 to 7 years of  treatment 
(8-10). 
 In general, rGH replacement therapy in adults is regarded as safe. Recently, 
Van Bunderen et al. reported no differences in overall or malignancy-related mortality 
rate between GHD treated patients and the background population (11). However, 
an increased risk in cardiovascular death was observed in rGH-treated women. This 
increased cardiovascular mortality, however, is not easily explained. These recent 
findings accentuate the necessity to critically evaluate long-term efficacy and safety data.
 We performed a systematic review of  all available papers on long-term rGH 
replacement in adult GHD patients. We aimed to evaluate the effects of  long-term rGH 
replacement in GHD adults on cardiovascular parameters, bone metabolism, muscle 




Search strategy and eligibility criteria
To identify studies that investigated the long-term effects of  rGH replacement in GHD 
adults, we searched the following databases, up to September 2012 (Date of  initial 
search 9th March, 2012): Medline, EMBASE, Web of  Science, and the Cochrane Library, 
in collaboration with a trained clinical librarian (J.S.). We composed a search strategy 
focusing on long-term rGH treatment, GHD adults, bone metabolism, QoL, metabolic 
effects, muscle strength, mortality, and adverse events. Chronic stable replacement was 
arbitrarily defined as replacement for ≥5 years, since such a period will reflect a stable 
metabolic situation without confounding by ongoing metabolic changes induced by the 
start and titration of  rGH replacement (3;12). We used all relevant keyword variations, 
including free text words. Duplicated articles were excluded. The complete search 
strategy is provided in Appendix 1. References of  relevant articles were checked for 
additional articles. Only original articles were included. 
Studies were eligible when all of  the following criteria were met: (1) they investigated 
effects on biochemical, metabolic/anthropometric parameters, bone metabolism, QoL, 
muscle strength, mortality, or adverse events, (2) in adult patients with either childhood-
onset (CO) or adult-onset (AO) GHD and (3) with at least 5 years of  rGH treatment 
and (4) were written in English. Only human studies were evaluated. 
Data extraction and analysis
Data extraction and eligibility were assessed by two independent investigators 
(K.M.J.A.C. and N.M.A.-D.). Inconsistencies were resolved by consensus. The following 
data were extracted: (1) study population (patient characteristics, population size, GHD 
assessment, control population); (2) exposure to rGH (duration of  rGH treatment, 
rGH dose), (3) outcome (biochemical and anthropometric parameters, QoL, bone 
metabolism, muscle strength, mortality, serious adverse events (SAEs)) (4) potential 
confounders (age, sex, CO/AO). 
Methodological quality assessment 
The quality of  each included paper was assessed in consensus by two independent 
reviewers (K.M.J.A.C. and N.M.A.-D.), using a standardized set of  criteria based on the 
STROBE statement (Appendix 2), which was modified to cover the topic of  our review 
(12). A maximum score of  10 points could be obtained. According to the total quality 
score, articles were considered as having poor (0-2), intermediate (3-5), good (6-8), or 
excellent methodological quality (9-10).







Identification and selection of the literature
From initial 841 potentially relevant studies identified, 803 were excluded on the basis 
of  title and abstract. Thirty-eight papers were retrieved for detailed assessment: 9 were 
excluded because of  rGH treatment duration <5 years, 2 studies described pediatric 
patients only, 1 study did not report original data and 3 studies did not address the long-
term effects of  rGH suppletion. Consequently, 23 studies were eligible for inclusion, 
several describing part of  the same patient cohort (Göteborg) (4;6;9;10;13-16) (KIMS 






841 potentially relevant publications 
identified from electronic search 
38 publications retrieved for more 
detailed assessment 
23 eligible for inclusion 
803 studies excluded on the basis of 
title and abstract 
15 articles did not fulfill the 
inclusion criteria because of the 
following reasons: 
 
9 articles: follow-up <5yr 
2 articles: children with GHD 
3 articles: other primary question 
1 article: no original article 
FIGURE 1.




According to the predefined quality criteria, no studies were classified as having 
poor quality. Two studies scored intermediate (18;19), 15 studies had a good 
quality (4-6;9;11;15;18;21-28) and 6 studies had an excellent methodological quality 
(7;10;13;15;16;20) (Table 1). Mean quality score was 7.3 (range 5.0-9.0), indicating that 
overall methodological quality was good. However, especially the items on potential 
bias, handling with missing data, reasons for non-participation at each study stage and 
the use of/handling with co-medication were not clearly described. 
Methodology
All selected studies (n=23) were prospective follow-up studies, eleven of  these had a 
controlled design. Healthy controls were included in six studies (5;13;19-22), of  which 
two studies used National Registries. Four other studies included GHD patients with 
intermittent rGH treatment or untreated GHD patients as controls (11;22;24;25). 
Gibney et al. compared rGH-treated patients with both untreated GHD patients and 
healthy controls (23). Four reports involved multi-center studies (5;11;17;24). No 
randomized controlled trials were available.
Endocrine evaluation
Different established stimulation tests were used for the diagnosis of  severe GHD. The 
insulin tolerance test (ITT) was used as standard test in 16 studies and the combined 
GHRH-arginine test, glucagon stimulation test or stimulation with clonidine alone, in 
case of  contraindications for ITT. Eight studies did not specify which stimulation tests 
were used (5;11;14;17;22;24-26). Thirteen studies applied the generally used cut-off  
value for severe GHD of  a peak GH<3µg/L (4;6;7;9;10;13;15;16;19;20;23;27;28), in 
seven studies no exact cut-off  value was reported (5;11;14;17;22;24;26), and three studies 
used, respectively, <1.7µg/L (21), <5µg/L (18) and <10mU/L (25) as cut-off. In all 
studies, except for one (25), information on additional pituitary deficiencies was given. 
Most patients had multiple anterior deficiencies, especially gonadotrope deficiency, but 
thyreotrope and corticotrope deficiency was also frequently encountered. 
Duration of rGH treatment
Mean treatment duration with rGH ranged from 5 years to 15 years: 8 studies reported 
5-year effects, 2 studies had a 6-year follow-up (11;18), 3 studies investigated 7-year 
effects (7;21;28), 1 study investigated the 9-year effects (25), 8 studies reported 10-year 
effects (6;10;13-15;23;24;26), 1 study described 15 years of  rGH suppletion (4). In one 
study, treatment duration varied among the different countries from 4-8 years (5). 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dose of rGH treatment & IGF-1 levels
Fourteen studies (nine from Göteborg) calculated the GH starting dose based on body 
weight (4;6;9;10;13-16;19;21-23;25;27). Of  the remaining nine studies, three studies 
used dose titration of  rGH on an individual basis in the beginning of  treatment, with 
the aim to reach IGF-1 levels within the normal age- and sex-related range, and adjusted 
the rGH dose accordingly (7;20;26). Six studies did not report their rGH dosage 
regimen (5;11;17;18;24;28). GH start dose ranged from 0.2mg/day (7;20) to 1.1mg/day 
(21). Twelve studies reported mean GH dose after dose titration (at 1 year) (6;9;10;13-
17;19;21;24;27), ranging from 0.3mg/day (19) to 0.85mg/day (21) (median dose 0.54 
mg/day).
 Sixteen studies reported mean IGF-1 levels (4;7;9;10;13-16;18;19;21-24;26;28), 
and thirteen studies described IGF-1 SDS to evaluate treatment response (4;6;9;10;13-
17;20-22;24) (Appendix 3). Based on available IGF-1 values, we can conclude that all 
patients were physiologically substituted at least after 5 to 7 years treatment with rGH, 
independently of  the applied starting dosage regimen.
Outcome of long-term rGH replacement (Table 2)
Anthropometric parameters 
Thirteen studies (N=1185) assessed the effects on body weight, body mass index (BMI) 
and/or waist-hip ratio (WHR) (4;6;7;9;10;13;14;20;21;24;26-28). rGH suppletion did 
not affect WHR or waist circumference (7;20;21;26-28), except for one study reporting 
an increased waist circumference (24). Seven studies reporting BMI found a significant 
increase during rGH suppletion ≥5years, the other six studies reported no change 
(4;6;7;9;13;14;16;19-21;24;27;28). Two of  the eight studies reporting body weight found 
an increase in weight during rGH suppletion; the other studies reported no change 
(4;10;13;14;16;21;27;28). 
In conclusion, results on long-term effects on BMI appear to be inconclusive with 
seven studies reporting an increase, and six reporting no change. In addition, there is 
little evidence for an increase in body weight. 
Body composition
Eleven studies (N=538) (6;9;13;14;16;19;21;23;26-28) assessed the effects of  rGH 
suppletion on body composition using dual-energy X-ray absorptiometry (DEXA) scan 
(6;9;13;14;16;26;28), bioelectrical impedance analysis (BIA) (19;21) or a helicoidal CT 
scan (27). Gibney et al. measured body composition with radioisotope potassium (23). 
The majority of  studies (n=9) reported consistent effects with an increase in lean body 
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could not detect any effect of  rGH on body composition (26). Cenci et al. reported only 
a decrease in visceral fat (27).  
In conclusion, rGH suppletion had favourable effects on body composition, with an 
increase in LBM and a decrease in total BF. Several methods are available to evaluate body 
composition, which may account for differences between studies. These differences 
might have influenced the results significantly. In literature, DEXA is reported to be 
the best currently available technique for measuring body composition (29); however, 
in this respect, it has to be noted that DEXA cannot distinguish between body cell 
mass (BCM) and water. Therefore, the LBM data may not be accurate, since rGH 
replacement is associated with an increase in the intracellular water component (30-33). 
However, also when using other modalities to evaluate body composition, positive long-
term effects of  rGH replacement were found.
Lipid metabolism 
Ten studies (N=827) assessed the effects of  rGH suppletion on fasting plasma lipid 
profiles (6;7;9;20;21;23;24;26-28). Three studies did not find any effect of  rGH therapy 
on plasma lipids (24;26;27). The seven remaining studies reported generally similar 
results, i.e. reduction of  total cholesterol (TC) and low-density lipoprotein (LDL) 
cholesterol, an increase in high-density lipoprotein (HDL) cholesterol and no effect on 
triglycerides (6;7;9;20;21;23;28). In 6 patients, new-onset hyperlipidaemia was reported 
(Göteborg). However, only four studies reported the number of  patients on lipid-
lowering medication, especially statins, (6;7;20;26) but without excluding these patients 
from analysis.  
In summary, there are ongoing beneficial effects of  rGH suppletion on plasma lipids. 
However, a strong limitation is the lack of  data concerning lipid-lowering treatment, 
which has a considerable influence on the outcome parameter. Due to the lack of  
information on lipid-lowering drugs and the overlap in patient groups, meta-analysis 
was not an option. 
Glucose metabolism
Eleven studies (N=847) assessed the effects of  rGH suppletion on glucose and 
insulin levels (6;7;9;19-21;23;24;26-28). Seven studies showed no effect on glucose 
(7;20;23;24;26-28), three an increase (6;9;19) and one study found a transient increase 
of  glucose levels only during the first year of  rGH therapy (21). Insulin levels increased 
only in one study (19). HbA1c was evaluated in three studies, two of  which observed 
a decrease (6;9); the other found no change (26). Three studies investigated insulin 
resistance by the homeostasis model assessment (HOMA) (19;26;27), reporting no 
significant effects of  rGH suppletion. Insulin sensitivity was not affected in two studies 






(21;26), while another study reported a transient decrease, using the quantitative insulin 
check index (QUICKI), showing a trend to return towards basal values afterwards (19). 
In at least ten patients, new-onset diabetes mellitus type 2 (DM2) was diagnosed (4 
Göteborg, 6 KIMS (24)). Five studies reported the number of  patients starting anti-
diabetic medication during follow-up (6;9;21;26;27). Only one study excluded diabetic 
patients from analysis (9), the other studies did not report the handling with anti-diabetic 
medication in their statistical analysis. 
In conclusion, there is moderate evidence for an increase in mean glucose levels after 
chronic rGH treatment; however, insulin sensitivity appeared not to be affected in the 
long-term. Due to the lack of  information on anti-diabetic medication and the overlap 
in patient cohorts, we were not able to perform a meta-analysis on this parameter.
Cardiovascular parameters
Four studies (N=135) investigated the effects of  rGH suppletion on blood pressure 
(7;9;20;23;28). No effect was found on systolic blood pressure (SBP); one study reported 
a decrease in resting diastolic blood pressure (DBP) (28). Only two studies described 
the number of  patients on antihypertensive medication (7;20), without excluding them 
from analysis. Prevalence of  the metabolic syndrome (MS) was assessed in one study, 
reporting a strong increase when compared to healthy controls, despite 5 years of  rGH 
treatment (38.0% vs 15.7%) (20).
Two studies (N=22) evaluated the long-term effects on cardiac function (23;28) 
using echocardiography; Chrisoulidou et al. also performed an exercise test (28). Left 
ventricular mass (LVM) was not affected. In addition, no effect on end diastolic or 
systolic diameter (23) nor on isovolumetric relaxation time (IVRT) or LVM, was 
demonstrated (23;28). Two studies (N=24) evaluated carotid intima media thickness 
(IMT), reporting a decrease in IMT up to 18% after long-term rGH therapy (23;27). 
In conclusion, no effect on SBP of  LVM was reported. In addition, conclusions on the 
prevalence of  MS cannot be made, since this parameter was only evaluated in one study. 
Long-term rGH suppletion had positive effects on IMT.
Muscle strength
Five studies (N=278, all AO-GHD) investigated the effects of  rGH suppletion on 
muscle strength (13-16;23). In general, 5 years of  rGH improved knee flexor and 
extensor strength and hand-grip strength. However, these effects were not sustained 
after 10 years. One study also investigated muscle endurance; no significant effects of  
rGH suppletion were demonstrated (15). In addition, rGH suppletion did not affect 
muscle strength in the elbow, shoulder or hip (23). Compared with population-based 
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controls, rGH was found to be protective to the normal age-related decline in muscle 
performance and neuromuscular function (13;14). 
In general, rGH suppletion improved muscle strength during the first 5 years of  
treatment; however, these effects were not sustained after prolonged follow-up. Since 
almost all studies described one patient group, we were not able to perform a meta-
analysis on this parameter.
Bone parameters
Four studies (N=343) evaluated the long-term effects of  rGH on bone (4;9;10;18). 
After an initial decline, all studies reported an increase in both BMD and BMC within 
the first 5 years of  treatment. After 5 years, all studies reported a plateau phase, 
which lasted for the entire study period (i.e. sustained effects) (4;9;10;18). Only one 
study investigated (symptomatic) fracture prevalence, reporting 1 hip fracture and 1 
symptomatic vertebral fracture (4). None of  the studies described the use of  calcium 
or Vitamin D suppletion, or the use of  bisphosphonates, selective estrogen receptor 
modulator (SERM), teriparatide or strontium ranelate. Again, most patients were from 
the same study center, prohibiting the performance of  a meta-analysis. 
 
QoL
Two large cohort studies (both KIMS database, N=1686 and N=440, respectively) and 
two smaller studies (N=71) addressed the effects on QoL and neuropsychological well-
being, by QoL-Assessment of  GHD in Adults (QoL-AGHDA), Nottingham Health 
Profile (NHP), and Psychological General Well-Being (PGWB) questionnaires (5;23-
25). Within the first year of  treatment, a direct beneficial response on well-being was 
noticed, as assessed by QoL-AGHDA, with marginal changes after the dose-titrating 
phase (5;24). Improvement was related to the degree of  QoL impairment at baseline 
(5). Scores on NHP and PGWB improved in the long-term, especially with respect to 
energy level and emotional reaction (23;25). 
In conclusion, QoL seemed to improve during long-term rGH replacement, but positive 
effects on QoL were especially seen within the first year of  treatment. Since studies 
are scarce and none of  them had a placebo-controlled randomized controlled design, 
which is of  paramount importance for the interpretation of  QoL, no firm conclusions 
can be drawn on the effects of  long-term rGH replacement on QoL.
Effects of  rGH on mortality
Three cohort studies (N=16501) reported data on mortality after long-term rGH 
suppletion (11;17;22), of  which one study reports KIMS data (N=13983). In Gaillard et 






al., overall mortality rate was moderately increased, especially in females, young attained 
age, patients with aggressive tumours and lower IGF-1 SDS during therapy (17). The 
other studies did not report differences in overall mortality or malignancy-related death. 
In two studies (17;22), the rate of  cerebrovascular accidents (CVAs) was increased, but 
the incidence of  myocardial infarction was decreased (risk ratio (RR) 0.27, 95%CI 0.03-
0.99) when compared to the background population (22). In addition, rates of  death 
due to infections (standardized mortality ratio (SMR) 4.97, 95%CI 3.98-6.14), primary 
tumour progression (SMR=6.96, 95%CI 4.45-10.3) and endocrine complications 
(SMR=2.79, 95%CI 1.30-5.23) were increased (17). Van Bunderen et al. (N=2229; 
median rGH treatment of  5.7 yr) reported an increase in cardiovascular-related deaths 
in GHD-treated women (SMR 2.36) (11). This was not supported by the other long-
term studies (17;22). 
In summary, there is evidence for a moderate increased mortality rate despite long-
term rGH replacement, especially in females. Differences in pituitary disease, hormone 
replacement- and radiation therapies may account for differences between studies. 
However, since long-term studies on mortality are scarce, at this moment, no firm 
conclusions on the safety of  long-term rGH replacement can be drawn.
Serious adverse events (SAEs)
Twelve studies reported SAEs during long-term rGH treatment (n=9 from Göteborg) 
(4;6;7;9;13-16;21;24;28). Since several studies described the same patient cohort, the 
total number of  SAEs could not be extracted.
Malignancies
A total of  6 malignancy cases were reported in the GHD cohort of  Göteborg: colonic 
carcinoma (N=1), prostate carcinoma (N=1), chronic lymphatic leukaemia (N=1), 
renal carcinoma (N=1), bladder carcinoma (N=1), and pulmonary carcinoma (N=1). 
In addition, 12 cases of  de novo malignancies, not further specified, were reported (7;24). 
Cardiovascular events
Three cases of  myocardial infarction (Göteborg, Van der Klaauw et al. (7)) were reported, 
of  which two with fatal outcome. Five patients suffered from a CVA (Göteborg, Van 
der Klaauw et al. (7)), resulting in death in four cases, and one patient died from a 
subarachnoid hemorrhage (Göteborg). In addition, angina pectoris was reported (N=3) 
(Göteborg), and 1 patient died from a pulmonary embolism (Göteborg). In at least ten 
patients, new-onset DM2 was diagnosed (4 Göteborg, 6 KIMS (24)). In, respectively, 6 
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and 4 patients new-onset hyperlipidaemia and hypertension were reported (Göteborg, 
(28)).
Other SAEs
Two studies reported primary tumour growth (N=11), either recurrence of  the pituitary 
or central nervous system tumour (7;24). In conclusion, half  of  the studies reported 
SAEs during rGH therapy. Due to the lack of  a control group including non-treated 
GHD patients, no firm conclusions can be drawn.
DISCUSSION
The short-term effects of  rGH treatment are well-established, showing favourable 
effects of  rGH therapy within the first 3 years on body composition, lipid profile, 
bone turnover, BMD, muscle strength, cognitive function, and QoL. This is the first 
systematic review focusing on the long-term effects of  rGH treatment (beyond ≥5 
years of  treatment). Overall, long-term rGH therapy beneficially affected QoL and 
BMD. In addition, sustained beneficial effects were reported on lipid spectrum and on 
carotid IMT after 10 years of  treatment. Consistent effects on body composition were 
reported with an increased LBM and a decreased total BF. Muscle strength increased 
after 5 years of  rGH suppletion, but these effects were not sustained during longer 
follow-up. Negative effects were reported on mean glucose levels; however, insulin 
sensitivity appeared not to be affected by long-term rGH treatment. 
 The effects of  rGH replacement on bone turnover, and thus on BMD, are 
dynamic over time. Initially, BMD decreases due to increased bone resorption and 
formation, followed by an increase within the first years of  treatment, finally resulting 
in a plateau phase. The five studies addressing this topic, showed a significant increase 
within the first 5 years of  treatment. Thereafter, BMD was conserved but did not further 
increase (4;9;10). Only one study described the number of  symptomatic fractures (4), 
however, without radiographic assessment of  the vertebral column. As a consequence, 
the reported fracture rate is most probably underestimated, since 21% of  the fractures 
in patients with osteopenia or osteoporosis are asymptomatic (34). Fracture incidence 
was also studied by Holmer et al. (35), but a considerable proportion of  patients were 
treated <5 years. In CO-GHD women, not in AO-GHD women or CO-GHD men, 
fracture risk was doubled, and in men with AO-GHD fracture incidence was even 
decreased (35). Further research has to establish the efficacy of  rGH treatment with 
respect to fracture risk.
Presently, in clinical practice, QoL is the most frequently addressed outcome parameter, 
but in the long-term, QoL was studied only in four studies (5;23-25). The two largest 






studies (KIMS database) showed improvement within the first year of  treatment, with 
thereafter steady progress towards the country-specific mean (i.e. normalization) (5;24). 
The other two studies found ongoing beneficial effects on energy level and emotional 
reaction (23;25). Unfortunately, none of  these studies had a placebo-controlled 
randomized controlled design. Thus, based on current literature, long-term effects on 
QoL are inconclusive, and therefore, in daily clinical practice, QoL should be individually 
evaluated in each patient. 
With respect to plasma lipids, seven out of  ten studies investigating the long-term 
effects of  rGH replacement on the lipid profile report ongoing beneficial effects, with a 
reduction of  TC and LDL-C levels, an increase in HDL-C and no effect on triglycerides. 
However, in this respect, a strong limitation is the lack of  data concerning lipid-lowering 
treatment, prohibiting to draw firm conclusions on this outcome parameter. When 
comparing these long-term results to short-term studies on plasma lipids, it has be 
noted that there were also several (randomized controlled) short-term studies reporting 
no change or minimal effects on lipid levels, and that even these effects were limited to 
men (36;37). Overall, however, as shown in a meta-analysis of  Maison et al. investigating 
37 placebo-controlled randomized controlled studies (follow-up up to 18 months), rGH 
replacement was shown to improve LDL-C and TC levels in the short-term (3). 
Concerning the safety of  rGH suppletion, in children, long-term safety data have 
shown conflicting data, raising the question whether long-term use of  rGH is safe. 
Several large studies did not find an increased mortality in pediatric GHD patients 
after rGH replacement, especially not due to new-onset malignancies or recurrence 
of  central nervous system tumors. Cause of  death was assessed as unrelated to rGH 
replacement in the majority of  patients (38-42). In contrast, a recent study of  Carel 
et al. showed an increased incidence in bone tumor-related mortality and mortality 
due to cardiovascular diseases in a large cohort of  French children, especially in those 
with highest GH doses (>50µg/kg/day) (43). Cancer mortality was also increased 
in a large pediatric UK cohort, especially in high-risk patients (44). Moreover, Bell et 
al. reported an increase in the occurrence of  second tumors in children with a prior 
history of  malignancy, especially in case of  prior exposure to radiotherapy (38). These 
discrepant results could be possibly explained by the different dosage regime, with 
higher GH doses in the French study. A recent meta-analysis underlines this hypothesis, 
establishing that both low and high IGF-1 levels are associated with increased mortality 
(hazard ratio (HR) 1.18, 95%CI 1.04-1.34) (45). Adult studies did not show an increased 
mortality or malignancy rate (11;22), except for one study showing moderate increase 
in overall mortality in females (17). However, the studies do not represent unselected 
patients, since initiation of  rGH replacement is not likely in patients with an a priori 
increased cancer risk, thus creating a clear selection bias. With respect to cardiovascular 
outcomes, an increase in cardiovascular deaths and number of  CVAs was reported in 
women, whereas the myocardial infarction rate decreased (11;17;22). The increased 
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incidence in cardiovascular deaths in women might partly be attributed to the more 
atypical presentation of  cardiovascular diseases in women (46). Other factors such as 
inadequately substituted hypogonadism causing preterm menopause or hypocortisolism 
may also have influenced this risk. In this respect, it has to be noted that available data 
suggest that both mortality risk and the causes for mortality are related in both patients 
receiving and those not receiving rGH replacement. However, it is of  paramount 
importance to accentuate that all observed increased mortality rates reported to date 
have been associated only with the presence of  hypopituitarism per se, but that it is still 
uncertain if, and to what extent, this can be attributed to GHD. 
We assessed the methodological quality of  all studies using a modified STROBE 
list (12), classifying 21 of  the 23 included studies as having a good or excellent 
methodological quality. Several quality criteria were not clearly described, specifically, 
information on potential bias, handling with missing data and reasons for dropout was 
lacking in most studies. In addition, the use of  co-medication, especially lipid-lowering 
and anti-diabetic drugs, was not clearly reported. It is of  importance to emphasize 
this limitation, because the effects of  rGH therapy on lipid profile, glucose levels and 
other cardiovascular parameters could not be interpreted without this information. 
In addition, no randomized controlled trials (RCT) were identified with a follow-up 
duration >5 years and only a limited number of  centers have reported their data, with 
half  of  the long-term studies describing (part of) the same patient cohort (Göteborg). 
Other studies were relatively small and might have been, therefore, underpowered to 
allow firm conclusions. Due to these limitations, we were not able to perform a meta-
analysis.
Another limitation is the report of  outcomes only for patients that had completed 5 or 
10-years of  follow-up, instead of  describing the original cohort. This may introduce a 
significant selection bias, since patients discontinued rGH therapy for specific reasons, 
and, therefore, are likely to differ from patients with complete follow-up. Furthermore, 
a major limitation of  most studies is the lack of  a control group and thereby the lack 
of  control for ageing. This limitation is important to notice when interpreting the long-
term effects of  rGH replacement on for example body weight, BMI, blood pressure, 
lipid profile, body composition and BMD (47-49). Consequently, it is very difficult to 
discriminate between effects as a consequence of  natural ageing processes and effects 
by rGH replacement per se. Firm conclusions on the effects of  rGH per se can therefore 
not be drawn from present results. Another feature that needs to be addressed is the 
change in patient characteristics and approach to rGH suppletion over time, which may 
represent an important confounder for any analysis (50). This emphasizes the need of  
ongoing monitoring during rGH treatment.
In summary, available literature on long-term rGH replacement in adult GHD patients 
shows inconsistent results with respect to its expected beneficial effects, in the presence 






of  several drawbacks to enable a definite interpretation. First, long-term studies were 
generally uncontrolled and lacked a control group (of  non-treated GHD patients) 
enabling adjustment for subjective changes or changes due to ageing. Second, only 
a limited number of  centers have reported their data, resulting in a low number of  
evaluable patients with a follow-up duration of  ≥5 years of  rGH replacement with half  
of  the long-term studies describing (part of) the same patient cohort. Especially the 
course of  QoL during ongoing therapy is unestablished. With respect to the metabolic 
profile, rGH therapy has shown prolonged, beneficial effects on the long-term for body 
composition, lipid profile, carotid IMT and BMD, but overall cardiovascular risk, as 
assessed by the prevalence of  the metabolic syndrome, glucose levels, BMI appeared 
not to be influenced or were even negatively affected. Therefore, the benefit of  long-
term rGH treatment should be a matter of  ongoing research to enable adequate risk-
benefit analyses and, in clinical daily practice, the benefits of  rGH should be considered 
carefully in each patient.
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APPENDIX 1. SEARCH STRATEGY USED FOR SYSTEMATIC LITERATURE 
SEARCH
The following combined key words were used: ((“recombinant growth hormone” OR 
“recombinant growth hormones” OR “recombinant human growth hormone” OR “recombinant human 
growth hormones” OR “r-hGH” OR ((“Growth Hormone”[mesh] OR “growth hormone” OR 
“growth hormones” OR Somatotropin OR Somatotropins OR Somatropin OR hGH OR Serostim 
OR Zomacton OR “Cryo-Tropin” OR “Cryo Tropin” OR CryoTropin OR “r-hGH-M” OR 
Humatrope OR Umatrope OR Maxomat OR Norditropin OR Norditropine OR Nutropin OR 
Omnitrope OR Saizen OR Genotropin OR Genotonorm) AND (“Recombinant Proteins”[mesh] 
OR recombinant[tw]))) AND (“long term effects” OR “long term effect” OR “longterm effects” OR 
“longterm effect” OR longterm OR “long term” OR ((“Twenty years” OR “Twenty year” OR “20 
years” OR “20 year” OR “Nineteen years” OR “Nineteen year” OR “19 years” OR “19 year” 
OR “Eighteen years” OR “Eighteen year” OR “18 years” OR “18 year” OR “Seventeen years” 
OR “Seventeen year” OR “17 years” OR “17 year” OR “Sixteen years” OR “Sixteen year” OR 
“16 years” OR “16 year” OR “Fifteen years” OR “Fifteen year” OR “15 years” OR “15 year” 
OR “Fourteen years” OR “Fourteen year” OR “14 years” OR “14 year” OR “Thirteen years” OR 
“Thirteen year” OR “13 years” OR “13 year” OR “Twelve years” OR “Twelve year” OR “12 
years” OR “12 year” OR “Eleven years” OR “Eleven year” OR “11 years” OR “11 year” OR 
“Ten years” OR “Ten year” OR “10 years” OR “10 year” OR “Nine years” OR “Nine year” 
OR “9 years” OR “9 year” OR “Eight years” OR “Eight year” OR “8 years” OR “8 year” OR 
“Seven years” OR “Seven year” OR “7 years” OR “7 year”) AND (effect[tiab] OR effects[tiab] 
OR outcome OR outcomes))) AND (adult OR adults)) OR ((“recombinant growth hormone” OR 
“recombinant growth hormones” OR “recombinant human growth hormone” OR “recombinant human 
growth hormones” OR “r-hGH” OR ((“Growth Hormone”[mesh] OR “growth hormone” OR 
“growth hormones” OR Somatotropin OR Somatotropins OR Somatropin OR hGH OR Serostim 
OR Zomacton OR “Cryo-Tropin” OR “Cryo Tropin” OR CryoTropin OR “r-hGH-M” OR 
Humatrope OR Umatrope OR Maxomat OR Norditropin OR Norditropine OR Nutropin OR 
Omnitrope OR Saizen OR Genotropin OR Genotonorm) AND (“Recombinant Proteins”[mesh] 
OR recombinant[tw]))) AND (“long term effects” OR “long term effect” OR “longterm effects” OR 
“longterm effect” OR longterm OR “long term” OR ((“Twenty years” OR “Twenty year” OR “20 
years” OR “20 year” OR “Nineteen years” OR “Nineteen year” OR “19 years” OR “19 year” 
OR “Eighteen years” OR “Eighteen year” OR “18 years” OR “18 year” OR “Seventeen years” 
OR “Seventeen year” OR “17 years” OR “17 year” OR “Sixteen years” OR “Sixteen year” OR 
“16 years” OR “16 year” OR “Fifteen years” OR “Fifteen year” OR “15 years” OR “15 year” 
OR “Fourteen years” OR “Fourteen year” OR “14 years” OR “14 year” OR “Thirteen years” OR 
“Thirteen year” OR “13 years” OR “13 year” OR “Twelve years” OR “Twelve year” OR “12 
years” OR “12 year” OR “Eleven years” OR “Eleven year” OR “11 years” OR “11 year” OR 
“Ten years” OR “Ten year” OR “10 years” OR “10 year” OR “Nine years” OR “Nine year” 
OR “9 years” OR “9 year” OR “Eight years” OR “Eight year” OR “8 years” OR “8 year” OR 
“Seven years” OR “Seven year” OR “7 years” OR “7 year”) AND (effect[tiab] OR effects[tiab] 
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OR outcome OR outcomes))) NOT (“child”[mesh] NOT “Adult”[mesh])) NOT (“Animals”[mesh] 
NOT “Humans”[mesh]).
APPENDIX 2. LIST OF CRITERIA USED FOR METHODOLOGICAL QUALITY 
ASSESSMENT, MODIFIED STROBE STATEMENT
Item Criterion
1. Clear presentation of  key elements of  study design
2. Description of  setting, locations, relevant dates including periods of  recruitment, exposure, follow-up, and data collection
3.
Description of  eligibility criteria, and the sources and methods of  selection of  participants
   i) Description of  methods of  follow-up (cohort study)
   ii) Rationale for the choice of  cases and controls (case-control study)
4. Clear definition of  all outcomes, exposures, predictors, potential confounders.
5. Description of  any effects to address potential sources of  bias.
6. Clear description of  statistical methods and handling with missing data.
7. Report of  reasons of  non-participation at each stage of  the study (for example, flow diagram).
8. Clear description of  characteristics of  study participants.
9. Clear description of  follow-up time.
10. Presentation of  unadjusted estimates and, if  applicable, confounder-adjusted estimates and their precision (i.e. 95% confidence interval). 






APPENDIX 3. MEAN SERUM IGF-1 LEVELS AND IGF-1 SDS AT START OF RGH 
SUPPLETION AND DURING FOLLOW-UP, SPECIFIED PER STUDY



















































































































































































































































































































































































































































Data are presented as mean (SD), unless specified otherwise. 
IGF-1, insulin-like growth; NR, not reported; R, range; M, males; F, females

Chapter 5
Metabolic profile in growth hormone deficient (GHD) 
adults after long-term recombinant human growth 
hormone (rGH) therapy 
Natasha M. Appelman-Dijkstra, Kim M.J.A. Claessen, Desirée M.M.M. Adoptie, 
Ferdinand Roelfsema, Johannes W.A. Smit, Nienke R. Biermasz, Alberto M. Pereira




Background: The metabolic effects of  recombinant human growth hormone (rGH) 
therapy in adults are well documented in the short-term. The effects of  long-term rGH 
therapy beyond five years on metabolic parameters are presently unknown. 
Objective: To evaluate the long-term effects of  rGH treatment on biochemical and 
anthropometric parameters in a large cohort of  GHD adults.
Methods: Ninety-eight adult GHD patients treated with rGH for ≥10 years were included 
(mean age 59.4 years, 50% female). Total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, 
anthropometric parameters, IGF-1, and glucose were evaluated at baseline, and after 5, 
10 and 15 years of  treatment. In addition, the prevalence of  the metabolic syndrome 
(MS) and the incidence of  cardiovascular events were assessed. 
Results: TC and LDL-C concentrations were lower, and HDL-C levels were significantly 
higher during long-term rGH replacement when compared to baseline (all p<0.001). 
Both waist circumference (p<0.001) and BMI (p=0.018) were significantly higher 
after 10 years, as were fasting plasma glucose levels (p<0.001). No significant changes 
were observed in TG, WH ratio and blood pressure during follow-up. In the subset 
of  patients with 15-yr rGH treatment (N=43), generally similar metabolic effects were 
found. MS prevalence was increased after 10 years of  rGH treatment (57.1% vs 32.7%, 
p<0.001), especially in males (69.4% vs 32.7%, p<0.001). 
Conclusion: Despite improvement of  several cardiovascular risk factors, MS prevalence 
increased significantly during rGH treatment. The effect of  long-term rGH treatment 
on overall cardiovascular risk profile needs to be established in a larger cohort. 







Recombinant human growth hormone (rGH) replacement therapy has been a 
regular treatment option for adult growth hormone deficient (GHD) patients since 
the nineties. Adult GHD is hypothesized to be a cardiovascular risk factor associated 
with increased mortality, by inducing abdominal obesity, hypercholesterolemia, and 
hypertriglyceridemia (1;2). In short-term studies, GH replacement reduces some, but 
not all of  these cardiovascular risk factors (3). Consistent ‘short-term’ effects on body 
composition and lipid metabolism were documented, resulting in reduction of  body fat 
combined with an increase of  fat-free mass, and a reduction of  total cholesterol (TC) 
and low-density lipoprotein cholesterol (LDL-C) levels (3). In addition, favorable effects 
on bone mineral density (BMD) and quality of  life (QoL) have been reported (3-6). 
Sustained improvement of  lipid spectrum and diastolic blood pressure (DBP) has been 
reported over 7-10 years (7-9). However, despite a significant improvement of  some, 
but not all individual cardiovascular risk factors, overall cardiovascular risk profile, as 
reflected by the prevalence of  the metabolic syndrome (MS), was still increased when 
compared to general population and was not affected by rGH after 5years of  treatment 
(10). Moreover, a recent study reported an increased risk of  cardiovascular death in 
GHD women treated with rGH when compared to background population (11). A 
recent review addressing the effects of  rGH replacement in elderly patients (>60 years) 
with GHD, revealed that rGH replacement decreases LDL-C levels and improves QoL, 
but the effects on other parameters were not unequivocal (12). However, sufficient 
data concerning the use of  long-term rGH therapy in elderly are currently unavailable, 
as is the case in younger patients. In view of  the overall scarce documentation of  
cardiovascular effects over ten years (8;13;14), the efficacy of  ongoing rGH therapy in 
reducing cardiovascular risk in adult GHD still has to be established. 
Therefore, the aim of  this study was to evaluate the long-term effects of  rGH treatment 
on biochemical and anthropometric parameters in a large cohort of  GHD adults, which 
were treated with rGH for at least 10 years. 
PATIENTS AND METHODS
Patients 
Since 1994, consecutive patients diagnosed with GHD at the Endocrinology Department 
of  the Leiden University Medical Center were collected in a database, including both 
adult-onset (AO) and childhood-onset (CO) GHD. Severe GHD had been defined prior 
to start of  treatment by a GH peak response to the Insulin Tolerance Test (ITT) <3µg/l 
(glucose nadir<2.2mmol/l) or Growth Hormone Releasing Hormone/Arginine-test 
(GHRH/Arg) (with BMI-adjusted GH cut-offs) in case of  contraindications for ITT, 
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according to guidelines (10;15). All patients with rGH treatment during childhood were 
retested at time of  transition to the adult outpatient clinic, after treatment cessation 
for >3months. Following dose titration, aiming at an IGF-1 level in the normal range, 
patients were evaluated at least yearly at the outpatient clinic according to a standard 
protocol.
For the present analysis, we selected patients who started with rGH treatment in 2002 
or before (N=184). Exclusion criteria were: 1) rGH treatment duration <10years; 2) 
cessation for ≥2years; 3) >3 missing visits. Part of  this GHD cohort used for present 
analysis was previously described (9;10;16;17).
Treatment protocol
All patients were treated with s.c. injections of  rGH (Genotropin Pharmacia/Pfizer, 
Zomacton Ferring, or Norditropin NovoNordisk) injected in the evening. The 
initial dose of  rGH was 0.2mg/day, which was individually adjusted each month in 
the first half  year to achieve serum IGF-1 concentrations within the age-dependent 
laboratory reference range, aimed at SDS between 0 and +2. When stable plasma 
concentrations were reached, this individualized dose was continued and adjusted 
as necessary. Adrenocorticotropic hormone (ACTH) deficiency was defined as an 
insufficient increase in cortisol levels (absolute value 0.55mmol/l) after a corticotropin-
releasing hormone stimulation test or ITT. When secondary amenorrhea was present 
for >1year, premenopausal women were classified as gonadotropin deficient. In men, 
gonadotropin deficiency was defined as a testosterone level below the reference range 
(8.0nmol/l). Thyroid-stimulating hormone (TSH) deficiency was defined as total 
thyroxine (T4) or free T4 level below the reference range (<10pmol/l). Hypopituitarism 
was supplemented by hydrocortisone, l-thyroxine, testosterone in men, and estrogen in 
combination with prostagens in premenopausal women only. Dosages were monitored 
and adjusted as required. Thyroid hormone replacement, lipid-lowering medication and 
antihypertensive medication was started according to the discretion of  their attending 
physicians. 
Efficacy parameters
The following efficacy parameters were assessed at baseline and at the yearly visits at 
the outpatient clinic:
i. Biochemical parameters: levels of  glucose, total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C), and triglycerides (TG) after an overnight fast. 
LDL-C concentrations were calculated using the Friedewald formula. 






ii. Anthropometric parameters: body weight and height, waist circumference, hip 
circumference, systolic and diastolic blood pressures (SBP and DBP, respectively) 
were measured. BMI and waist-to-hip (WH)-ratio were calculated. Body weight was 
measured to the nearest 0.1kg, and body height was measured barefoot to the nearest 
0.001m. The BMI was calculated as weight in kilograms divided by the square of  
height in meters. 
iii. Additional information with respect to medication use, co-morbidity and possible 
side effects and adverse events was gathered from patient records.  
For the present study, we analyzed the efficacy parameters at baseline and after 5, 10 and 
15 years of  rGH therapy.
Metabolic Syndrome (MS)
The MS was defined according to the updated third report of  the 2006 National 
Cholesterol Education Program’s Adult Treatment Panel (NCEP-ATP III) criteria, 
which required at least three of  the following conditions (18;19): 
1. Fasting plasma glucose concentration ≥100mg/dl or on anti-diabetic drug treatment;
2. TG concentration ≥150mg/dl or on drug treatment;
3. HDL-C concentration <40mg/dl in men and <50mg/dl in women, or on drug 
treatment;
4. BP ≥130/85mmHg or on anti-hypertensive treatment
5. Waist circumference >102cm in men and >88cm in women.
Assays
Serum GH was measured with a sensitive IFMA (Wallac,Turku,Finland), specific for the 
22 kDA GH protein (detection limit: 0.01µg/l,interassay coefficient of  variation (CV): 1.6-
8.4% of  0.01-15.4µg/l) from 1992 onwards. For the conversion of  µg/l to mU/l, multiply 
by 2.6. Before 1992, GH was measured by RIA (Biolab,Serona,Coissins,Switzerland), 
detection limit: 0.5mU/l, with an interassay CV<5%; for the conversion of  µg/l to 
mU/l, multiply by 2.
From 1986 to 2005, serum IGF-1 concentrations were determined by RIA (Incstar, 
Stillwater,MN) with a detection limit of  1.5nmol/l and an interassay CV less than 11%. 
IGF-1 is expressed as SD score for age- and sex-related normal levels determined in the 
same laboratory (20). Since 2005, serum IGF-1 concentrations (nmol/l) were measured 
using an immunometric technique on an Immulite 2500 system (Siemens Healthcare 
Diagnostics,Deerfield,IL,USA). The intra-assay variations at mean plasma levels of  8 
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and 75nmol/l were 5.0 and 7.5%. IGF-1 levels were expressed as SDS, using lambda-
mu-sigma smoothed reference curves based on 906 controls (21;22). 
A Hitachi 747 autoanalyzer (Roche) was used to quantify serum concentrations of  
glucose, TC, and TG. HDL-C was measured with a homogenous enzymatic assay 
(Hitachi 911,Roche). In 2003, the Hitachi 747 was replaced by a modular P800 with no 
change in the chemistry components.
Statistics
SPSS for Windows, Version 17.0 (SPSS,Inc.,Chicago,IL,USA) was used for statistical 
analysis. Results are presented as mean±SD, unless stated otherwise. ANOVA repeated 
measurements with Bonferroni correction for multiple comparisons were used to 
compare biochemical and anthropometric parameters between baseline and after 
rGH treatment. We incorporated age, sex, childhood-onset versus adult-onset GHD, 
hydrocortisone use, radiotherapy and GH dose in a linear regression model to identify 
factors influencing the metabolic effects of  long-term rGH suppletion. The Friedman 
test for related fractions was used to assess the effect of  rGH treatment on the MS 
prevalence. Furthermore, we calculated the incidence rate of  cardiovascular events 
(i.e. cardiovascular death, myocardial infarction, cerebrovascular attack, intermittent 
claudication, (progressive) angina pectoris or coronary bypass surgery, pulmonary 
embolism) during rGH therapy. 
RESULTS
One hundred eighty-four adult patients with GHD started rGH suppletion in 2002 or 
before (Figure 1). Forty-two patients are on current rGH treatment, but did not complete 
10years of  treatment yet. Fourty-four patients discontinued rGH treatment for various 
reasons (Figure 1). Reasons for preliminary discontinuation of  rGH treatment were: 
no subjective beneficial effect (N=10), death (N=9), tumor growth (N=7), malignancy 
(N=12), high age (N=1), new-onset diabetes mellitus type 2 (N=1), other (N=4). 
Consequently, we included 98 patients (50% female, mean age 59.4 yr) for the present 
analysis, of  which 43 patients completed 15 years of  rGH therapy (44% female, mean 
age 61.3 yr). Baseline characteristics are shown in Table 1. 
No differences were found between the patients with and without complete ≥10 
yr rGH treatment, with respect to sex, BMI, age of  start rGH therapy, etiological 
diagnosis, surgery, radiotherapy, pituitary deficiencies, and use of  lipid-lowering or 
antihypertensive medication. Only the number of  patients with childhood-onset GHD 
was higher among non-completers (p=0.009) (data not shown). 









All adult GHD patients 
started with rhGH 
therapy in 2002 or 
before from LUMC 
N=184 
Exclusion N=86 
Patients which did not 
complete 10yr rhGH 
treatment 
Patients with complete 
10yr rhGH treatment 
N=98 
Patients with complete 
15yr rhGH treatment 
N=43 
Exclusion N=55 
Stop rhGH treatment 
<15yr N=13 
Continuous rhGH 
therapy, but <15yr N=42 
Reasons for discontinuation: 
No subjective beneficial 
effect N=4 
Malignancy N=6 
High PSA N=1 
CVA N=1 
Unknown N=1 
<10yr rhGH treatment N=42 
Reasons for discontinuation: 
No subjective beneficial 
effect N=10 
Death N=9 
Tumor growth N=7 
Malignancy N=12 
High age N=1 
New onset DM2 N=1 
Other N=4 
FIGURE 1. 
Flowchart of  patient selection and follow-up
GH dose and IGF-1 concentration
Mean GH dose after dose titration (after 1yr) was 0.46±0.20mg/day (range 0.20-
1.50mg), 0.48±0.25mg/day at 5years (range 0.15-1.50mg), at 10 and 15years mean 
GH doses were 0.44±0.26mg/day (range 0.10-1.50mg) and 0.39±0.21mg/day (range 
0.10-1.50mg), respectively (5, 10 and 15-yr GH doses were not significantly different 
from the GH dose after dose titration). Serum IGF-1 levels remained significantly 
higher during rGH replacement for the duration of  the study up to 15years compared 
to baseline (Table 2a). During the entire study period, mean IGF-1 SDS was within 
the normal range, increased from -0.68±2.27 at baseline to 0.20±2.25 at 15years of  
rGH suppletion (Figure 2). In males, mean IGF-1 SDS was -0.24±2.26 at baseline and 
increased to 0.21±2.31 at 15years (p=0.007); in females, mean IGF-1 SDS increased 
from -1.13±2.17 at baseline to 0.19±2.25 after 15years of  rGH treatment (p<0.001). 
Effects on glucose, lipid profile, anthropometric parameters and blood pressure
Fasting plasma glucose levels significantly increased from 4.7±0.8mmol/l at baseline to 
5.0±1.1mmol/l at 5years (6% increase), thereafter remaining stable at 5.1±1.0mmol/l 
after 10years rGH treatment (Table 2a) (p<0.001 vs baseline). TC and LDL-C 
concentrations decreased, and HDL-C levels increased significantly after 5 years when 
compared to baseline (all p<0.001), improving further after 10years of  rGH treatment. 
Both waist circumference and BMI increased after 10years of  rGH suppletion (p<0.001 
and p=0.018, respectively). No significant changes were observed in TG, WH-ratio and 
SBP; only DBP decreased slightly after 5 and 10years (p<0.01 and p=0.016, resp.). 
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TABLE 1. BASELINE CHARACTERISTICS OF 98 PATIENTS WITH GHD, WHICH COMPLETED 
MINIMAL 10 YEARS OF RECOMBINANT GROWTH HORMONE (RHGH) REPLACEMENT THERAPY 
Patient characteristics GHD patients with complete 10yr follow-up 
(N=98)
Sex, female / male (n) 49 / 49
Age at start rhGH therapy, yr (range) 44.9 ± 13.6 (17 – 84)
AO / CO (n) 87 / 11 
BMI, kg/m2 (range) 28.2 ± 5.9 (16.9 – 45.4)
Etiological diagnosis of  GHD (n)
   NFA
   Functioning adenoma
   Craniopharyngeoma
   Cerebral malignancy
   Congenital







Surgery, TS / TC (n) 53 / 24 
Radiotherapy (n) 37 
Pituitary deficiencies (n)
   TSH
   ACTH
   FSH/LH
   ADH






Lipid-lowering drugs (n) 10
Antihypertensive medication (n) 10
Data are presented as mean ± SD, unless specified otherwise. n, number of  patients. 
GHD, growth hormone deficiency; AO, adult-onset GHD; CO, childhood-onset GHD; NFA, non-functioning 
adenoma; TSH, thyroid stimulating hormone; ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; 
LH, luteinizing hormone; ADH, anti-diuretic hormone
Among the subgroup of  patients who completed 15years of  rGH treatment (N=43), 
comparable significant effects of  rGH suppletion were found on fasting glucose levels, 
lipids and waist circumference (Table 2b). The effects on TC, HDL-C, LDL-C and TG 
were not affected when patients using lipid-lowering medication at any time point 
during follow-up were excluded (N=41, 42%). TG, WH ratio, BMI and DBP did not 
change when compared to baseline; SBP was significantly higher (p=0.001). Within the 






15-yr treated group, there were, in general, no differences between 10 and 15years of  
rGH therapy; except for SBP, being significantly higher after 15years. Excluding patients 
on antihypertensive medication at any time point (N=41, 42%) revealed no changes in 
DBP; however, the observed increase in SBP between 10 and 15years of  treatment was 
not significant anymore.
Influence of  sex
The dose of  rGH was significantly higher in women in comparison to men at all time 
points, resulting in a higher GH dose/IGF-1 SDS ratio in female GHD patients. 
After 10years of  rGH treatment, the GH dose was 0.53±0.30mg (range 0.20-1.50mg) 
and 0.36±0.18mg (range 0.10-1.20mg) in females and males, respectively (p=0.001); 
at 15years 0.47±0.23mg (range 0.20-1.20mg) and 0.30±0.14mg (range 0.10-0.60mg), 
respectively (p=0.009). We found no differences in the metabolic response to rGH 
treatment between both sexes.
Other potential influencing factors
Forty-nine patients (50%) were <60years, 49 patients (50%) were ≥60years of  age at 
baseline. The individualized rGH dose used in older patients did not differ from the 
dose in younger patients. In addition, there were no significant differences in the rGH 
































































Mean IGF-1 SD scores during 15 years of  rGH therapy, for the total cohort of  GHD patients (A, N=98) and separated 
for males (B) and females (C), respectively
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WH-ratio, BMI or blood pressure. Furthermore, the number of  pituitary insufficiencies 
did not affect the response to rGH treatment. Mean HC doses were 25.6±7.3mg/day, 
23.1±5.8mg/day, 21.4±4.1mg/day, and 21.1±4.3mg/day at baseline and after 5, 10 
and 15 years of  rGH suppletion, respectively. However, patients with hydrocortisone 
substitution did not differ from hydrocortisone-independent patients, except for a 
greater decrease in LDL-C levels after 10 years (-1.35 vs -0.70mmol/l, p=0.021). Patients 
with CO-GHD did not differ from AO-GHD patients in their response to any of  the 
metabolic parameters studied. In addition, there was no difference between patients 
with or without cranial irradiation, except for a higher waist circumference (p=0.024) 
among irradiated patients. 
When incorporating all factors in a linear regression model, neither age, sex, CO vs AO-
GHD, nor hydrocortisone use significantly influenced any of  the metabolic parameters. 
Radiotherapy, however, influenced waist circumference and DBP negatively. In addition, 
TABLE 2A. EFFECTS OF 10 YEARS OF RHGH REPLACEMENT IN 98 ADULTS WITH GHD ON 
BIOCHEMICAL AND ANTHROPOMETRIC PARAMETERS 
Baseline† 5 years of  rhGH 
replacement††
10 years of  rhGH 
replacement†††
IGF-1, nmol/l 14.8 ± 10.3 25.4 ± 13.3 * 22.2 ± 10.7 *
Fasting glucose, mmol/l 4.7 ± 0.8 5.0 ± 1.1 ** 5.1 ± 1.0 *
TC, mmol/l 6.2 ± 1.4 5.5 ± 1.0 * 5.2 ± 1.0 *, b
LDL-C, mmol/l 4.5 ± 1.4 3.7 ± 0.9 * 3.3 ± 0.8 *, a
HDL-C, mmol/l 1.3 ± 0.5 1.5 ± 0.5 * 1.6 ± 0.6 *
TG, mmol/l 1.8 ± 1.1 1.8 ± 1.0 1.8 ± 1.1
Waist circumference, cm 94.6 ± 13.7 97.0 ± 14.3 98.9 ± 14.2 *, a
WH ratio 0.95 ± 0.07 0.97 ± 0.12 0.96 ± 0.06
BMI, kg/m2 28.2 ± 5.9 28.8 ± 6.3 29.9 ± 6.9 ***, c
SBP, mmHg 129.9 ± 14.7 130.4 ± 17.8 130.9 ± 16.6
DBP, mmHg 83.5 ± 9.7 80.4 ± 9.8 ** 80.4 ± 9.1 ***
Data are presented as mean ± SD. IGF-1, insulin-like growth factor-1; TC, total cholesterol; LDL-C, low density 
lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; WH ratio, waist-hip ratio; SBP, 
systolic blood pressure; DBP, diastolic blood pressure. 
†, statins N=10 (10.2%), antihypertensive medication N=10 (10.2%); ††, statins N=32 (32.7%), antihypertensive 
medication N=32 (32.7%); †††, statins N=34 (34.7%), antihypertensive medication N=33 (33.7%)
*, p<0.001; **, p<0.01; ***, p<0.05 vs baseline 
a, p<0.001; b, p<0.01; c, p<0.05 10 vs 5 years of  rhGH treatment






higher GH dose was associated with higher BMI and waist circumference after 10years 
of  rGH suppletion. 
Prevalence of  the MS
The prevalence of  the MS increased from 32.7% at baseline to 46.9% after 5years of  
rGH therapy (p=0.040), further increasing to 57.1% after 10years of  rGH treatment 
(p<0.001 vs baseline). As shown in Figure 3, this was mainly due to a gradual increase in 
abdominal obesity, hypertriglyceridemia, and hyperglycaemia. 
At baseline, the MS was equally prevalent in men and women (32.7% vs 32.7%). After 
5years of  rGH suppletion, 49.0% of  the males and 44.9% of  the female GHD patients 
had MS (p=0.687). After 10years of  rGH suppletion, 69.4% of  men fulfilled the criteria 
of  MS vs 44.9% of  the women, p=0.015. This indicates that males especially drove 
the increase in MS prevalence over time, and that MS prevalence stabilized in females 
TABLE 2B. EFFECTS OF 15 YEARS OF RHGH TREATMENT IN 43 ADULTS WITH GHD ON 
BIOCHEMICAL AND ANTHROPOMETRIC PARAMETERS 
Baseline† 15 years of  rhGH 
replacement††
IGF-1, nmol/l 9.6 ± 5.5 19.6 ± 8.2 *, a
Fasting glucose, mmol/l 4.5 ± 0.7 5.0 ± 0.5 **
TC, mmol/l 6.6 ± 1.5 5.4 ± 1.1 *
LDL-C, mmol/l 4.9 ± 1.4 3.4 ± 0.9 *
HDL-C, mmol/l 1.4 ± 0.5 1.7 ± 0.6 *
TG, mmol/l 1.7 ± 1.0 1.5 ± 0.6
Waist circumference, cm 91.2 ± 10.5 99.5 ± 11.9 *
WH ratio 0.96 ± 0.06 0.95 ± 0.07
BMI, kg/m2 25.9 ± 3.6 29.2 ± 8.3 ***
SBP, mmHg 128.2 ± 14.0 134.6 ± 15.3 **, b
DBP, mmHg 83.5 ± 9.1 80.8 ± 9.1
Data are presented as mean ± SD. IGF-1, insulin-like growth factor-1; TC, total cholesterol; LDL-C, low density 
lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; WH ratio, waist-hip ratio; SBP, 
systolic blood pressure; DBP, diastolic blood pressure. 
†, statins N=4 (9.3%), antihypertensive medication N=5 (11.6%); ††, statins N=20 (46.5%), antihypertensive medication 
N=20 (46.5%)
*, p<0.001; **, p<0.01; ***, p<0.05 vs baseline 
a, p<0.001; b, p<0.01; c, p<0.05 15 vs 10 years of  rhGH treatment 
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after 5years. In a logistic regression model incorporating age, sex, hydrocortisone 
use, radiotherapy and GH dose, only higher GH dose negatively influenced the MS 
prevalence after 10years of  rGH suppletion. 
FIGURE 3. 
Prevalence of  (individual components of) the MS in 98 GHD adults at baseline, and after 5 and 10 years of  rGH 
suppletion, respectively, separated for males and females
Cardiovascular events
We assessed the number of  major cardiovascular events in the patients who completed 
≥10year rGH treatment (N=98). In total, 25 events were reported: myocardial 
infarction (N=2), progressive angina pectoris and/or coronary bypass surgery (N=7), 
cerebrovascular attack (N=2), intermittent claudication (N=1), pulmonary embolism 
(N=1). No cardiovascular death was reported. Consequently, the incidence rate of  
major cardiovascular events in our GHD cohort was 25/16552 (mean duration of  rGH 
therapy 168.9 months x 98 patients)=1.5/1000py. 
In addition, new-onset DM (N=3), new-onset hypertension or start of  antihypertensive 
medication (N=24), new-onset hypercholesterolaemia or start of  lipid-lowering 
treatment (N=23) was reported during rGH therapy.
DISCUSSION
The present study demonstrates ongoing beneficial effects of  rGH treatment on lipids in 
patients with GHD after 10 and 15years in the presence of  an increase in anthropometric 
parameters such as BMI, waist circumference and SBP. As a consequence, overall 
cardiovascular risk, as assessed by the prevalence of  the MS increased significantly after 
10years of  rGH replacement. This increase in MS prevalence was higher than expected 
as a consequence of  ageing alone in non-GHD adults (23). The short-term effects of  
rGH therapy on cardiovascular risk factors are well documented. A meta-analysis of  
placebo-controlled studies in GHD adults showed favorable effects of  short-term (up 






to 1.5yr) rGH replacement therapy on TC and HDL-C levels, DBP, as well as on lean 
body- and fat mass, but unfavorable effects on glucose and insulin concentrations (3). 
Data on the long-term effects of  adult rGH replacement therapy are limited, and based 
on observational studies. The metabolic changes after ≥10 years of  rGH substitution 
have been reported in only three studies (8;13;14), including a total of  119 patients, and 
their conclusions were inconclusive. The first study (Gibney et al.) reported favorable 
effects on HDL-C and LDL-C, but no changes in TC, TG, insulin, or blood pressure 
(13), whereas the second study (Götherström et al.) reported a decrease in TC and 
LDL-C, an increase in HDL-C levels, and an increase in BMI and glucose levels (8). 
The third study did not demonstrate any effect of  treatment on lipids, glucose or 
anthropometric parameters(14). In this study, we documented a decrease in TC and 
LDL-C levels, and an increase in HDL-C, in accordance with the findings reported by 
Gibney et al. and Götherström et al. (8;13). TG levels, however, did not change during 
rGH therapy. The pattern of  observed changes in lipid concentrations did not change 
after exclusion of  patients using lipid-lowering drugs. The observed mean decrease 
in TC and LDL-C levels after 15years of  rGH therapy was 1.3 (20%) and 1.6mmol/l 
(32%), respectively. In the general population, every 10% decrease in cholesterol levels 
by statins reduces cardiovascular mortality risk in patients with hypercholesterolemia 
by 15% (24). Whether lowering of  TC levels by rGH replacement is associated with 
the same magnitude of  reduction in cardiovascular mortality remains to be established. 
Furthermore, it is crucial not only to ascertain whether the beneficial effects of  rGH 
suppletion on lipid profile are comparable to the effects obtained with conventional 
lipid-lowering drugs, but also if  these effects can be superimposed. From a cost-
effectiveness point of  view, the latter is of  paramount importance, but to date, only 
one study, including 61 GHD patients on statin treatment, has demonstrated such an 
additional beneficial effect of  rGH treatment on lipid profile (25). In addition, Schneider 
et al. reported a cardiovascular risk reduction of  approximately 50% after 2years of  
rGH treatment, using Framingham and Procam risk scores (26). Since hypopituitarism 
per se is also associated with increased cardiovascular mortality (12,13), any additional 
effect of  rGH substitution next to conventional lipid-lowering drugs may be beneficial. 
Despite improvement of  lipid spectrum, the MS prevalence increased after 10years 
of  rGH replacement when compared to baseline, especially in males. Previously, we 
demonstrated an increased MS prevalence in untreated GHD adults, defined by the 
NCEP-ATP III criteria (27), in comparison to a Dutch historical reference population 
(data collected between 1993-1997) (38.0% vs 15.7%) (10). Subsequently, age-adjusted 
prevalence rates of  29% for the MS were reported by Attanasio et al. before start 
of  rGH treatment in 1420 European adults with AO and CO-GHD (Hypopituitary 
Control and Complications Study, HypoCCS) (28), and of  41% before start of  rGH 
suppletion by Verhelst and colleagues among 2479 patients with severe adult-onset 
GHD, using the same updated NCEP-ATP III criteria (27). Two studies have shown a 
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persistently high MS prevalence after 3 and 5years of  rGH treatment, resp. (10;28). In 
our study, we found a further increase in MS prevalence to 57% after 10years of  rGH 
substitution, mainly due to an increase in abdominal obesity, hypertriglyceridaemia and 
hyperglycaemia. 
A limitation of  the present study, and a general drawback of  long-term follow-up studies, 
is the lack of  a non-treated control group. Since the beneficial effects of  rGH therapy 
are well-established in the short-term, it is unethical to withhold patients with GHD 
receive rGH in case of  no contra-indications. This makes it difficult, if  not impossible, 
to perform long-term randomized, controlled follow-up studies including GHD patients 
without rGH treatment. However, several Dutch population-based studies reported 
the MS prevalence in the general population. In a Dutch survey among 4000 subjects, 
conducted in 2009-2010, an overall MS prevalence of  34% and 24% was reported, in 
males and females, respectively. When stratified by age (per decade), MS prevalence for 
males and females, respectively, were 20% and 10% (30-39yr), 29% and 17% (40-49yr), 
41% and 29% (50-59yr), and 48% and 44% (60-69yr) (23). Another study involving 
a cohort of  Dutch adults aged ≥65years (Longitudinal Aging Study Amsterdam, 
LASA) reported an MS prevalence of  37.1% (29). Based on these literature data, the 
MS prevalence of  57.1% in our cohort of  GHD patients (mean age 59yr) is strongly 
increased, despite 10years of  rGH replacement. As demonstrated previously (8;30;31), 
we observed a significant increase in fasting glucose levels during rGH replacement. 
This finding is in accordance with the well-known negative effects of  GH on peripheral 
insulin sensitivity, thereby impairing peripheral glucose uptake. These increased fasting 
glucose levels may have significantly affected cardiovascular morbidity or mortality, 
because previous reports have indicated that even when glucose levels were below the 
diabetic threshold, there was a positive correlation with the occurrence of  cardiovascular 
events (32;33). Previous radiotherapy was shown to negatively influence abdominal 
obesity and blood pressure in GHD adults. This finding is consistent with earlier studies 
among long-term survivors of  childhood cancer, reporting a higher MS prevalence after 
cranial irradiation (34;35). A possible explanation might be that, in addition to pituitary 
damage, cranial irradiation induces damage to the hypothalamic area. Therefore, cranial 
radiotherapy might be an independent risk factor for cardiovascular disease. Due to the 
presence of  multiple pituitary hormone deficiencies in almost all patients, it is difficult 
to examine to what extent the reported effects can be attributed to rGH treatment, 
or whether they are the consequence of  suboptimal or excessive replacement therapy 
of  other hormones. Isolated GHD (IGHD) provides the ideal model to characterize 
GHD without interference from other pituitary deficiencies or their treatment. Abs 
et al. showed generally similar clinical presentation and rGH treatment response in 
IGHD patients and patients with multiple deficiencies, especially in AO-GHD (36), 
supporting the concept that GH per se, at least in part, affects the metabolic phenotype 
of  substituted patients with multiple pituitary hormone deficiencies. In accordance 






with these findings, in a recent meta-analysis, both low and high IGF-1 levels increase 
mortality in general population (hazard ratio (HR) 1.18, 95%CI 1.04-1.34) (37). 
Paradoxically, there are also human studies linking reduced IGF-1 levels/signaling 
to a reduced cancer risk as well as improved longevity (38). In addition, functional 
mutations of  the IGF-1R gene resulting in altered IGF-1 signaling are more common 
in centenarians than in younger controls. The activity of  the GH/IGF-1 axis decreased 
with ageing, yet smaller individuals within a species usually live longer (39). Life span 
was also expanded in mice lacking GHR, resulting in lower IGF-1 levels. Although these 
mutant mice lack other hormones, their extended longevity is thought to be primarily 
due to GHD, as restoration of  GH levels reverted their longevity to that of  non-mutants 
(40;41). Collectively, these data suggest that optimizing the GH/IGF-1 axis to promote 
healthy ageing in humans is more complex than originally appreciated, and will require 
a greater understanding of  its array of  interactions and tissue specificity.  
Another feature that needs to be addressed is the presence of  interactions between 
glucocorticoids and rGH during substitution. In the past, HC doses used in 
hypopituitarism resulted in supraphysiological cortisol levels, accounting for at least 
part of  the adverse metabolic profile. Decreasing the glucocorticoid dose from 20-
30mg/day to 15mg/day had beneficial effects (42). In our study, mean HC dose was 
lowered during 15years of  follow-up from 25.6±7.3 to 21.1±4.3mg/day. When HC 
use was incorporated in a regression model, no relation to MS presence/worsening 
was found. Possible explanations for the absence of  an effect may be the lower HC 
substitution scheme when compared to Danilowicz et al, in addition to less variation 
in the HC doses used. Furthermore, it has been reported that GH accelerates cortisol 
metabolism by inhibiting 11β-HSD1 resulting in decreased tissue exposure to cortisol 
(43;44), thereby reducing HC bioavailability. IGF-1 SD levels were closely monitored 
and were titrated on a physiological level, adjusted for age during the entire study period. 
This is one of  the most important differences between our GHD cohort and other 
GHD cohorts, in which an initial high dose resulted high IGF-1 SDS (over +2SDS) and 
excessive changes in body composition, especially in men. Our data showed no obvious 
differences in IGF-1 levels or metabolic effects of  rGH suppletion between men and 
women, taken into account the need of  a higher rGH substitution dose in women to 
maintain stable plasma IGF-1 concentrations. In addition, we did not find differences 
between younger and older GHD patients with respect to response to long-term rGH 
treatment. However, we cannot exclude lack of  power to detect any differences due to 
the relatively small number of  patients within each age group. 
In conclusion, the present study showed ongoing beneficial effects of  rGH therapy 
in GHD adults on lipid profile, whereas other cardiovascular risk factors continued to 
deteriorate after long-term rGH treatment. The increases in glucose levels and BMI were 
striking, and negatively affected the prevalence of  the MS in the long-term. Therefore, 
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the net beneficial effects of  long-term rGH treatment on overall cardiovascular risk still 
need to be established in further studies that adequately address and balance all these 
factors involved, including cost-effectiveness and QoL.
REFERENCE LIST
1. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 
1990; 336(8710):285-288.
2. Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. 
West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357(9254):425-431.
3. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of  growth hormone 
(GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of  Blinded, 
Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004; 89(5):2192-2199.
4. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years 
of  GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH 
deficiency. Eur J Endocrinol 2012; 166(5):787-795.
5. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. Ten-year GH replacement 
increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J 
Endocrinol 2007; 156(1):55-64.
6. Koltowska-Haggstrom M, Mattsson AF, Monson JP et al. Does long-term GH replacement therapy in 
hypopituitary adults with GH deficiency normalise quality of  life? Eur J Endocrinol 2006; 155(1):109-
119.
7. Chrisoulidou A, Beshyah SA, Rutherford O et al. Effects of  7 years of  growth hormone replacement 
therapy in hypopituitary adults. J Clin Endocrinol Metab 2000; 85(10):3762-3769.
8. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study 
of  the metabolic effects of  growth hormone replacement in adults. J Clin Endocrinol Metab 2007; 
92(4):1442-1445.
9. van der Klaauw AA, Romijn JA, Biermasz NR et al. Sustained effects of  recombinant GH replacement 
after 7 years of  treatment in adults with GH deficiency. Eur J Endocrinol 2006; 155(5):701-708.
10. van der Klaauw AA, Biermasz NR, Feskens EJ et al. The prevalence of  the metabolic syndrome is 
increased in patients with GH deficiency, irrespective of  long-term substitution with recombinant 
human GH. Eur J Endocrinol 2007; 156(4):455-462.
11. van Bunderen CC, van N, I, Arwert LI et al. Does growth hormone replacement therapy reduce 
mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of  
Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96(10):3151-3159.
12. Kokshoorn NE, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA. GH replacement 
therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 2011; 164(5):657-665.
13. Gibney J, Wallace JD, Spinks T et al. The effects of  10 years of  recombinant human growth hormone 
(GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84(8):2596-2602.
14. Roemmler J, Kuenkler M, Schneider HJ, Dieterle C, Schopohl J. Comparison of  glucose and lipid 
metabolism and bone mineralization in patients with growth hormone deficiency with and without 
long-term growth hormone replacement. Metabolism 2010; 59(3):350-358.
15. Ghigo E, Aimaretti G, Corneli G. Diagnosis of  adult GH deficiency. Growth Horm IGF Res 2008; 
18(1):1-16.
16. Janssen YJ, Frolich M, Roelfsema F. A low starting dose of  genotropin in growth hormone-deficient 
adults. J Clin Endocrinol Metab 1997; 82(1):129-135.






17. Janssen YJ, Hamdy NA, Frolich M, Roelfsema F. Skeletal effects of  two years of  treatment with low 
physiological doses of  recombinant human growth hormone (GH) in patients with adult-onset GH 
deficiency. J Clin Endocrinol Metab 1998; 83(6):2143-2148.
18. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of  metabolic syndrome: 
Report of  the National Heart, Lung, and Blood Institute/American Heart Association conference on 
scientific issues related to definition. Circulation 2004; 109(3):433-438.
19. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of  the metabolic syndrome: 
an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Circulation 2005; 112(17):2735-2752.
20. Janssen YJ, Frolich M, Roelfsema F. A low starting dose of  genotropin in growth hormone-deficient 
adults. J Clin Endocrinol Metab 1997; 82(1):129-135.
21. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 
44(1):45-60.
22. Rikken B, van DJ, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma levels of  insulin-like 
growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of  childhood growth 
hormone deficiency. Horm Res 1998; 50(3):166-176.
23. WWW.RIVM.NL/NLDEMAAT. RIVM. 2012. 
24. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical 
benefit: impact of  statin trials. Circulation 1998; 97(10):946-952.
25. Monson JP, Jonsson P, Koltowska-Haggstrom M, Kourides I. Growth hormone (GH) replacement 
decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA 
reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 2007; 67(4):623-628.
26. Schneider HJ, Klotsche J, Wittchen HU et al. Effects of  growth hormone replacement within the 
KIMS survey on estimated cardiovascular risk and predictors of  risk reduction in patients with growth 
hormone deficiency. Clin Endocrinol (Oxf) 2011; 75(6):825-830.
27. Executive Summary of  The Third Report of  The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of  High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001; 285(19):2486-2497.
28. Attanasio AF, Mo D, Erfurth EM et al. Prevalence of  metabolic syndrome in adult hypopituitary 
growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 
2010; 95(1):74-81.
29. Oosterwerff  MM, van Schoor NM, Lips P, Eekhoff  EM. Osteocalcin as a predictor of  the metabolic 
syndrome in older persons: a population-based study. Clin Endocrinol (Oxf) 2012.
30. Giavoli C, Porretti S, Ronchi CL et al. Long-term monitoring of  insulin sensitivity in growth hormone-
deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004; 
53(6):740-743.
31. Gotherstrom G, Svensson J, Koranyi J et al. A prospective study of  5 years of  GH replacement 
therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic 
indices. J Clin Endocrinol Metab 2001; 86(10):4657-4665.
32. Coutinho M, Gerstein HC, Wang Y, Yusuf  S. The relationship between glucose and incident 
cardiovascular events. A metaregression analysis of  published data from 20 studies of  95,783 
individuals followed for 12.4 years. Diabetes Care 1999; 22(2):233-240.
33. Gerstein HC. Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. 
Evid Based Cardiovasc Med 1997; 1(4):87-88.
34. Heikens J, Ubbink MC, van der Pal HP et al. Long term survivors of  childhood brain cancer have an 
increased risk for cardiovascular disease. Cancer 2000; 88(9):2116-2121.
Chapter 5
120
35. van Waas M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM. Components of  the metabolic 
syndrome in 500 adult long-term survivors of  childhood cancer. Ann Oncol 2010; 21(5):1121-1126.
36. Abs R, Mattsson AF, Bengtsson BA et al. Isolated growth hormone (GH) deficiency in adult patients: 
baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary 
patients. A sub-analysis of  the KIMS database. Growth Horm IGF Res 2005; 15(5):349-359.
37. Burgers AM, Biermasz NR, Schoones JW et al. Meta-analysis and dose-response metaregression: 
circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab 2011; 
96(9):2912-2920.
38. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M et al. Growth hormone receptor deficiency 
is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl 
Med 2011; 3(70):70ra13.
39. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of  metabolic pathways in aging. 
Diabetes 2012; 61(6):1315-1322.
40. Russell SJ, Kahn CR. Endocrine regulation of  ageing. Nat Rev Mol Cell Biol 2007; 8(9):681-691.
41. Tatar M, Bartke A, Antebi A. The endocrine regulation of  aging by insulin-like signals. Science 2003; 
299(5611):1346-1351.
42. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of  cortisol overreplacement 
ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008; 11(3):279-285.
43. Filipsson H, Johannsson G. GH replacement in adults: interactions with other pituitary hormone 
deficiencies and replacement therapies. Eur J Endocrinol 2009; 161 Suppl 1:S85-S95.
44. Walker BR, Andrew R, MacLeod KM, Padfield PL. Growth hormone replacement inhibits renal and 
hepatic 11 beta-hydroxysteroid dehydrogenases in ACTH-deficient patients. Clin Endocrinol (Oxf) 
1998; 49(2):257-263.
Natasha M. Appelman-Dijkstra, Kim M.J.A. Claessen , Alberto M. Pereira, Sjoerd.D. 
Joustra, Renee de Mutsert,  Karen B. Gast, Martin den Heijer, Johannes W.A. Smit, 
Olaf  M. Dekkers en  Nienke R. Biermasz
Eur J Endocrinol. 2013 Dec 21 ;170(2):265-74
Chapter 6
Abnormal metabolic phenotype in middle-aged Growth 
Hormone Deficient (GHD) adults despite long-term 




Background: Adult GH deficiency (GHD) is associated with increased cardiovascular 
mortality. Recombinant human GH (rGH) replacement has beneficial short-term 
metabolic effects. Although these positive effects sustain during longer follow-up, the 
prevalence of  the metabolic syndrome (MS) remains increased in comparison with 
population data not adjusted for the higher mean BMI in GHD adults. 
Objective: To explore whether middle-aged patients with proposed physiological rGH 
replacement have been normalized with respect to MS and its individual components in 
comparison to the general population, adjusted for age, sex and BMI. 
Methods: One-hundred sixty-one GHD patients (aged 40-70yr) were studied before the 
start and after 5 years of  rGH replacement, and were compared with 1671 subjects 
(aged 45-66yr) from the general population (NEO Study).
Results: MS proportion in GHD patients was 41.0% before the start of  rGH suppletion, 
increasing to 53.4% after 5 years (p=0.007). Despite chronic rGH replacement, 
GHD patients had a 1.3-times higher MS proportion than the general population, 
independently of  age, sex and BMI (95%CI 1.1-1.5, p=0.008). The GHD population 
showed a different metabolic profile than the general population with similar BMI: 
an increased risk of  hypertriglyceridaemia (adjusted prevalence ratio (PR) 2.0, 95%CI 
1.7-2.3) and low HDL-C (adjusted PR 1.8, 95%CI 1.5-2.2), but less hyperglycaemia 
(adjusted PR 0.5, 95%CI 0.4-0.7). 
Conclusions: Despite 5 years of  rGH replacement, GHD patients still have a different 
metabolic profile and more frequently MS than the general population. These differences 
were independent of  BMI, and resemble the unfavorable metabolic profile of  untreated 
GHD patients, pointing into question the long-term benefits of  rGH replacement.







Growth Hormone Deficiency (GHD) in adults is associated with an adverse metabolic 
profile, including abdominal obesity, dyslipidemia, and an increased mortality risk 
(1;2). Short-term follow-up studies have shown that recombinant human GH (rGH) 
replacement reduced some, but not all of  these cardiovascular risk factors (3). Consistent 
effects were reported on body composition and lipid metabolism, characterized by 
reduction of  body fat and an increase of  lean body mass, and a reduction of  total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels (3). Based on 
these positive short-term metabolic effects, as well as an improvement in quality of  life 
(QoL), rGH replacement has become widely accepted as chronic therapy in adult GHD. 
Despite improvement of  individual components of  the metabolic syndrome (MS), the 
overall prevalence of  the MS, was not normalized in GHD patients after several years 
of  physiological rGH replacement (4;5). At present, data on long-term efficacy and 
safety of  rGH replacement are limited and uncontrolled for the effect of  aging (5-18). 
Recently, we reported a further increase in body mass index (BMI) and MS prevalence 
despite 10 years of  rGH replacement (19). Thus, it can be questioned whether in the 
long-term rGH replacement is able to improve or even normalize the adverse metabolic 
profile present in hypopituitary patients. Since an ideal unselected GHD control group 
without rGH replacement is not available, we selected the Leiderdorp cohort of  the 
Netherlands Epidemiology of  Obesity (NEO) Study as representation of  the general 
population for comparison. The NEO Study is a population-based cohort study of  
middle-aged Dutch adults from the same geographic area as the GHD patients. 
The primary aim of  the present study was to compare the metabolic profile, as reflected 
by proportion of  the MS and its individual components, between GHD patients after 
chronic rGH replacement and the general population, adjusted for age and sex, to assess 
the ability of  current rGH replacement strategies to normalize MS features. Second, 
we critically compared metabolic parameters between treated GHD patients and the 
general population, while additionally adjusting for BMI. Finally, we compared the MS 
proportion in GHD patients before start and after chronic rGH replacement. 
PATIENTS AND METHODS
Study design
In the present study, we compared the proportion of  the MS and its individual 
components between middle-aged GHD patients and the general population. First, 
adult GHD patients were studied before the start of  rGH suppletion and after 5 years 
of  rGH replacement, to study the metabolic effects of  chronic rGH suppletion. Second, 
we compared chronically treated GHD patients (defined as 5 years) with the general 
population, using data from the Leiderdorp cohort of  the NEO Study (vide infra) (20), 
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adjusting for age and sex and subsequently with additional adjustments for BMI, to 
assess the ability of  current rGH replacement strategies to completely normalize MS 
features.
Patient selection
From 1994 onwards, all consecutive patients diagnosed with adult-onset (AO) and 
childhood-onset (CO) GHD at the Endocrinology Department of  the LUMC were 
collected in a database. We investigated the effects of  chronic stable rGH replacement 
in middle-aged GHD patients. Chronic stable replacement was arbitrarily defined as 
replacement for ≥5 years, since in such a period metabolic changes induced by rGH 
therapy start will have been stabilized (3;21). We selected all GHD patients aged 40-70 
years, who started rGH replacement ≤2007, to enable a 5-year follow-up period. The 
age criterion used was chosen to match the GHD patients with middle-aged persons 
from the general population from the Leiderdorp cohort (vide infra) and to avoid non-
positivity. This resulted in a total inclusion of  161 eligible GHD patients (AO 155/6 
CO). The 6 patients with CO-GHD received rGH replacement during childhood, and 
re-started with rGH replacement since this therapy became widely accepted for adult 
GHD patients. 
Treatment protocol
GHD had been defined prior to start of  rGH replacement by a GH peak response to the 
Insulin Tolerance Test (ITT) <3µg/l (glucose nadir <2.2mmol/l) according to current 
guidelines or Growth Hormone Releasing Hormone/Arginine-test (GHRH/Arg) with 
BMI-adjusted GH cut-offs, in case of  contraindications for ITT (5;22). All patients 
receiving rGH replacement during childhood were retested at the time of  transition 
to the adult outpatient clinic, after treatment cessation for >3 months. All patients 
were treated with rGH (Genotropin Pharmacia/Pfizer, Skokie, IL; Zomacton Ferring, 
Troy Hills, NJ; or Norditropin NovoNordisk, Princeton, NJ), injected subcutaneously 
in the evening. In all patients, GH starting dose was 0.2mg/day, which was individually 
adjusted each month in the first half  year to achieve serum IGF-1 concentrations within 
the age-dependent laboratory reference range, aimed at SDS between 0 and +2. After 
reaching stable plasma concentrations, this individualized dose was continued and 
adjusted according to the IGF-1 SDS. 
Adrenocorticotropic hormone (ACTH) deficiency was defined as an insufficient 
increase in cortisol levels (absolute value 0.55mmol/l) after an ITT or corticotropin-
releasing hormone stimulation test in case of  contraindications for ITT. When 
secondary amenorrhea was present for >1 year, premenopausal women were 
classified as gonadotropin-deficient. In men, gonadotropin deficiency was defined as 






a testosterone level <8.0nmol/l. Thyroid-stimulating hormone (TSH) deficiency was 
defined as total thyroxine (T4) or free T4 level <10pmol/l in addition to ≥2 deficient 
pituitary axes. Hypopituitarism was adequately supplemented by hydrocortisone, 
L-thyroxine, testosterone in men, and/or estrogen in combination with progestagens 
(in premenopausal women only). Dosages of  the hormonal replacement therapy were 
monitored and adjusted as required. 
Patients were treated with lipid-lowering medication and antihypertensive medication 
according to the discretion of  their attending physicians. Efficacy and safety parameters 
were assessed yearly, next to a routine assessment of  pituitary function. 
General population
The NEO Study is currently performed at the Leiden University Medical Center 
(LUMC) to investigate pathways that lead to obesity-related diseases. The NEO Study 
is a population-based prospective cohort study of  individuals aged 45-65 years, with 
an oversampling of  individuals with overweight or obesity (BMI ≥27kg/m2) (20). 
Within the NEO Study, as reference group, all inhabitants aged between 45-65 years 
from one municipality (Leiderdorp) were invited, irrespective of  their BMI. Baseline 
measurements have been performed between 2008 and 2012. The study was approved 
by the Medical Ethics Committee of  the LUMC and all participants gave informed 
consent. 
We used the Leiderdorp cohort (N=1671) for comparison with our chronically rGH-
treated GHD patients. GHD patients and subjects from the general population were 
from the same geographic area. 
Study parameters
The following efficacy parameters were studied:
1. Biochemical parameters: fasting glucose, total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. LDL-C concentrations 
were calculated by the Friedewald formula. Blood samples were taken after an 
overnight fast. 
2. Anthropometric parameters: body weight and height, waist circumference, hip 
circumference, systolic and diastolic blood pressures (SBP and DBP, respectively) 
were measured. BMI (in kg/m2) and waist-hip ratio were calculated.
3. Additional information on medication use and co-morbidity was gathered from 




The MS was defined according to the updated third report of  the 2006 National 
Cholesterol Education Program’s Adult Treatment Panel (NCEP-ATP III) criteria, 
which required the presence of  ≥3 of  the following conditions (23;24): 
1. Fasting plasma glucose concentration ≥100mg/dl or on anti-diabetic drug treatment;
2. TG concentration ≥150mg/dl or on lipid-lowering drug treatment (statins and/or 
fibrates);
3. HDL-C concentration<40mg/dl in men and<50mg/dl in women, or on lipid-
lowering drug treatment (statins and/or fibrates);
4. BP ≥130/85mmHg or on anti-hypertensive treatment;
5. Waist circumference ≥102cm in men and ≥88cm in women.
Assays
From 1986 to 2005, serum IGF-1 concentrations were determined by RIA 
(Incstar,Stillwater,MN) with a detection limit of  1.5nmol/l and an interassay CV <11%. 
IGF-1 is expressed as SD score for age- and gender-related normal levels determined 
in the same laboratory (21). Since 2005, serum IGF-1 concentrations (nmol/l) were 
measured using an immunometric technique on an Immulite 2500 system (Siemens 
Healthcare Diagnostics,Deerfield,IL,USA). The intra-assay variations at mean plasma 
levels of  8 and 75nmol/l were 5.0 and 7.5%, respectively. IGF-1 levels were expressed 
as SDS, using lambda-mu-sigma smoothed reference curves based on 906 controls 
(25;26). 
In GHD patients, a Hitachi 747 autoanalyzer (Roche) was used to quantify serum 
concentrations of  glucose, TC, and TG. HDL-C was measured with a homogenous 
enzymatic assay (Hitachi 911,Roche). In 2003, a Roche Modular Analytics P800 replaced 
the Hitachi 747 with no change in the chemistry components. In the general population, 
glucose, TC, HDL-C and TG levels were measured by Roche Modular Analytics P800. 
Samples in patients and controls were analyzed in the same laboratory. Samples of  
patients were obtained between 1994 and 2013; samples of  controls between 2008 and 
2012.
Statistical analysis 
SPSS for Windows, Version 20.0 (SPSS,Inc.,Chicago,IL,USA) was used for statistical 
analysis. Results are presented as mean±SD, unless stated otherwise. For comparison of  
the MS proportion in GHD patients before start and after 5 years of  rGH suppletion, 






we performed the Friedman Test for related fractions. Although 19 patients did not 
complete 5 years of  rGH replacement for various reasons (vide infra), these patients 
were included using the last observation carried forward method (intention-to-treat 
approach), thereby including the last available measurements during rGH replacement 
in the analyses. Independent T tests were used to compare crude metabolic data between 
5-year rGH-treated GHD patients and the general population. The relationships in MS 
(components) proportion between GHD patients after 5 years of  rGH replacement and 
the general population are reported as prevalence ratios (PRs), using the log-binominal 
regression model using STATA Statistical Software version 12.1(Statacorp,College 
Station,TX), allowing direct estimation of  PRs (27;28), which is, because of  the high 
incidence of  the MS, more appropriate than logistic models that only allow estimation 
of  odds ratios. Analyses were adjusted for age and sex, and subsequently with additional 
adjustments for BMI. P<0.05 is considered statistically significant.
RESULTS
Characteristics of patients and controls
We studied 161 adult GHD patients, aged 40-70 years at the time of  GHD diagnosis 
(Table 1). Pituitary deficiency was mainly caused by pituitary tumors or their treatment. 
Patients had been treated with surgery (transsphenoidal N=109/transcranial N=24) 
and radiotherapy (N=76). Etiological diagnoses of  GHD were non-functioning 
adenoma (N=67), functioning adenoma (N=52), craniopharyngeoma (N=12), cerebral 
malignancy (N=2), congenital (N=6) and other causes (N=22). Most patients had 
multiple pituitary hormone deficiencies (ACTH deficiency N=142, TSH deficiency 
N=132, FSH/LH deficiency N=120, ADH deficiency N=27), whereas only 6 patients 
had isolated GHD. Sex steroids were supplemented in 21% of  female patients (N=15) 
and 87% of  male patients (N=77). 
All GHD patients (aged 
40-70 yr) started with 
rhGH replacement  
≤ 2007 from the LUMC 
N=161 
Patients receiving 5 yr 
rhGH replacement 
N=142 
Reasons for discontinuation: 
Death N=5 
No subjective beneficial 
effect N=4 
Side-effects N=3 
Follow-up other center N=2 
Malignancy N=2 
Growth primary tumor N=2 
High PSA N=1 
Discontinued N=19 
Preliminary stop of 
rhGH replacement, for 
various reasons 
FIGURE 1. 
Flow chart of  selection and follow-up of  our middle-aged GHD cohort
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One-hundred forty-two patients completed 5 years of  rGH replacement (Figure 1). 
Reasons for preliminary discontinuation in 19 patients (11.8%) were: death (N=5), 
malignancy (N=2), growth of  primary tumor (N=2), increase in prostate-specific 
antigen (PSA) level (N=1), lack of  subjective benefit (N=4), side-effects: carpal tunnel 
syndrome (N=2), weight increase (N=1), and follow-up in other centers (N=2).
At 5 years of  rGH replacement, GHD patients were compared with 1671 subjects from 
the general population (Table 1). Proportion of  men and mean BMI were higher in 
patients than in the general population (p=0.006 and p<0.001, respectively). 
TABLE 1. CHARACTERISTICS OF 161 MIDDLE-AGED GHD PATIENTS BEFORE THE START AND 
AFTER 5 YR OF RHGH REPLACEMENT AND 1671 CONTROLS REPRESENTING THE GENERAL 
POPULATION
Patient characteristics GHD patients
Before start of  rhGH 
(N = 161)
GHD patients






Sex, female (N(%)) 72 (44.7%) 72 (44.7%) 937(56.1%)*
Age, years 54.7 ± 8.5 
(40 – 70)
59.7 ± 8.5 
(45 – 75)
56.0 ± 6.0 
(45 – 66)*
BMI, kg/m2 (range) 27.5 ± 4.5 
(19.6 – 57.1)
28.0 ± 4.5 
(18.5 – 53.8)
26.3 ± 4.5 
(17.2 – 57.1)*
Lipid-lowering drugs (N(%)) 36 (22.3%) 78 (48.4%) 182 (10.9%)*
Antihypertensive medication 
(N(%))
36 (22.3%) 77 (47.8%) 402 (24.1%)*
Anti-diabetic medication 
(N(%))
8 (5.0%) 14 (8.7%) 52 (3.1%)*
Data are presented as mean ± SD, unless specified otherwise. 
#, The Leiderdorp cohort of  the NEO Study was used as control group representing the general population (20).
*, p<0.05 (Patients after 5 years of  rhGH replacement vs general population).
N, number of  patients; GHD, Growth Hormone Deficiency; rhGH, recombinant human Growth Hormone replacement; 
BMI, body mass index.
GH dose, IGF-1 SDS and hydrocortisone dose during rGH replacement
Mean GH doses after dose titration (1 year) and 5 years of  rGH replacement were, 
respectively, 0.35±0.16mg/day and 0.37±0.19mg/day (p=0.399). After 5 years of  rGH 
replacement, females received higher mean GH doses than males (0.40±0.23mg/day 
and 0.34±0.17mg/day, respectively, p=0.05). 






During the entire period of  rGH suppletion, median of  IGF-1 SDS was within the 
normal range. Median IGF-1 SDS increased significantly from the untreated state from 
to -1.30 (interquartile range (IQR) -2.43, +0.16) to 0.47 (IQR -0.50, +1.93) after 5 years 
of  rGH suppletion (p<0.001). In males, median IGF-1 SDS increased from -1.17 (IQR 
-2.17, +0.92) before treatment to 0.42 (IQR -0.43, +2.03) after 5 years (p<0.001); in 
females, median IGF-1 SDS increased from -1.63 (IQR -3.04, +-0.47) before treatment 
to 0.51 (IQR -0.57, +1.71) after 5 years (p<0.001). 
Mean hydrocortisone doses were 17.43±12.40mg/day and 18.18±10.81mg/day at the 
start and after 5 years of  rGH suppletion, respectively, indicating no significant change 
during follow-up. Mean fT4 levels did not significantly change during 5 years of  rGH 
replacement (16.2±3.7pmol/l at the start and 16.8±3.7pmol/l after 5 years of  rGH).
MS proportion in untreated GHD patients
Before the initiation of  rGH replacement, 66 out of  161 patients fulfilled the NCEP-
ATP III criteria, resulting in an MS proportion of  41.0% in untreated GHD (37.1% in 
males, 45.8% in females). Hyperglycaemia, hypertriglyceridaemia, low HDL-C levels, 
hypertension and abdominal obesity were present in respectively 13.0%, 59.0%, 47.8%, 
68.3% and 35.4% of  the patients.   
Effects of 5 years rGH replacement on the MS proportion in GHD adults
The MS proportion increased significantly from 41.0% before to 53.4% after 5 
years of  rGH replacement (p=0.007), especially due to an increased proportion of  
hyperglycaemia (p=0.02). In males, HDL-C levels decreased significantly (p<0.001). As 
indicated in Figure 2, the increase in MS proportion was most prominent in males (from 
37.1% at the start of  rGH replacement to 53.9% after 5 years, p=0.005). Exclusion 
of  CO-GHD patients (N=6) did not significantly change these results. BMI did not 
significantly change over time, from 27.5±4.5 kg/m2 before rGH replacement to 
28.0±4.5 kg/m2 after 5 years (p=0.772). 
Comparison of MS proportion between GHD patients on chronic rGH 
replacement and the general population, adjusted for age and sex (Table 2)
In the general population, we observed an MS proportion of  30.3%. The MS proportion 
in chronically treated GHD patients was increased when compared to controls, 
taking into account age and sex (53.4% vs. 30.3%) (adjusted PR (95%CI) = 1.4(1.1-
1.6), p=0.001) (Table 2B). For clinical interpretation, mean laboratory values were also 














































































Proportion of  MS (components) in adult GHD patients, before the initiation of  rGH replacement and after 5 years, in 
comparison to the general population, separated for females and males
We studied the MS proportion and its individual components in: (1) 5-year treated GHD patients in comparison to 
situation before the start of  rGH replacement, using the Friedman test for related fractions; and (2) between GHD 
patients after 5 years of  rGH replacement compared to the general population, using a log-binominal regression model 
with adjustments for age and BMI. Analyses were stratified for sex. MS was defined according to the NCEP-ATP III 
criteria (23;24).
*, p<0.05
TG, triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; waist, waist circumference; MS, 
metabolic syndrome; rGH, recombinant human Growth Hormone. 






Comparison of MS proportion between GHD patients after 5 years of rGH 
replacement and the general population, additionally adjusted for BMI
After additional correction for BMI, besides age and sex, GHD patients still had a 
1.3-times increased MS proportion when compared to the general population, despite 
5 years of  rGH replacement (adjusted PR (95%CI) = 1.3(1.1-1.5), p=0.008) (Table 
2B). Both in male and female GHD patients, an significant increased MS proportion 
was seen when compared to the general population (Figure 2). When looking at the 
individual MS components, treated GHD patients differed from BMI-matched controls 
with respect to glucose, triglycerides and HDL-C levels (Table 2B).
TABLE 2. A. MEAN VALUES OF THE METABOLIC PARAMETERS OF THE MS AS INCLUDED IN THE 
NCEP-ATP III CRITERIA, IN ADULT GHD PATIENTS BEFORE THE START AND AFTER 5 YEARS OF 
RHGH REPLACEMENT, AND THE GENERAL POPULATION
GHD patients









Fasting glucose (mmol/l) 4.8 ± 0.8** 5.2 ± 1.6* 5.5 ± 1.1
Triglycerides (mmol/l) 2.0 ± 1.2 1.9 ± 0.9* 1.2 ± 0.8
HDL-C (mmol/l) 1.4 ± 0.4** 1.5 ± 0.5# 1.6 ± 0.5
Systolic blood pressure 
(mmHg)
134.0 ± 17.8 135.7 ± 17.6* 130.4 ± 16.9
Diastolic blood pressure 
(mmHg)
83.9 ± 9.3 83.4 ± 9.5 83.4 ± 10.1
Waist circumference (cm) 97.2 ± 11.8 98.6 ± 11.2* 91.2 ± 12.8
Values are expressed as mean ± SD. 
N, number of  patients; rhGH, recombinant human Growth Hormone replacement; GHD, Growth Hormone 
Deficiency; MS, metabolic syndrome; HDL-C, high-density lipoprotein cholesterol.
*, p<0.01; #, p<0.05 (GHD after 5 years rhGH replacement vs the general population).




The present study demonstrates a high MS proportion of  41.0% in middle-aged GHD 
patients before the start of  treatment, which further increases to 53.4% after 5 years of  
rGH replacement. Especially a higher proportion of  hyperglycaemia contributed to this 
increase, whereas the lipid profile was not affected. Despite chronic rGH replacement, 
GHD patients still have a 1.3-times increased MS proportion when compared to the 
general population, independently of  age, sex and BMI. GHD patients remain to have 
a different metabolic profile, characterized by hypertriglyceridaemia and low HDL-C, 
whereas the proportion of  hyperglycaemia is lower than that observed in the general 
population. 
In middle-aged GHD patients, the increased cardiovascular risk profile is a main 
justification of  rGH replacement. Important components of  this risk are dyslipidemia, 
manifesting as raised levels of  LDL-C and triglycerides, and reduced HDL-C levels (29). 
In addition, increased fat mass, reduced insulin sensitivity, and increases in inflammatory 
TABLE 2. B. COMPARISON OF MS PROPORTION, ACCORDING TO THE NCEP-ATP III CRITERIA, 







PR (95%CI)1 PR (95%CI)2
Fasting glucose 37 / 161 
(23.0%)
539 / 1663 
(32.4%)
0.5 (0.4 – 0.7)* 0.5 (0.4 – 0.7)*
Triglycerides 106 / 161 
(65.8%)
427 / 1666 
(25.6%)
2.0 (1.7 – 2.4)* 2.0 (1.7 – 2.3)*
HDL-C 92 / 161 
(57.1%)
418 / 1666 
(25.1%)
2.0 (1.7 – 2.3)* 1.8 (1.5 – 2.2)*
Blood pressure 109 / 161 
(67.7%)
1054 / 1668 
(63.2%)
0.9 (0.8 – 1.0) 0.9 (0.8 – 1.1)
Waist 69 / 161 
(42.9%)
597 / 1669 
(35.8%)
1.1 (0.9 – 1.4) 1.0 (0.8 – 1.3)
Metabolic 
syndrome
86 / 161 
(53.4%)
503 / 1660 
(30.3%)
1.4 (1.1 – 1.6)* 1.3 (1.1 – 1.5)*
Values are expressed as number (percentage). Chronic rhGH replacement was defined as 5 years. MS was defined 
according to the NCEP-ATP III criteria (23;24). Log-binominal regression models were applied with robust standard 
errors, allowing direct estimations of  PRs adjusted for age and sex, and, subsequently, with additional adjustments for 
BMI. N, number of  patients; rhGH, recombinant human Growth Hormone replacement; GHD, Growth Hormone 
Deficiency; HDL-C, high-density lipoprotein cholesterol; waist, waist circumference; BMI, body mass index; PR, 
prevalence ratio; 95%CI, 95% confidence interval. RR1, adjusted for age and sex. RR2, adjusted for age, sex and BMI.
*, p<0.01.






markers are often present (29;30). Mortality is substantially higher in GHD adults than 
in general population, particularly among women (1;2). RGH replacement has beneficial 
metabolic effects in the short-term, including improvement in the lipid profile, body 
composition and cardiac function (3), which were reported to be sustained during 
longer follow-up (14;18), although glucose and insulin levels increase. However, despite 
improvement of  several cardiovascular risk factors, MS prevalence remains increased 
(4;5;19). Obvious limitations of  the few available long-term studies are the lack of  an 
untreated GHD control population and difficulties with physiological rGH replacement. 
This study is the first to investigate the metabolic profile of  chronically treated GHD 
patients in a controlled manner, taking into account not only age and sex, but also 
BMI. In this respect, the Leiderdorp cohort represents the general population with 
comparable BMI distribution to that observed in other Dutch population-based studies 
(http://www.rivm.nl/nldemaat.rivm.2012). We demonstrated that, independent of  
BMI, chronically treated GHD patients have a persistently different metabolic profile 
than the general population, with a lower prevalence of  insulin resistance, but an 
adverse lipid profile. It is remarkable that although this GHD cohort is thought to be 
adequately substituted, as reflected by mean IGF-1 SDS within the physiological range 
as well as no hydrocortisone oversubstitution, the metabolic profile after chronic rGH 
replacement resembles the profile of  an untreated GHD patient, with predominantly 
lipid abnormalities. Additional analyses in which we compared the GHD patients before 
starting rGH replacement with general population show similar results, suggesting that 
the metabolic profile is not significantly influenced by long-term rGH replacement (data 
not shown).  
These findings give rise to several questions. First, there is an increasing awareness of  
intrinsic imperfections of  endocrine replacement therapy in general (31), that may also 
well apply to GHD patients. It is questioned whether circulating total IGF-1 levels truly 
reflect peripheral IGF-1 activity, since several earlier reports indicate that measuring 
free unbound IGF-1 levels and IGF-1 bioactivity better reflect GH/IGF-1 status (32). 
Further study is needed to identify sensitive biomarkers to monitor rGH replacement 
therapy. Second, it is previously shown that there is an optimum for GH dosing with 
respect to insulin resistance (33).In this respect, further lowering of  the GH dose is 
probably needed to minimize insulin resistance. On the other hand, the MS proportion 
in GHD patients remained increased despite chronic rGH replacement, and resembles 
the metabolic profile of  untreated GHD, suggesting that GHD may have irreversible 
effects on the cardiovascular system. In the context of  increasing evidence for, on the 
one hand, a limited or even negative role of  GH and IGF-1 in cancer, longevity and 
cardiovascular disease (34-36), and, on the other hand, the limited evidence for benefit 
of  rGH substitution in the elderly GHD population and long-term positive effects on 
QoL (37), long-term rGH use in GHD adults should be critically re-evaluated. Third, 
we cannot exclude co-existing hypothalamic damage, especially in case of  a history of  
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large tumors with suprasellar extension (38). Obesity is a well-recognized complication 
in patients treated for tumors in the hypothalamic-pituitary region, which is attributed 
to compression of  surrounding tissues (39). This hypothalamic damage could be an 
independent factor influencing the metabolic profile in GHD patients. Finally, most 
patients had multiple pituitary hormone deficiencies, making distinction between 
effects of  rGH replacement or effects of  suboptimal or excessive replacement therapy 
of  other hormones difficult.
Several validated definitions can be applied for the definition of  the MS, precluding 
direct comparisons between studies (40). We used the NCEP-ATP III criteria (23;24) 
to be comparable to our previous studies on MS (5;19). In the NCEP-ATP III criteria, 
the use of  antihypertensive, anti-diabetic and lipid-lowering medication is incorporated. 
In the original description of  the NCEP-ATP III criteria, statins are not specifically 
mentioned. However, the lipid-lowering effects of  statins are well-established in the 
general population, and thereby significantly influencing the lipid criteria of  the MS 
(41). 
We found sex-specific differences in MS proportion and the metabolic response to rGH 
replacement. In untreated GHD females, MS proportion was very high compared to 
the general population. This might be in line with a recent report of  Van Bunderen et 
al., describing an increased risk of  cardiovascular death in GHD females, despite rGH 
substitution (42). The increased incidence in cardiovascular deaths in females might 
partly be attributed to the more atypical presentation of  cardiovascular diseases (43) or 
inadequately substituted hypogonadism causing preterm menopause or hypocortisolism. 
The most predominant increase of  the MS proportion during rGH replacement in 
males further supports that the cardiovascular risk pattern in GHD patients is sex-
specific. 
When compared to other population-based control cohorts, such as the MORGEN 
cohort (1993-1997) or the Tromsø Study (1994-1995) (44), the MS proportion 
found in the Leiderdorp cohort was nearly doubled (30.3% in Leiderdorp cohort vs 
15.7% in MORGEN cohort and 19.2% (males) and 17.8% (females) in the Tromsø 
Study) (5). Since the same criteria for MS were applied, we expect that this increase 
in MS proportion most likely reflects the increase in BMI and an increased use of  
antihypertensive medication in the general population over 15 years, and emphasizes 
the importance for a contemporary comparison group from the general population.
A strength of  the present study is the availability of  large recent population-based 
control data and the inclusion of  analysis on the crude metabolic laboratory data in 
addition to the age-, sex, and BMI-adjusted analysis using the NCEP-ATP III criteria 
of  MS. Our relatively large middle-aged GHD cohort reflects the best-case scenario 
in which hormonal suppletion of  all pituitary axes is optimalized and adequately 
monitored. A potential limitation could be the fact that we evaluated the MS proportion 






in the untreated GHD situation only in patients in whom rGH replacement was 
actually initiated. This could introduce a selection bias, since GHD patients without 
receiving rGH replacement are likely to differ from patients that actually received rGH 
replacement. Second, it has to be noted that the patients in our GHD cohort are very 
heterogeneous with respect to the cause of  GHD, failure of  other pituitary hormone 
axes and history of  cranial irradiation and/or surgery, which may have influenced the 
results. Third, we only reported the metabolic parameters included in the MS according 
to the NCEP-ATP III criteria, not for example LDL-C or body fat percentages, which 
are also GH-dependent parameters. Another feature that needs to be addressed is 
the presence of  interactions between glucocorticoids and rGH during substitution. 
In the past, hydrocortisone suppletion in hypopituitary patients frequently resulted 
in supraphysiological cortisol levels, which accounted for at least part of  the adverse 
metabolic profile in these patients. However, since most patients received hydrocortisone 
doses of  20 mg/day or less during the entire follow-up period and cortisol levels were 
highly monitored, we expect that in our cohort hydrocortisone oversuppletion is not 
likely to have negatively influenced the results. In this respect, it has also be noted 
that minor thyroid dysfunction and insufficient thyroid replacement has a significant 
independent negative impact on cardiovascular risk factors in hypopituitary adults (45), 
further emphasizing the importance of  adequate hormonal suppletion of  all deficient 
pituitary axes. In addition, it would be ideally preferred to include a longitudinally follow-
up control group for comparison; however, such a control group was not available in 
the Netherlands. Finally, it has to be noted that a priori GHD patients are more likely 
to receive anti-diabetic and/or lipid-lowering medication than controls in case of  lipid 
and/or glucose abnormalities, since these patients are regularly followed up at the Dept. 
of  Endocrinology, which is not the case for controls without a history of  pituitary 
disease. 
In conclusion, despite 5 years of  rGH replacement, GHD patients still have a different 
metabolic profile and a higher MS proportion than the general population. These 
differences were independent of  BMI, and resemble the metabolic profile of  untreated 
GHD patients. This emphasizes the need for further study to establish whether rGH 
replacement is actually beneficial in the long-term, adequately incorporating the cost-
effectiveness, QoL, and the potential negative effects of  GH/IGF-1 on cancer, longevity 
and cardiovascular risk.
ACKNOWLEDGEMENTS
We would like to thank Dr. N. van Duinen, Dr. N.E. Kokshoorn, Dr. A.A. van der 
Klaauw, E. de Lange and D.M.M.M. Adoptie for their help with the data collection of  
GHD patients during the yearly GH control visits at the outpatient clinic.
Chapter 6
136
In addition, we would like to thank the NEO Study Group, the NEO research team, 
and participants of  the NEO Study. The NEO Study is supported by the participating 
Departments, the Division and the Board of  Directors of  the Leiden University Medical 
Centre, and by the Leiden University, Research Profile Area ‘Vascular and Regenerative 
Medicine’.







1. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 
1990;336:285-288.
2. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart 
PM. Association between premature mortality and hypopituitarism. West Midlands Prospective 
Hypopituitary Study Group. Lancet 2001;357:425-431.
3. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of  growth hormone 
(GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of  Blinded, 
Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004;89:2192-2199.
4. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P. 
Prevalence of  metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients 
before and after GH replacement. J Clin Endocrinol Metab 2010;95:74-81.
5. van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, 
Romijn JA, Pereira AM. The prevalence of  the metabolic syndrome is increased in patients with GH 
deficiency, irrespective of  long-term substitution with recombinant human GH. Eur J Endocrinol 
2007;156:455-462.
6. Cenci MC, Conceicao FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M. 
Impact of  5 years of  growth hormone replacement therapy on cardiovascular risk factors in growth 
hormone-deficient adults. Metabolism 2008;57:121-129.
7. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff  B, 
Murphy M, Thomas E, Robinson S, Foale R, Johnston DG. Effects of  7 years of  growth hormone 
replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000;85:3762-3769.
8. Elbornsson M, Gotherstrom G, Bosaeus I, Bengtsson BA, Johannsson G, Svensson J. Fifteen years 
of  GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH 
deficiency. Eur J Endocrinol 2012;166:787-795.
9. Giavoli C, Porretti S, Ronchi CL, Cappiello V, Ferrante E, Orsi E, Arosio M, Beck-Peccoz P. Long-
term monitoring of  insulin sensitivity in growth hormone-deficient adults on substitutive recombinant 
human growth hormone therapy. Metabolism 2004;53:740-743.
10. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon 
F, Sonksen PH, Russell-Jones D. The effects of  10 years of  recombinant human growth hormone 
(GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999;84:2596-2602.
11. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G. A 
prospective study of  5 years of  GH replacement therapy in GH-deficient adults: sustained effects on 
body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86:4657-4665.
12. Gotherstrom G, Bengtsson BA, Sunnerhagen KS, Johannsson G, Svensson J. The effects of  five-
year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients. Clin 
Endocrinol (Oxf) 2005;62:105-113.
13. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. Ten-year GH replacement 
increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J 
Endocrinol 2007;156:55-64.
14. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective 
study of  the metabolic effects of  growth hormone replacement in adults. J Clin Endocrinol Metab 
2007;92:1442-1445.
15. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. 
Ten years of  growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. 
J Clin Endocrinol Metab 2009;94:809-816.
Chapter 6
138
16. Roemmler J, Kuenkler M, Schneider HJ, Dieterle C, Schopohl J. Comparison of  glucose and lipid 
metabolism and bone mineralization in patients with growth hormone deficiency with and without 
long-term growth hormone replacement. Metabolism 2010;59:350-358.
17. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of  seven years of  GH-
replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 
2002;87:2121-2127.
18. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van DJ, Dekkers OM, Roelfsema F, Pereira 
AM. Sustained effects of  recombinant GH replacement after 7 years of  treatment in adults with GH 
deficiency. Eur J Endocrinol 2006;155:701-708.
19. Claessen KM, Appelman-Dijkstra NM, Adoptie DM, Roelfsema F, Smit JW, Biermasz NR, Pereira 
AM. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant 
human growth hormone (rGH) therapy. J Clin Endocrinol Metab 2013;98:352-361. doi:jc.2012-2940 
[pii];10.1210/jc.2012-2940 [doi].
20. de Mutsert R, den Heijer M, Rabelink AJ, Smit JWA, Romijn JA, Rabe KF, Jukema JW, de Roos A, 
le Cessie S, Middeldorp, Rosendaal. The Netherlands Epidemiology of  Obesity (NEO) Study: study 
design and data collection.
21. Janssen YJ, Frolich M, Roelfsema F. A low starting dose of  genotropin in growth hormone-deficient 
adults. J Clin Endocrinol Metab 1997;82:129-135.
22. Ghigo E, Aimaretti G, Corneli G. Diagnosis of  adult GH deficiency. Growth Horm IGF Res 
2008;18:1-16.
23. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of  metabolic syndrome: 
Report of  the National Heart, Lung, and Blood Institute/American Heart Association conference on 
scientific issues related to definition. Circulation 2004;109:433-438.
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, 
Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of  the metabolic syndrome: 
an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Circulation 2005;112:2735-2752.
25. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990;44:45-
60.
26. Rikken B, van DJ, Ringeling A, Van den Brande JL, Massa G, Wit JM. Plasma levels of  insulin-like 
growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of  childhood growth 
hormone deficiency. Horm Res 1998;50:166-176.
27. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J 
Epidemiol 2004;159:702-706.
28. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of  cross 
sectional data: what is to be done? Occup Environ Med 1998;55:272-277.
29. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients 
with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:195-200.
30. Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen 
activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 1994;14:434-437.
31. Romijn JA, Smit JW, Lamberts SW. Intrinsic imperfections of  endocrine replacement therapy. Eur J 
Endocrinol 2003;149:91-97.
32. Varewijck AJ, Lamberts SW, Uitterlinden P, Hofland LJ, Janssen JA. IGF-I bioactivity better 
reflects growth hormone deficiency than total IGF-I. J Clin Endocrinol Metab 2011;96:2248-2254. 
doi:jc.2011-0051 [pii];10.1210/jc.2011-0051 [doi].






33. Brugts MP, van Duijn CM, Hofland LJ, Witteman JC, Lamberts SW, Janssen JA. Igf-I bioactivity in an 
elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome. Diabetes 
2010;59:505-508. doi:db09-0583 [pii];10.2337/db09-0583 [doi].
34. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of  metabolic pathways in aging. 
Diabetes 2012;61:1315-1322.
35. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, 
Woodmansee WW, Cutler GB, Jr., Chipman JJ, Melmed S. Prospective safety surveillance of  
GH-deficient adults: comparison of  GH-treated vs untreated patients. J Clin Endocrinol Metab 
2013;98:980-988. doi:jc.2012-2684 [pii];10.1210/jc.2012-2684 [doi].
36. Rozing MP, Westendorp RG, Frolich M, de Craen AJ, Beekman M, Heijmans BT, Mooijaart SP, Blauw 
GJ, Slagboom PE, van HD. Human insulin/IGF-1 and familial longevity at middle age. Aging (Albany 
NY) 2009;1:714-722.
37. Kokshoorn NE, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA. GH replacement 
therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 2011;164:657-665.
38. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev 2006;27:371-397. 
doi:er.2006-0002 [pii];10.1210/er.2006-0002 [doi].
39. Iughetti L, Bruzzi P. Obesity and craniopharyngioma. Ital J Pediatr 2011;37:38. doi:1824-7288-37-38 
[pii];10.1186/1824-7288-37-38 [doi].
40. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of  cardiovascular 
disease in non-diabetic subjects--a population-based study comparing three different definitions. 
Diabet Med 2007;24:464-472. doi:DME2142 [pii];10.1111/j.1464-5491.2007.02142.x [doi].
41. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical 
benefit: impact of  statin trials. Circulation 1998;97:946-952.
42. van Bunderen CC, van N, I, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely 
AJ, Drent ML. Does growth hormone replacement therapy reduce mortality in adults with growth 
hormone deficiency? Data from the Dutch National Registry of  Growth Hormone Treatment in 
adults. J Clin Endocrinol Metab 2011;96:3151-3159.
43. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle 
KA. Sex-related differences in the presentation, treatment and outcomes among patients with acute 
coronary syndromes: the Global Registry of  Acute Coronary Events. Heart 2009;95:20-26.
44. Herder M, Arntzen KA, Johnsen SH, Mathiesen EB. The metabolic syndrome and progression of  
carotid atherosclerosis over 13 years. The Tromso study. Cardiovasc Diabetol 2012;11:77. doi:1475-
2840-11-77 [pii];10.1186/1475-2840-11-77 [doi].
45. Klose M, Marina D, Hartoft-Nielsen ML, Klefter O, Gavan V, Hilsted L, Rasmussen AK, Feldt-
Rasmussen U. Central hypothyroidism and its replacement have significant influence on cardiovascular 
risk factors in adult hypopituitary patients. J Clin Endocrinol Metab 2013;98:9. doi:10.1210/jc.2013-
1610.

Natasha M. Appelman-Dijkstra, Kim M.J.A. Claessen, 
Neveen A.T. Hamdy, Alberto M. Pereira en Nienke R. Biermasz
Clin Endo 2014 Nov;81(5):727-35.
Chapter 7
Effects of up to 15 years treatment with recombinant 
human GH (rGH) on bone metabolism of adults with 
Growth Hormone Deficiency (GHD): 




Background: Growth Hormone Deficiency (GHD) in adulthood is associated with 
a decreased bone mineral density (BMD), a decreased bone mineral content (BMC) 
and an increased fracture risk. Recombinant human GH (rGH) replacement induces 
a progressive increase in BMD under up to 5-7 years of  treatment. Data on longer 
follow-up are however scarce. 
Methods: Two-hundred and thirty adult GHD patients (mean age 47.1 years, 52.6% 
female) receiving rGH replacement for ≥5 years were included in the study. Bone 
turnover markers, BMC and BMD and T-scores at the lumbar spine and femoral neck 
were evaluated at baseline, and after 5, 10 and 15 years of  rGH supplementation. In 
addition, clinical fracture incidence was assessed. 
Results: Mean lumbar spine BMD gradually increased during long-term rGH replacement 
therapy (p=0.002). Lumbar spine BMC and T-scores increased during the first 10 
years of  rGH replacement, but remained stable thereafter. Largest effects of  rGH 
supplementation were found in men. Use of  bisphosphonates did not impact additional 
beneficial effects in the long-term. Low baseline BMD and high GH dose at 1 year 
significantly affect the change in BMD and BMC over time. Clinical fracture incidence 
during long-term rGH supplementation was 20.1 / 1000 py.
Conclusions: Fifteen years of  rGH supplementation in GHD adults resulted in a sustained 
increase in BMD values at the lumbar spine, particularly in men. Clinical fracture 
incidence was observed to be similar to the incidence in age- and sex-matched controls 
from general population. 







Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) are important 
regulators of  bone growth and metabolism during the life span (1). IGF-1 mediates 
most of  the effects of  GH on skeletal metabolism via the IGF-1 receptor (2), although 
GH also exerts direct effects on bone (3).GH and IGF-1 act as anabolic hormones on 
bone by stimulating proliferation, and to some extent, differentiation of  osteoblasts. 
Furthermore, osteoclastic bone resorption is stimulated, resulting in an overall increase 
in bone remodeling (3;4). 
Untreated Growth Hormone Deficiency (GHD) is characterized by low bone turnover, 
decreased bone mineral density (BMD) and bone mineral content (BMC) (5-7). 
Recombinant human GH (rGH) replacement therapy was shown to increase bone 
turnover as reflected by an increase in bone formation and bone resorption markers, 
resulting in an initial decline in (or unchanged) BMD, followed by a small increase of  
about 1-2% in the first 2 years of  rGH replacement due to a net positive balance in 
bone formation (3;8). 
Data on the effects of  long-term rGH replacement on BMD are, however, scarce. 
Previous studies reported that rGH supplementation induces a progressive increase 
in BMD and BMC up to 5-7 years of  treatment, which is followed by a plateau phase 
(9-12). Götherström et al. found an increase of  total body and lumbar spine BMD and 
BMC even up to 10 years of  rGH replacement, whereas femoral neck BMD and BMC 
reached a peak value after 5-7 years (13). Only one study reported the effects of  15 
years of  rGH supplementation, showing a sustained increase in total body and lumbar 
BMD and BMC over 15 years, whereas femoral neck BMD and BMC returned towards 
baseline values after 7 years (14). 
The primary aim of  our study was to assess the effects of  5, 10 and 15 years of  
rGH replacement on bone metabolism in a well-characterized cohort of  adult GHD 
patients. In addition, we aimed to identify factors influencing the bone response to rGH 
replacement and we studied the incidence of  clinical fractures during long-term rGH 





Consecutive patients with an established diagnosis of  childhood-onset (CO) or 
adulthood-onset (AO) GHD who were followed up at the Department of  Endocrinology 
and Metabolic Diseases of  the Leiden University Medical Center were collected in a 
database from 1994 onwards. In the present study, we selected all GHD patients who 
started rGH replacement therapy in or before 2007, and, therefore, had the potential to 
receive rGH replacement therapy for ≥5 years. We arbitrarily defined chronic treatment 
as replacement for ≥5 years, since such a period will reflect a stable situation without 
confounding by ongoing changes induced by the start and titration of  rGH replacement 
(15;16). This strategy resulted in a total inclusion of  230 eligible GHD patients, of  
which part of  the included patients has been previously described (17). 
GHD was diagnosed on the basis of  a GH peak response to the Insulin Tolerance Test 
(ITT) <3µg/l (glucose nadir <2.2mmol/l) according to current guidelines or Growth 
Hormone Releasing Hormone/Arginine-test (GHRH/Arg) with BMI-adjusted GH cut-
offs, in case of  contraindications for ITT (18;19). All patients receiving rGH replacement 
during childhood were retested at the time of  transition to the adult outpatient clinic, 
after treatment cessation for >3 months. GHD was treated according to a standardized 
Leiden protocol, in which patients received rGH replacement (Genotropin Pharmacia/
Pfizer, Skokie, IL; Zomacton Ferring, Troy Hills, NJ; or Norditropin Novo Nordisk, 
Princeton, NJ), injected subcutaneously in the evening. GH starting dose was 0.2mg/
day, which was individually adjusted each month in the first half  year to achieve serum 
IGF-1 concentrations within the age-dependent laboratory reference range, aimed at 
SDS between 0 and +2 (i.e. titration phase). When stable plasma concentrations were 
reached, this individualized dose was continued during the entire study period and 
adjusted according to the IGF-1 standard deviation score (SDS). After dose titration, 
patients were evaluated at least yearly at the outpatient clinic, according to a standard 
protocol. 
Adrenocorticotropic hormone (ACTH) deficiency was defined as an insufficient 
increase in cortisol levels (absolute value 0.55mmol/l) after an ITT or a corticotropin-
releasing hormone stimulation test in case of  an ITT could not be performed. Standard 
hydrocortisone replacement was 20 mg divided in 3 doses, individually adjusted 
when necessary. Premenopausal women were classified as gonadotropin-deficient 
when secondary amenorrhea persisted for >1 year. In men, gonadotropin deficiency 
was defined as a testosterone level <8.0nmol/l. Thyroid-stimulating hormone (TSH) 
deficiency was defined as total thyroxine (T4) or free T4 levels below the normal 
laboratory reference range (<10pmol/l). Hypopituitarism was supplemented by 
hydrocortisone, L-thyroxine, testosterone in men, and/or estrogen in combination with 






progestagens (in premenopausal women only) and adequacy of  supplementation was 
regularly controlled and adjusted as required. 
Patients were treated with bone-modifying medication according to the discretion of  
their attending physicians. 
Methods
Data were collected from the patients’ electronic hospital records on the following 
efficacy parameters which were assessed on a yearly basis after establishment of  
diagnosis and start of  treatment at the outpatient clinic:
1. Anthropometric parameters: body weight was measured to the nearest 0.1 kg, and 
body height was measured barefoot to the nearest 0.001 m. BMI was calculated as 
weight in kilograms divided by the square of  height in meters (kg/m2). 
2. Biochemical parameters: data were collected on serum concentrations of  IGF-1, 
GH, TSH, fT4, LH, FSH, estradiol, testosterone and prolactin, which were collected 
after an overnight fast. Serum GH was measured with a sensitive IFMA (Wallac, 
Turku, Finland), specific for the 22 kDA GH protein (detection limit: 0.01µg/l, 
interassay coefficient of  variation (CV): 1.6-8.4% of  0.01-15.38µg/l) from 1992 
onwards. For the conversion of  µg/l to mU/l, multiply by 2.6. Before 1992, GH was 
measured by RIA (Biolab, Serona, Coissins, Switzerland), detection limit: 0.5mU/l, 
with an interassay CV <5%; for the conversion of  µg/l to mU/l, multiply by 2. 
From 1986 to 2005, serum IGF-1 concentrations were determined by RIA (Incstar, 
Stillwater, MN) with a detection limit of  1.5 nmol/l and an interassay CV less than 
11%. IGF-1 is expressed as SD score for age- and gender-related normal levels 
determined in the same laboratory (Janssen et al. JCEM 1997). Since 2005, serum 
IGF-1 concentrations (nmol/l) were measured using an immunometric technique 
on an Immulite 2500 system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). 
The intra-assay variations at mean plasma levels of  8 and 75nmol/l were 5.0 and 
7.5%, respectively. IGF-1 levels were expressed as SDS, using lambda-mu-sigma 
smoothed reference curves based on 906 controls (21;22). 
3. Markers of  bone metabolism: Data on serum creatinine, calcium, albumin, alkaline 
phosphatase, vitamin D, PTH, procollagen type 1 amino-terminal propeptide (P1NP, 
bone formation) and β-crosslaps concentrations (bone resorption) (the latter two 
markers available from 2006 onwards). B-crosslaps and P1NP concentrations were 
measured by an electrochemolumiscent immunoassay with a Modular Analytics 
E-170 system (Roche Diagnostics, Almere, The Netherlands). Vitamin D25OH was 
measured by RIA (Incstar/DiaSorin, Stillwater, MN, USA).
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4. BMD and BMC: Data on BMD and BMC measurements were collected. BMD was 
measured yearly at the lumbar spine (L1-L4) and femoral neck using dual energy 
X-ray absorptiometry (DXA) (Hologic QDR 1000 (until 2008) and Hologic QDR 
4500 (thereafter), Hologic Inc., Waltham, MA, USA) equipped with reference values 
based on the National Health and Nutrition Examination Survey (NHANES III) 
from the time of  start of  rGH replacement onwards. Coefficient of  variation 
of  lumbar spine and femoral neck BMD measurements was 1%. An in-house 
comparison using 300 measurements provided a conversion formula for all Hologic 
1000 measurements which were converted for comparison for the laterly acquired 
Hologic 4500 BMD measurements. BMD T-scores were used to reflect the number 
of  standard deviations (SD) above or below the mean for a healthy age- and sex-
matched adult. World Health Organization (WHO) criteria were used to define 
osteopenia (T-score between -1.0 and -2.5) and osteoporosis (T-score ≤-2.5). BMC 
was measured at the lumbar spine using the same DXA apparatus.
5. Fracture data: Specific information on clinical fractures was retrieved from the 
medical charts. No routine spine radiographs were performed to assess the presence 
of  vertebral fractures; however, additional radiographs were made in case of  height 
loss >3cm or specific complaints at the discretion of  the treating physician. Vertebral 
fractures were defined as clinical fractures (i.e. pain or decrease in height) and/or 
radiographic fractures in case of  available radiographs, defined as the presence of  
Genant≥2(20). 
6. Data on medication use and co-morbidity was also obtained from electronic files.
Statistical analysis 
SPSS for Windows, Version 20.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical 
analysis. Results are presented as mean ± SD, unless stated otherwise. ANOVA repeated 
measurements with Bonferroni correction for multiple comparisons were used to 
compare anthropometric parameters, bone markers, BMD, T-scores and BMC between 
baseline and after rGH treatment. Although 19 patients did not complete 5 years of  
rGH replacement for various reasons (vide infra), these patients were included using the 
last observation carried forward method according to the intention-to-treat approach 
used. In addition, we identified factors influencing the response to long-term rGH 
supplementation on bone by incorporating age, sex, childhood-onset versus adult-onset 
GHD, hydrocortisone use, GH dose, hypogonadism, number of  pituitary deficiencies 
(<2 vs ≥2), bisphosphonate use, baseline Vitamin D levels and baseline BMD values 
in a linear regression model. We repeated the analyses after exclusion of  patients using 
bisphosphonates at any time point during the follow-up period. Finally, we calculated 
the incidence rate of  clinical fractures during rGH replacement. 







Description of patients 
We studied 230 adult GHD patients (202 adulthood-onset (AO) / 28 childhood-onset 
(CO)) of  whom baseline characteristics are shown in Table 1. Pituitary deficiency 
was mainly caused by pituitary tumors or their treatment. Most patients had multiple 
pituitary hormone deficiencies. Two-hundred and eleven patients completed 5 years of  
rGH replacement therapy (Figure 1). Reasons for earlier discontinuation in 19 patients 
(8.3%) were: death (N=5), malignancy (N=2), growth of  primary tumor (N=2), increase 
in prostate-specific antigen (PSA) level (N=1), lack of  subjective benefit (N=4), side-
effects: carpal tunnel syndrome (N=2), weight increase (N=1), and follow-up in other 
centers (N=2). There was no difference between patients completing 5 years of  rGH 
replacement and non-completers with respect to age, sex, pituitary hormone deficiencies 
or co-morbidity. Ninety-eight and 43 patients completed, respectively, 10 and 15 years 
of  rGH replacement.
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All adult GHD patients 
from LUMC started with 
rhGH replacement  
≤2007 
N=230 
Patients receiving ≥5 yr 
rhGH replacement 
N=211 
Reasons for discontinuation 
Death N=5 
No subjective beneficial 
effect N=4 
Side-effects N=3 
Follow-up other center N=2 
Malignancy N=2 
Growth primary tumor N=2 
High PSA N=1 
 
Discontinuation N=19 
Patients receiving ≥10 yr 
rhGH replacement 
N=98 
Patients receiving ≥15 yr 
rhGH replacement 
N=43 
<10yr treatment N=69 
Reasons for discontinuation 
No subjective beneficial 
effect N=10 
Death N=9 
Growth primary tumor N=7 
Malignancy N=12 
High age N=1 




<15yr treatment N=42 
Discontinuation N=13 
Reasons for discontinuation 








Flow chart of selection and follow-up of our adult GHD cohort (N=230)
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With respect to concomitant medication, at baseline, 10 patients (4.3%) received 
bisphosphonates, and, respectively, 84 (36.5%) and 85 patients (37.0%) received 
calcium and Vitamin D supplements. After respectively 5, 10 and 15 years of  rGH 
replacement 28 (12.2%), 19 (19.4%) and 8 (18.6%) patients used bisphosphonates. 
Thirty-eight patients used bisphosphonates at any time point during the study. Mean 
duration of  bisphosphonate use was 6.9 ± 4.3 years. Indications for bisphosphonate use 
TABLE 1. Baseline characteristics of 230 adult GHD patients
Patient characteristics GHD patients
(N = 230)
Sex, female / male (N) 121 / 109
Age at start rhGH replacement, years (range) 47.1 ± 14.9 (15 – 81)
AO / CO (N) 202 / 28
BMI, kg/m2 (range) 27.3 ± 5.1 (16.9 – 57.1)
Etiological diagnosis of  GHD (N)
   NFA
   Functioning adenoma
Craniopharyngeoma
   Cerebral malignancy
   Congenital







Surgery, TS / TC (N) 136 / 38
Radiotherapy (N) 102
Pituitary deficiencies (N)
   TSH
   ACTH









Calcium supplementation (N) 84
Vitamin D supplementation (N) 85
Data are presented as mean ± SD, unless specified otherwise. 
N, number of  patients; GHD, Growth Hormone Deficiency; rhGH, recombinant human Growth Hormone replacement; 
AO, adult-onset GHD; CO, childhood-onset GHD; BMI, body mass index; NFA, non-functioning adenoma; TS, 
transsphenoidal; TC, transcranial; TSH, thyroid stimulating hormone; ACTH, adrenocorticotropic hormone; FSH, 
follicle-stimulating hormone; LH, luteinizing hormone; ADH, anti-diuretic hormone; Vitamin D, vitamin D.






were osteoporosis (N=23), clinical fractures (N=10), osteoporosis and clinical fractures 
(N=8) and other (N=7). Mean age at start of  bisphosphonate-therapy was 52.6 ± 13.5 
years.
GH dose, IGF-1 SDS and hydrocortisone dose during rGH replacement
Mean GH doses after dose titration (i.e. after 1 year) and 5 years of  rGH replacement 
were, respectively, 0.39 ± 0.20 mg/day and 0.43 ± 0.27 mg/day (p=0.016 compared to 
1 yr dose). Mean doses after, respectively, 10 and 15 years of  rGH replacement were 
0.44± 0.26 mg/day (NS compared to 1 yr dose) and 0.39 ± 0.21 mg/day (p=0.041 
compared to 1 yr dose). 
Mean IGF-1 SDS was within the normal range during the entire study period, and 
increased significantly from -1.09 ± 2.46 at baseline to 0.66 ± 2.01 after 5 years and was 
1.24 ± 2.45 after 10 years (both p<0.01 compared to baseline). In males, mean IGF-1 
SDS increased significantly from -0.60 ± 2.21 at baseline to 0.95 ± 1.88 after 5 years 
(p=0<001) and to 1.64 ± 2.57 after 10 years (p=0.011). In females, mean IGF-1 SDS 
increased significantly from -1.73 ± 2.63 at baseline to 0.35 ± 2.11 after 5 years of  rGH 
replacement (p<0.001) and to 0.83± 2.29 after 10 years (p=0.003) (Figure 2). 
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 Mean hydrocortisone doses were 24.1 ± 7.3 mg/day, 21.4 ± 4.10 mg/day 
and 21.1 ± 4.3 mg/day at baseline, after 10 and after 15 years of  rGH replacement, 
respectively, indicating no change in hydrocortisone dose during rGH replacement.
Biochemical bone markers
Baseline calcium and Vitamin D levels were, respectively, 2.40± 0.24 mg/dL and 60.3 ± 
26.7 nmol/L. After 5 years, mean calcium and Vitamin D levels were 2.40 ± 0.11 mg/
dL (NS compared to baseline) and 63.3 ± 24.5nmol/L (p=0.02 compared to baseline), 
respectively, and 2.39 ± 0.26 mg/dL and 61.8 ± 26.0nmol/L (both NS compared to 
baseline) after 10 years of  rGH replacement. 
At baseline, P1NP and β-crosslaps concentrations were only available in 12 and 30 
patients and were therefore not reported. After 5 years or rGH replacement, mean 
P1NP and β-crosslaps concentrations were 45.3 ± 26.6 ng/mL and 0.42 ± 0.24ng/mL, 
respectively, and 48.4 ± 25.4 ng/mL and 0.71 ± 2.19ng/mL after 10 years. After 15 years 
of  rGH replacement, mean P1NP and β-crosslaps concentrations were 42.1± 24.7 ng/
mL and 0.37± 0.20ng/mL. These data indicate normal bone turnover throughout the 
entire study period.
BMC and BMD
Mean height, weight and BMI at the different time points during rGH replacement 
are shown in Table 2. Mean lumbar spine BMD gradually increased during 15 years of  
rGH replacement, from 0.98± 0.15 g/cm2 at baseline to 1.02 ± 0.14 g/cm2 after 15 
years (p=0.002) (Table 2). After 15 years of  rGH supplementation, mean lumbar spine 
BMD was 4% above the baseline value. Mean lumbar spine T-scores increased during 
the first 10 years of  rGH replacement from -0.69 ± 1.30 to -0.43 ± 1.33 (p<0.001), and 
then stayed at a constant level. Lumbar spine BMC increased throughout the first 10 
years of  rGH replacement being 4% above the baseline level after 10 years (from 63.2 
± 15.4 kg to 65.8 ± 18.0 kg), and then reached a plateau. Similar results were obtained 
after stratification for bisphosphonate use, indicating that in the long-term there was no 
beneficial effect impacted from additional bisphosphonate use (Figure 3). 
 Left femoral neck BMD did not change during 15 years of  rGH replacement 
(Table 2), also after exclusion of  patients with additional bisphosphonate therapy. 
Osteopenia and osteoporosis
At baseline, 29.1% and 31.7% of  the patients has osteopenia (T-score <-1.0SD) in 
the lumbar spine and femoral neck, respectively. After 10 years of  rGH replacement, 
37.8% of  the patients has osteopenia at the lumbar spine and 35.7% at the femoral 






neck. The patients with persisting osteopenia at the femoral neck and/or lumbar spine 
at the study end, were older (68.5yr vs 59.2 yr, p=0.014) and included more females 
(66.7% vs 46.7%, although NS). No differences were found with respect to 1 year GH 
dose or number of  pituitary deficiencies between patients with and without persisting 
osteopenia and/or osteoporosis at the study end. 
At baseline, 11 GHD patients (4.8%) had osteoporosis at the lumbar spine (4 females, 
7 males), with a mean age of  54.1 ± 15.2 yr. Six of  these patients used bisphosphonates 
and respectively 7 and 5 patients had calcium and Vitamin D supplementation. 
Seventeen patients (7.4%) had baseline osteoporosis at the femoral neck (7 females, 
10 males), of  whom nine patients used bisphosphonates, 11 calcium and 9 Vitamin D 
supplementation. In this small subgroup of  patients with osteoporosis, no change in 
femoral neck BMD was found during rGH supplementation. However, lumbar spine 
BMD increased during the first 5 years of  rGH supplementation, without a further 
increase afterwards. After 10 years of  rGH supplementation, osteoporosis was found 
in, respectively, 7.1% and 1.1% of  patients at the femoral neck and the lumbar spine.
TABLE 2. Effects of 15 years of rhGH replacement in 230 adults with GHD on BMC, BMD and T-scores 




















































Statistical analyses were done by performing a Repeated Measurements ANOVA. To take into account multiple testing, 
p<0.01 was considered statistically significant. 
N, number of  patients on rhGH replacement at different time points; rhGH, recombinant human Growth Hormone; 
GHD, Growth Hormone Deficiency; BMC, bone mineral content; BMD, bone mineral density; DXA, dual energy X-ray 
absorptiometry; BMI, body mass index; SD, standard deviation. 
*, p<0.01 (versus baseline)




Mean GH dose was significantly higher in women compared to men for the first 10 
years of  rGH replacement, resulting in a higher GH dose/IGF-1 SDS ratio in female 
GHD patients. After 5 years of  rGH treatment, mean GH dose in men and women 
was respectively 0.37 ± 0.26 mg/day and 0.49 ± 0.28 mg/day (p=0.001) and at 10 years 
respectively 0.36 ± 0.18 mg/day and 0.53 ± 0.30 mg/day (p=0.001).
 Men had a greater increase in lumbar spine BMD at all time points (p<0.01 
compared to baseline), however not in femoral neck BMD (Figure 3A+3B). These data 
were similar between patients with and without bisphosphonate use (Figure 4A-D). 
Similar sex differences, with highest response to rGH replacement in men, were seen 
Figure  3.  Sex  differences  in  the  effects  of  15  years  of  rhGH  replacement  in  230  adult  GHD  






Data	  are	  presented	  as	  mean	  BMD	  values	  (g/cm2),	  stratified	  by	  sex.	  Vertical	  bars	  indicate	  SEM	  
values.	  Men	  had	  a	  greater	  increase	  in	  lumbar	  spine	  BMD	  than	  women	  at	  all	  time	  points	  when	  
compared	  to	  baseline	  (all	  p<0.001).	  
rhGH,	  recombinant	  human	  Growth	  Hormone	  therapy;	  GHD,	  Growth	  Hormone	  Deficiency;	  BMD,	  
bone	  mineral	  density;	  SEM,	  standard	  error	  of	  the	  mean.	  
*,	  p<0.001	  (versus	  baseline)	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FIGURE 3. Sex differences in the effects of 15 years of rhGH replacement in 230 adult GHD patients on 
lumbar (L1-L4) spine BMD (A) and left f moral eck BMD (B)
Data are presented as mean BMD values (g/cm2), stratified by sex. Vertical bars indicate SEM values. Men had a greater 
increase in lumbar spine BMD than women at all time points when compared to baseline (all p<0.001).
rhGH, recombinant human Growth Hormone therapy; GHD, Growth Hormone Deficiency; BMD, bone mineral 
density; SEM, standard error of  the mean.
*, p<0.001 (versus baseline)






for lumbar spine BMC. Also in lumbar spine T-scores highest increase was seen in men 
after 10 and 15 years of  rGH replacement, although this was not shown for femoral 
neck T-scores (data not shown).
FIGURE 4. BMD changes during 15 years of rhGH replacement at the lumbar spine and the left femoral 
neck, stratified for the use of bisphosphonates in male (A) and female GHD adults (B)
Data are presented as mean BMD values (g/cm2), stratified by the use of  bisphosphonates. Vertical bars indicate SD 
values. 
rhGH, recombinant human Growth Hormone therapy; GHD, Growth Hormone Deficiency; BMD, bone mineral 
density; SD, standard deviation.
*, p<0.01 (versus baseline)
Figu e  4.  BMD  changes  during  15  years  of  rhGH  replacement  at  the  lumbar   pine  and  the  
left  femoral  neck,  stratified  for  the  use  of  bisphosphonates  in  male  (A)  and  female  GHD  






Data	  are	  presented	  as	  mean	  BMD	  values	  (g/cm2),	  stratified	  by	  the	  use	  of	  bisphosphonates.	  
Vertical	  bars	  indicate	  SD	  values.	  	  
rhGH,	  recombinant	  human	  Growth	  Hormone	  therapy;	  GHD,	  Growth	  Hormone	  Deficiency;	  BMD,	  
bone	  mineral	  density;	  SD,	  standard	  deviation.	  
*,	  p<0.01	  (versus	  baseline)	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Other potential influencing factors 
Subsequently, we identified factors influencing the response to rGH replacement on 
BMD and BMC, in GHD females and males. GH dose at 1 year, low Vitamin D levels, 
hydrocortisone use, use of  bisphosphonates, presence of  ≥2 pituitary or hypogonadism 
were not found to influence the effects of  rGH replacement on femoral neck BMD, 
lumbar spine BMD or BMC. A lower baseline lumbar BMD was found to be associated 
with a higher increase in lumbar BMD during 15 years of  rGH replacement, in both 
sexes. Bone response to rGH replacement did not differ between patients with a history 




When incorporating all factors in a linear regression model, we found only higher GH 
dose at 1 year was associated with a decreased response to rGH on BMC over 15 years. 
No other influencing factors were found.
Fracture data 
Twenty-three patients (10%, 11 females / 12 males) had a history of  clinical fractures, 
of  which 12 patients had fractures at ≥2 sites. Fifteen patients had vertebral fractures 
(10 patients had ≥2 fractures) and 9 patients suffered from non-vertebral fractures (hip 
N=6 (2 patients bilateral hip fracture), toe N=2, clavicula N=1). Consequently, the 
incidence rate of  fractures during rGH replacement was 46 / 2288.5 (mean duration of  
rGH therapy 9.95 years x 230 patients) = 20.1 / 1000 py in our GHD cohort.
DISCUSSION
The present study describes the long-term effects of  rGH replacement on bone 
metabolism in a well-defined cohort of  adult patients with GHD. We found a sustained 
increase in BMD at the lumbar spine, but not at the femoral neck, during 15 years of  
rGH replacement. In addition, lumbar spine BMC and T-scores increased during the 
first 10 years of  rGH replacement, but remained stable thereafter. At all time points, 
the largest effects of  rGH supplementation on lumbar spine BMD and BMC were 
observed in men. Use of  bisphosphonates did not impact additional beneficial effects 
beyond an initial early effect (34-35). With respect to potential influencing factors, lower 
baseline BMD and high GH dose at 1 year significantly influenced the bone response 
to 5, 10 or 15 years of  rGH replacement. Clinical fracture incidence during long-term 
rGH supplementation was 20.1 / 1000 py.
GH and IGF-1 are important anabolic hormones. Most of  the effects of  GH are 
mediated by systemic and/or local IGF-1, enhancing the differentiated function of  
osteoblasts and bone formation, although GH may also act directly on bone cells(1). On 
the other hand, IGF-1 induces receptor activator of  nuclear factor kB ligand (RANK-L) 
synthesis and thereby osteoclastogenesis. In contrast to IGF-1, GH stimulates the 
production of  osteoprotegerin, which competes with the RANK-L receptor and 
impairs osteoclastogenesis(2). Untreated GHD in adults is characterized by low bone 
turnover, decreased BMD and BMC(5-7), which was shown to be increased or even 
normalized by short-term rGH replacement(3;5;8). We have previously shown that 
also excessive GH production, as found in patients with acromegaly, is associated with 
increased fracture risk despite normal or high BMD, which is likely to be due to altered 
bone quality(23). These data indicate that there is a U-shaped association between GH/
IGF-1 levels and bone quality/quantity.






We have previously shown a significant increase in BMD after 2 years of  low physiological 
dose of  rGH in GHD adults(33) that sustained after 7 years of  treatment(34). In 
addition, during the first 4 years of  rGH supplementation, a significant greater increase 
in BMD was found in GHD patients with osteoporosis with additional bisphosphonate 
treatment(34). These additional beneficial effects of  bisphosphonates were maintained 
during another 3 years of  rGH supplementation(35). In the present study investigating 
skeletal effects of  15 years of  rGH replacement therapy, we observed a sustained increase 
of  lumbar spine BMD in the long-term, but not femoral neck BMD. These results are 
in line with previous reports showing sustained increase in BMD during 5-10 years of  
rGH replacement with a peak value after 5-7 years of  rGH replacement(10;12-14). 
When stratifying analyses for sex, lumbar spine BMD increases in both sexes during 
the first 5 years of  rGH replacement. Afterwards, a further increase in BMD was 
observed in males, whereas in females the BMD decreased towards baseline values. 
Gender-specific differences in the bone response to rGH supplementation were also 
demonstrated in several other studies, in which rGH effects were also only found in 
males(24;25). It has been suggested that the lack of  GH treatment effect on BMD in 
females with adult GHD may be due to the inhibition of  the effect of  GH on IGF-1 
production by orally administered estrogens(26;27) or by inhibiting direct actions of  
GH on both osteoblasts and osteoclasts by estrogen(3). Differences in bone structure 
between males and females may also contribute to the gender-specific bone response to 
rGH supplementation.
Literature on fracture risk in adult GHD patients treated with rGH supplementation 
is scarce and, to date, only three studies have addressed fracture risk during rGH 
supplementation. Holmer et al. studied clinical fracture incidence in 832 rGH-treated 
patients compared to 2581 matched healthy controls and reported a two-fold increase 
in fracture risk in CO-GHD women, although in AO-GHD men fracture risk was 
significantly lowered. No increased risk was found in AO-GHD women and CO-GHD 
men(28). Elbornsson et al. reported clinical fractures in a Swedish cohort of  GHD 
adults, and observed only 1 hip fracture and 1 symptomatic vertebral fracture (14). 
Mazziotti et al. reported a high prevalence of  radiographic vertebral fractures of  53.8% 
in rGH-treated GHD adults when compared to a prevalence of  78.6% in untreated 
GHD patients(29), indicating that rGH supplementation is able to decrease fracture 
risk in adult GHD patients. In our cohort of  especially AO-GHD patients, 10% of  
patients sustained clinical fractures during rGH replacement, resulting in an incidence 
rate of  fractures of  20.1 / 1000py during rGH supplementation. This a incidence rate is 
comparable to the incidence rate in the general population, as described by Donaldson 
et al. among a middle-aged population in England, showing a fracture incidence rate of  
36 / 1000py(30). Taking into account the younger age of  our cohort, our data do not 
suggest that fracture incidence is increased in rGH-treated AO-GHD patients. 
Chapter 7
156
Our study has strengths as well as limitations. Its main strength is the size of  our 
cohort study consisting of  GHD adults, who were regularly followed and stringently 
controlled over the years according to internationally, used guidelines. Care for attention 
was given to Vitamin D status as reflected by normal average levels of  vitamin D and 
normal bone turnover rates throughout the entire study period. In addition, we did a 
subanalysis among patients with osteoporosis at the start of  rGH supplementation and 
investigated fracture incidence during rGH supplementation. Limitations of  the present 
study are, first, the lack of  a non-rGH treated control group. Since the beneficial effects 
of  rGH therapy are well established in the short-term, rGH replacement became 
a widely available therapy for adult GHD in the Netherlands in case of  no contra-
indications. We believe it is therefore no longer possible or ethical to perform long-
term randomized placebo-controlled studies in GHD patients. A second limitation is 
the potential underestimation of  the fracture incidence in our patients as spinal X-rays 
were only performed in case of  a clinical fracture. Another feature that needs to be 
addressed that due to the presence of  multiple pituitary hormone deficiencies in almost 
all patients, it is difficult to examine to what extent the reported effects can be attributed 
to rGH treatment, or whether they are the consequence of  suboptimal or excessive 
replacement therapy of  other hormones. In this respect, the presence of  interactions 
between glucocorticoids and rGH during substitution and the negative effects of  
cortisol excess, either endogenous or supraphysiological supplementation, on bone has 
to be noted(31;32). However, in our study, there were no signs of  hydrocortisone over 
supplementation and when incorporating hydrocortisone use in a regression model, we 
found no significant association with BMD response. Finally, bisphosphonates, calcium 
and Vitamin D supplementation were initiated at the discretion of  the treating physician 
and not given using a standardized protocol. In this respect, little is known on the 
combined use of  bisphosphonates and rGH supplementation(34), which should be a 
topic for future research. 
In conclusion, findings from our cohort study of  GHD patients suggest ongoing 
beneficial effects of  long-term (≥5 years) rGH replacement therapy, particularly in men. 
Beneficial effects are most marked on BMD at the lumbar spine. Fracture incidence is 
similar to that of  age- and sex-matched general population. Sex-specific differences 
in bone response to rGH supplementation is asked to be elucidated and long-term 
beneficial effects of  bisphosphonates on fracture risk remain to be established.
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Chapter 8
Discontinuing recombinant growth hormone replacement 
in adult GH deficient patients: a cohort study and 




Background: Growth hormone (GH) replacement is advocated in adult Growth 
hormone deficient (GHD) patients to increase bone mass, to improve lipid profile 
and body composition, and Quality of  Life. However, data on the consequences of  
discontinuation of  GH replacement are scarce in adult GHD patients.
Design: Cohort study and a systematic literature search aimed at the evaluation of  
the metabolic effects of  GH discontinuation on anthropometry, glucose and lipid 
metabolism, and bone mass in adult GHD patients. 
Methods: We included 64 adult GHD patients who discontinued GH replacement for > 
12 months after a duration of  rhGH replacement of  8.7 years±4.6 years. AGE range! 
Data on anthropometry, lipids, glucose, and bone mass were assessed until 3 years after 
discontinuation of  therapy.  In addition, a systematic literature review was performed 
using the electronic databases Pubmed, Embase, and Web of  Science.
Results: Fat mass increased from 31.5±9.5% to 33.8 ± 9.0%(p<0.001) after 3 years of  
discontinuation. Total - and LDL-cholesterol levels decreased from 5.4±0.5 mmol/L to 
5.1±0.7 mmol/L (p=0.03), and 3.2±0.4 mmol/L to 2.9±0.6 mmol/L (p=0.016) after 
discontinuation in the presence of  an increase in the use of  lipid lowering medication. 
Fasting glucose levels and bone mass did not change. In patients aged > 60 years 
(n=34) no significant changes were observed in any of  the studied parameters. These 
observations, except for the changes in lipid profile, were in line with the results of  the 
systematic review, which included 7 studies with a maximum duration of  follow up of  
18 months.
Conclusions: We did not observe obvious adverse metabolic changes in the 3 yrs 
following discontinuation of  GH replacement for various reasons in adult patients with 
GHD. Further research is needed to determine optimal strategies for long-term GH 
reaplcement including the optimum time point for GH discontinuation.







Adult GHD is associated with an adverse metabolic profile, including abdominal 
obesity, dyslipidemia and an increased cardiovascular risk and mortality (1,2). Several 
studies have demonstrated that GHD patients have lower bone mass, increased fracture 
risk, and an impaired quality of  life (QoL) (3,4). Recombinant human growth hormone 
(rhGH) replacement therapy has shown to improve lipid profile, body composition, 
quality of  life, and to increase bone mass, and has become available for adult patients 
with GHD since 2 decades (5-10). However, long-term follow up studies have shown 
that the prevalence of  the metabolic syndrome does not ameliorate and BMI increases 
while on rhGH replacement. In addition, the metabolic profile of  long-term treated 
GHD patients remains significantly different from the general population (8, 11,12). 
At present, many issues regarding long-term treatment are not well established, for 
example the optimal duration of  rhGh replacement with advancing age, the long-
term efficacy and the consequences of  rhGH withdrawal in adulthood are not well 
established. Therefore, replacement is continued indefinitively in many cases. However, 
in case of  an active malignancy or lack of  subjective benefit it is advised to stop rhGH 
replacement. In addition, there are anecdotal data questioning the beneficial effects of  
rhGH replacement with advancing age, since GH secretion and IGF-1 levels decrease 
in healthy adults with advancing age, and low IGF-1 levels are even associated with 
increased longevity and decreased morbidity both in animal models and man (13,14). 
In addition, studies reporting on the efficacy of  rhGH replacement in elderly GHD 
patients are limited and show inconclusive results, and  data on rhGH discontinuation in 
adult GHD are scarce  (15). Therefore, we aimed to evaluate the long-term metabolic 
effects of  discontinuation of  rhGH replacement in our cohort of  adult GHD patients 
in general, and in the subset of  patients aged 60 years or older. At our center, the 
duration of  rhGH replacement is individualized and reasons for discontinuation of  
rhGH in case of  lack of  subjective benefit, malignancy, side effects, and at older age. 
Furthermore, we performed a systematic review of  studies reporting on the effects of  
discontinuing rhGH therapy in adults. 
PATIENTS AND METHODS
Patients
Patients were identified from the database of  our cohort of  adult patients with GHD. 
This cohort comprised all patients starting rhGH since 1994, with standardized 
evaluation of  clinical and metabolic parameters annually at the outpatient clinic of  the 
Center for Endocrine Tumors (8, 11,12, 16-18). For the present analyses, we included all 
GHD patients treated coniniously for at least 12 months with rhGH during adulthood, 
and who discontinued rhGH replacement therapy for at least for 12 months for various 
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reasons. Patients with a baseline visit before discontinuation and at least one follow up 
visit after discontinuation were included. 
Treatment protocol
Severe GHD was documented prior to start of  rhGH replacement and defined 
as a GH peak response to the Insulin Tolerance Test (ITT) <3µg/l (glucose nadir 
<2.2mmol/l) according to current guidelines, or, in case of  contraindications for ITT, 
by combined Growth Hormone Releasing Hormone/Arginine-stimulation (GHRH/
Arg) with BMI-adjusted GH cut-offs, (19-24). According to protocol patients receiving 
rhGH replacement during childhood were retested at the time of  transition to the 
adult outpatient clinic, after treatment cessation for at least 3 months. Hormone 
deficiencies were diagnosed and treated as previously reported (8,25). Patients were 
treated with bisphosphonates, calcium and vitamin D replacement, lipid-lowering and 
antihypertensive medication according to the discretion of  their attending physicians, 
in accordance with national guidelines, which was continued after withdrawal of  rhGH 
replacement. Efficacy and safety parameters were assessed yearly, next to a routine 
assessment of  pituitary function. 
STUDY DESIGN AND METHODS
A) Cohort Study
We performed a cohort study, aimed at evaluation of  the metabolic effects of  rhGH 
discontinuation. The baseline visit was defined as the last visit prior to discontinuation 
of  rhGH replacement. Data were assessed at baseline, and at 1, 2, and 3 years after stop.
During the periodical visits, the following data were assessed: 
1. Anthropometric parameters: body weight was measured in kilograms with 1 decimal 
precision, and body height was measured barefoot to the nearest 0.1 cm. BMI was 
calculated as weight in kilograms divided by the square of  height in meters (kg/m2). 
2. Biochemical parameters: serum concentrations of  IGF-1, GH, TSH, fT4, LH, 
FSH, estradiol, testosterone, prolactin, bone turnover markers, PTH, vitamin D, 
glucose, parameters for renal and kidney function, total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were collected after 
an overnight fast. Details on the different assays used were reported previously (8). 
3. Bone Mineral Density and Bodycomposition: Data on BMD, BMC and fatpercentage 
were collected. BMD was measured yearly at the lumbar spine (L1-L4) and femoral 
neck using dual energy X-ray absorptiometry (DXA) (Hologic QDR 1000 until 2008) 






and Hologic QDR 4500 thereafter) (25). Fatpercentage was assessed by  calculateing 
the total mass of  fat divided by total body mass. 
4. Data on medication use and co-morbidity was obtained from electronic patient files.
B) Literature search
We composed a search strategy focusing on discontinuation of  long-term rhGH 
treatment, GHD adults, bone metabolism, Quality of  life, metabolic effects, and body 
composition. Only articles reporting original data were included, studied reporting 
duplication of  cohorts were excluded.  References of  relevant articles were checked for 
additional articles. The search in Pubmed, Web of  Science, and Embase was performed 
on 05/09/2014 in collaboration with a trained clinical librarian, using the following 
search string: “Human Growth Hormone”[Majr] OR “Growth Hormone”[ti] OR “GH”[ti]) 
AND (“discontinuing”[ti] OR “discontinuation”[ti] OR “discontinued”[ti] OR “withdrawal”[ti] 
OR “withdrawing”[ti] OR “cessation”[ti] OR ”deprivation”[ti])  AND (“therapy”[Subheading] 
OR “therapy”[ti] OR “treatment”[ti] OR “therapeutics”[Majr Terms] OR “therapeutics”[ti] OR 
“replacement”[ti] OR “Hormone Replacement Therapy”[Majr] OR “administration”[ti])
Studies were eligible when all of  the following criteria were met: (1) they investigated 
effects on biochemical, metabolic/anthropometric parameters, bone metabolism, QoL, 
muscle strength, mortality, or adverse events, (2) had a duration of  follow up > 1 month 
and included > 10 patients, (3) were performed in patients with confirmed GHD in 
adulthood, and (4) were written in English.
The selection of  studies was done by two reviewers (N.M.A-D. en M.R.). The two reviewers 
evaluated studies independently, and disagreements were resolved by consensus. Data 
extraction was based on data from each study provided at the population level. The 
following data were extracted: (1) study population (patient characteristics, population 
size, GHD assessment, control population); (2) exposure to rhGH (duration of  rhGH 
treatment, rhGH dose), (3) outcome (biochemical and anthropometric parameters, 
QoL, bone metabolism) (4) risk of  bias.  
STATISTICAL ANALYSIS
SPSS for Windows, version 20.0 (SPSS, Inc.) was used for statistical analysis. Data 
are presented as mean ± SD, unless stated otherwise. ANOVA accounting for 
repeated measurements with Bonferroni correction was used to compare parameters 
between baseline and T= 1, 2 and 3 years, SPSS Bonferroni adjusted p-values are 
given unless stated otherwise. A linear regression model was used, including age, sex, 
radiotherapy, hydrocortisone use, BMI, to identify factors influencing the metabolic 
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4 diseased  
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  6 lost in follow up 
17 did not meet inclusion 
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64 patients studied 
10 restarted rhGh  
within 12 months 
n= 65  
1 re-classified as  
GH sufficient 
of  antihypertensive medication, use of  lipid-lowering medication, anti-diabetic agents, 
calcium and vitamin D supplementation, and the use of  bisphosphonates.  We also 
conducted a sub-analysis in elderly subjects (age >60, n=34). The age of  60 was chosen 
as cut-off, because the effects of  GH replacement therapy in GHD patients aged >60 
years is not well established (15). 
RESULTS
Clinical characteristics
A total of  102 patients who discontinued therapy were identified. Of  these, 4 patients 
died before the first annual visit after cessation of  rhGH replacement, 10 patients re-
initiated rhGH replacement within one year, 6 patients were lost to follow up, and 
18 patients did not meet the inclusion criteria. See Figure 1 for flow-chart of  patient 
inclusion.
A total of  64 patients, mean age 59.7± 15.7 years, were included in the study. Duration 
of  rhGH replacement was 8.7 years ± 4.6 years. Thirty-four patients (53% of  total) were 
60 years or older. Mean age in the subgroup of  elderly patients was 71.3 ± 7.0 years. 
Mean period of  discontinuation was 3.7 years (range 1-18 years). The main reasons 
for discontinuation were adverse events (n=25), or a lack of  subjective benefit (n=10). 
Table 1
FIGURE 1. 
Flow chart patient selection
rGH; recombinant human growth hormone, GH ; growth hormone






TABLE 1 . Baseline characteristics (n=64)
Age at baseline (yr) 59 ±15 (21-88)
Sex (M/F) 34/30
Cause of  GHD (%)
     NFA 21 (33%)
     Prolactinoma 6 (9%)
     Acromegaly 10 (16%)
     Cushing’s disease 7 (11%)
     Craniopharyngioma 4 (6%)
     Other 16 (25%)
Onset (%)
     AO 55 (86%)
     CO 9 (14%)
Other deficiencies (n)
     Corticotropic 43 (67%)
     Thyreotropic 45 (69%)
     Gonadotropic 46 (72%)
     Diabetes insipidus 10 (16%)
     Isolated GHD 2 (5%)
Rh-GH duration (yr) 9 ± 5 (1-18) 
Cumulative Dose (mg) 22.6 ± 5,7
Radiation (%) 33 (51.6%)
Medication (%)
     Antidiabetic 6.3%
     Antihypertensive 43.8% 
     Lipid-lowering 39.1%
     Oral contraceptives 1.6%
     Bisphosphonates 9.4%
     Calcium supplements 40.6%
     Vitamin D supplements 46.9%
     Thyroxine replacement 70.3%
     Dosage (µg) 118.7 ± 41.4
AO = adult onset, CO = childhood onset, GHD = Growth hormone deficiency, n = number of  patients, NFA = non-
functioning pituitary adenoma, rhGH = recombinant human growth hormone, yr = years.
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Anthropometry and blood pressure
Both systolic and diastolic blood pressure did not change significantly after 
discontinuation of  growth hormone replacement therapy, 134±10.1 mmHg vs 134.9 
±13.1 mmHg and 81.1±6.7 vs 81.2±4.9 mmHg respectively.
BMI decreased in in the first years after cessation of  rhGH therapy (Figure 2 A & B). 
In elderly subjects, BMI did not significantly decrease, mean difference 0.8 kg/m2, 95% 
CI -0.3- 1.8. Fat percentage increased from 31.5 ±9.5 % to 33.8 ± 9.0 % (p<0.001) after 
3 years. Subgroup analyses in patients > 60 years of  age did not show any significant 




   * 
FIGURE 2A&B. Changes in BMI up to 3 years after discontinuation. 
BMI: Body Mass Index kg/m2; *p < 0,05 compared to baseline
Lipid and glucose profile Figure 3A & B. 
After 3 years of  discontinuation serum total- and LDL-cholesterol (TC), decreased 
significantly from 5.4±0.5 mmol/L to 5.1±0.7 mmol/L (p=0.03), and from 3.2±0.4 
mmol/L to 2.9±0.6 mmol/L (p=0.016). HDL-C concentration after 3 years did not 
change, 1.4±0.2 vs 1.5±0.2 mmol/L. 
A
B






The percentage of  patients on lipid lowering agents, predominantly statins, was 39 %at 
baseline and increased during follow up to 44%. 
Glucose concentration and the number of  patients on glucose lowering therapy did 
not change after discontinuation, 4.9±0.5 mmol/L vs 5.4±1.7 mmol/L. In the elderly 











FIGURE 3A&B. Changes in total and LDL cholesterol levels up to 3 years after discontinuation
* = P < 0.05 compared to baseline
Bone metabolism
Lumbar spine BMD and femoral neck BMD remained stable, 1.0±0.1 g/cm2 vs 1.1±0.2 
g/cm2 and 0.8±0.1 g/cm2 vs 0.8±0.1 g/cm2 respectively. Bisphosphonate use increased 
from 9.4% at baseline to 12.1% after 3 years. In a small subgroup (n=17) bone markers 
were available at baseline and after 3 years. P1NP decreased from 42.2 ±8.8 ng/mL 
to 37 ±13.7 ng/mL (p=0.064).  Beta crosslaps decreased from 0.41 ±0.06 ng/mL to 
0.36±0.16 ng/mL (p= 0.056). 
SYSTEMATIC REVIEW
The initial search resulted in a total of  95 articles. Of  these, 26 publications were 





< 18 years, 1 because of  duration of  follow up of  only 5 days and 1 because of  a low 
number of  patients. Seven articles (that included a total number of  166 patients) met 
the inclusion criteria. The number of  included patients per study ranged from 10 to 42. 
Table 2
Study characteristics
Details of  the included studies are summarized in Table 2. Included studies were 
published between 1992 and 2012. Six studies (n= 90 patients in total) were randomized 
controlled trials, of  which 3 had a crossover design, there was one retrospective cohort 
study. The mean duration of  withdrawal was 3-18 months in all studies except one. This 
was a cohort study including 42 patients with duration of  follow up between 0-21 Years 
(26). Two out of  7 studies did not clearly report the duration of  rhGH therapy at time 
of  discontinuation  (26,29). Overall quality of  the studies was fair with a low risk of  
bias since there were designed as RCT, although none of  the studies mention handling 
of  statins, bisphosphonates and glucose lowering medication or even excluded patients 
on these medications. In addition data reported in the studies are heterogeneous and 
therefore precluded a formal meta-analyses. 
Anthropometry and Body composition:
One study reported on BMI, waist and hip circumference: no statistically significant 
changes were observed after 6 months of  follow up (30). Body composition was 
measured in three studies, and all reported an increase in fat mass and decrease in lean 
body mass after a follow up of  3-18 months (27,29,30). 
Lipid metabolism:
Total Cholesterol and LDL increased in 3 studies but was did not change in another 
study (26,28,30). Two studies also reported an increase of  hsCRP after discontinuation 
of  rhGH therapy (27,28) 
Glucose metabolism:
Two studies reported on glucose metabolism and insulin sensitivity after discontinuation 
(27,30). Fasting glucose, insulin levels, c-peptide and HBA1c were lower in 2, however 
one study reported an increase of  glucose levels. 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Several parameters were reported. One study found an increase in BMC during the 
study period where a second study did not report any difference in BMC (29,30). Two 
studies with a duration of  follow up of  6 months and 18 months respectively, reported 
a stable or increase of  BMD at the hip and spine (29,30). No study reported on fracture 
prevalence or bone markers. 
Quality of Life:
Only 2 studies reported on quality of  life (30,31). After discontinuation of  rhGH for 
a period of  3-4 months patients reported worsened scores on emotional reactions 
and well being. Furthermore they reported an increase in tiredness. Noteworthy, these 
effects were more profound in younger male participants, and almost absent in older 
patients (31).
In conclusion most studies investigated the effects of  growth hormone discontinuation 
in the follow up course after short-term rhGH suppletion. Only 2 studies reported on 
patients treated for more than 5 years of  rhGH suppletion and their follow up was < 
6 months (30,31). Therefore firm conclusions on the effects of  discontinuation rhGH 
suppletion cannot be made. 
DISCUSSION
In this study we demonstrated that adult GHD patients who discontinued rhGH 
replacement for various reasons do not show important adverse metabolic changes in 
the long-term.  Fat mass increased without negatively affecting lipid profile, glucose 
metabolism, or bone mass. In addition, in older patients no changes were observed at all. 
It thus appears that rhGH replacement can be discontinued without negative metabolic 
effects in the long term, provided that routine cardiovascular clinical guidelines for the 
treatment of  lipid abnormalities and hypertension are properly followed. We found 
a decrease in LDL- and total cholesterol in the presence of  an increase in the use of  
lipid lowering medication after discontinuation. In the subgroup of  patients aged > 
60 years no significant metabolic changes after cessation of  therapy were observed at 
all.  Furthermore, we observed no changes in lumbar spine BMD or fasting glucose 
level. BMI even slightly decreased within the 3 year follow up period as did bone 
turnover markers, although the latter changes were not significant possibly due to the 
sample size. The only parameter that significantly deteriorated after discontinuation was 
fatpercentage as measured by DXA. 
It is questionable whether the observed statistically significant changes are clinically 
relevant. At all time points, lipid- and fasting glucose concentrations remained within the 
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normal range in both groups and BMI even decreased after discontinuation of  rhGH. 
In the general population, for every 1 mmol/L LDL-C reduction, the risk of  major 
vascular events decreases by 20%(33). Given the adverse lipid profile in adult GHD 
patients that is associated with increased cardiovascular risk, it might be beneficial to start 
lipid-lowering medication in all middle-aged GHD patients. The clinical implications of  
the average 0.4 mmol/L increase in fasting glucose levels after discontinuation are less 
clear since fasting glucose levels remained within the normal range at all time points. It 
has been shown that the hazard ratio for coronary heart disease does not differ between 
patients with fasting glucose concentrations ranging between 3.9 and 5.6 mmol/L and the 
incidence of  coronary heart disease increases with increasing BMI (34, 35). On average, 
all subjects would be classified as overweight at all time points, however since BMI 
might not be the best anthropometric predictor for cardiovascular events, the observed 
increase in fatpercentage might counteract the decrease in BMI after discontinuation 
(36). Treatment of  adult GHD is mainly indicated for improvement of  cardiovascular 
risk factors and quality of  life. Short- and long-term studies have demonstrated that 
rhGH replacement is associated with improvement of  cardiovascular risk factors like 
lipid profile, bone mass, and quality of  life (5,7,9,25, 32). However, data also show that 
the metabolic phenotype of  GHD patients remains abnormal compared to the general 
population despite long-term replacement. Therefore, it is very well possible that the 
classic GHD phenotype might not be completely attributable to growth deficiency and/
or that not all effects are reversible (11,12).  
Since this is an observational study it obvious has limitations. There are no guidelines 
for discontinuation of  rhGH replacement; consequently the observed group was clearly 
pre-selected by the treating physician. Also, in this study we did not evaluate the effects 
on quality of  life, another important indication for rhGH replacement. However, since 
this was an observational study, patients who might have benefitted most from rhGH 
replacement were less likely to have discontinued therapy for a prolonged period, and 
patients were also always asked for their physical and psychological well being during 
the visits. In case of  severe deterioration of  quality of  life after discontinuation rhGH 
would have been re-initiated, as was reflected by the 10 patients that were identified 
prior to inclusion that re-initiated treatment within the first year. 
In order to put our observations in the best perspective, we additionally performed 
a systematic literature search on studies reporting on discontinuation of  rhGH 
replacement in adults. A total of  144 patients were reported, of  whom 84 were included 
in randomized controlled studies. The duration of  follow up was limited and ranged 
between 3 to 18 months. Overall, most studies reported that a parameter did not change 
without mentioning the outcome. This makes it hard to interpret these literature results 
since this implies that there was no change at all whereas the study only can report 
that there is no evidence of  a difference (37). The majority of  included patients had 
been on rhGH replacement for only 6-12 months prior to discontinuation whereas 






some studies did not report the duration of  therapy. This makes it difficult to interpret 
the results since the effects of  rhGH are time dependent. For instance, a decrease 
in BMD might be observed within the first year affecting the effects of  withdrawal 
when this occurs within the first year (7,9,18). Nevertheless, all studies reporting on 
body composition, including ours, have consistently shown an increase in fat percentage 
after discontinuation (27,20,30). Data on lipid profile after discontinuation were not 
conclusive, also because data on the use of  lipid-lowering medication could not be 
extracted or subjects on lipid lowering agents were excluded. Biller et al. reported an 
ongoing increase of  BMD after 18 months of  discontinuation, although data on bone 
modifying agents including calcium and vitamin D were not available in this study (29). 
One study reported on patients (n=29) who used rhGH during a longer period of  time 
(30). In the follow up period of  4 months in this study BMC and fatmass increased, lipid 
profile and quality of  life scores however worsened and glucose level remained grossly 
unchanged. From all studies selected this study resembled our patient population at 
most and the reported results are comparable with ours although handling of  statins 
and bisphosphonates were not mentioned.  
The rationale for being restrictive with GH replacement in elderly patients is based 
upon the following. The GH/IGF-1 axis declines physiologically with ageing and 
smaller individuals within a species usually live longer (38). Additionally, the GH/IGF-
1 axis has been linked with cancer risk and improved longevity (14), and functional 
mutations of  the IGF-1R gene resulting in altered IGF-1 signalling appear to be more 
common in centenarians than in younger controls. Life span is also extended in mice 
lacking GHR, resulting in lower IGF-1 levels. Although these mutant mice lack other 
hormones, restoration of  GH levels reverted their longevity to that of  non-mutants (39, 
40). Collectively, these results suggest that optimizing the GH/IGF-1 axis to promote 
healthy ageing in humans is more complex than originally appreciated, requires a greater 
understanding of  its array of  interactions and tissue specificity.  
In conclusion, the results of  this study indicate that discontinuation of  rhGH 
replacement in routine clinical practice does not result in apparent negative effects 
on overall metabolic profile. Since long-term replacement with rhGH generally will 
not normalize the metabolic profile and the beneficial effects of  unrestricted GH 
replacement therapy especially in elderly GHD are yet inconclusive, we advise to 
reconsider the need to continue rhGH treatment of  long-term treated GHD patients, 
and also explore alternative treatment strategies in patients, like a more stringent 
treatment of  dyslipidaemia and hypertension, especially in those aged > 60 years. 
We advocate the initiation of  further studies evaluating the effects of  discontinuing 
GH replacement in the long-term enabling to determinate the optimal time point for 
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Cranial radiation therapy for head- and neck tumours, and for non-pituitary cerebral 
tumours may affect pituitary function. This is because the pituitary gland often lies 
within the radiation field of  these tumours, more specifically; the hypothalamus and 
pituitary are often exposed to dosages equivalent to, or even higher than standard 
radiation schemes used for (non)-functioning pituitary adenomas. Consequently, the 
prevalence of  hypopituitarism in these patients may be high and of  clinical relevance, but 
clinical guidelines for the evaluation of  pituitary function after cranial radiation therapy 
for these tumours are not available. Chapters 2, 3 and the appendix, report on the 
effects of  cranial irradiation on pituitary function in patients treated for head and neck 
and non-pituitary tumours. In chapter 2 we have performed a meta-analysis of  available 
data reported in literature on pituitary function after cranial radiotherapy for head and 
neck and non-pituitary tumours. In this study, we found a 0,66 (CI 0,55-0,76) prevalence 
of  hypopituitarism of  any kind in a group of  studies with a high level of  heterogeneity. 
The studies, that included a total number of  813 patients, differed tremendously both in 
the number and in the type of  patients that were included. In addition, the evaluation of  
pituitary function and the definitions used to define hypopituitarism were not uniform. 
For instance, for the diagnosis of  growth hormone- and cortisol deficiency more than 
6 different tests and different cut-off  values were used. Due to this variation in quality 
of  the studies we also performed a sensitivity analysis among the 4 studies rated as high 
quality that showed the same results as for the whole group; furthermore, no differences 
were seen between tumour types. This implicates that a high prevalence of  pituitary 
insufficiency is likely to occur after cranial radiotherapy for these tumours regardless 
of  tumour type. Because periodical evaluation of  pituitary function has not yet been 
implemented in the routine clinical care of  patients irradiated for these tumours, we 
decided, in view of  these results, to perform a cross-sectional analysis of  the presence 
of  any hypopituitarism in the patients that were treated in the Leiden University Medical 
Center (charts of  the departments of  Endocrinology and Radiotherapy). These results 
are presented and discussed in chapter 3. We found that not all treated patients, alive 
had been screened for endocrine pathology. Therefore, in an attempt to obtain the best 
possible cross-sectional evaluation reflecting pituitary function after cranial irradiation 
in current clinical practice, we actively recruited all consecutive patients that fulfilled pre-
defined inclusion criteria. These patients underwent state-of-the art endocrine testing 
using stringent cut-off  values for hormone deficiencies. Of  all patients tested, including 
those already known at the outpatient clinic of  the Endocrinology department, we 
found that 62% of  these had developed hypopituitarism during a variable period after 
cranial irradiation. Pituitary insufficiency of  any form was present in 55% of  cases 
within 5 years after radiotherapy, and amounted to 75% and 90% of  patients after 10 







We have carefully described the origin of  our cohort, aiming at a consecutive cohort 
of  patients that underwent cranial radiotherapy for non-pituitary tumours as based on 
radiotherapy records, avoiding selection bias when patients had already been referred 
to the endocrine ward. However, since not all patients could be assessed, selection 
of  patients is unavoidable. Next, it is important to accentuate that only patients 
with a significant dose delivered to the pituitary were included, therefore the overall 
prevalence of  any form of  hypopituitarism in our study was high (62% of  any pituitary 
insufficiency). However, these results are in line with our meta-analysis on this topic 
that demonstrated a prevalence of  0.66 (CI 0.55-0.76) in the same patient groups. 
Besides selection bias there are other explanations for the discrepant results with some 
but not all previous studies, such as the use of  different tests and differences in test 
procedures, which, amongst others, reflects the complex, fragile and heterogeneous 
patient group. Unfortunately, we were not able to explore possible differences between 
tumours, dose and mode of  radiotherapy due to the limited number of  patients. In 
our study, we excluded patients treated with radiation doses < 20 Gy to the pituitary 
region. A sensitivity analyses revealed no hypopituitarism in any of  these patients (data 
not shown). Consequently, we proceeded with the threshold of  20 Gy. We selected this 
threshold based on 2 findings: 1) Data from historical cohorts that have indicated that 
a total dose of  7- 24 Gy delivered to the pituitary/hypothalamus region causes, if  any, 
growth hormone deficiency only, whereas dosages as high as 50-60 Gy will most certainly 
cause multiple pituitary hormone deficiencies. Using the threshold of  20 Gy delivered 
into multiple fractions to the pituitary region will generally exclude patients treated 
with TBI for the need of  follow-up for pituitary function, of  course these patients 
should receive follow up for primary endocrinopathies like hypothyroidism, premature 
testicular or ovarian failure and other metabolic consequences of  the previous radiation 
and chemotherapy. Whether such a threshold is accurate enough should be, of  course, 
be evaluated prospectively in future studies. 
Because life expectancy after treatment for the underlying diseases is increasing and 
hypopituitarism per se strongly influences quality of  life, it is important to correctly 
identify hypopituitarism in these patients. In particular, it is crucial to identify those 
with hypocortisolism, since these patients are exposed to additional, potentially life-
threatening risks, like addisonian crises in case of  intercurrent illnesses, and decreased 
Quality of  Life. Noteworthy, current guidelines for the follow-up of  patients treated 
with radiotherapy for NPC tumours include the routine checking of  TSH levels to 
screen for primary hypothyroidism because of  high prevalence rates of  0,48 whereas 
the risk for pituitary insufficiency, like TSH deficiency, in NPC patients may be at least 
as high but will be easily missed when only TSH is measured. 
For a critical evaluation of  the likelihood of  development of  pituitary deficiencies after 
cranial radiotherapy for the tumours, we advocate the following:  there should be an 
awareness that calculating the dose to the pituitary provides essential information on the 
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probability of  hypopituitarism in the future and should therefore be always performed. 
To date, this is not reported on a regular basis. 
Follow up after cranial irradiation of  patients treated with 20 Gy or more delivered to 
the pituitary region should include the following aspects (see also Figure 1). First: a baseline 
endocrine evaluation prior to radiotherapy, of  baseline hormone concentrations. 
Baseline levels of  FT4 and IGF-1 will serve as individual reference values for follow 
up after treatment, since for example a decrease >20% in FT4 might be indicative 
for the development of  central hypothyroidism. A second step includes measurement 
of  fasting morning cortisol concentration. In case of  a cortisol concentration >500 
-550 nmol/l, in the absence of  concurrent corticosteroid use, the activity of  the HPA-
axis is considered intact making further dynamic testing unnecessary. Also, when 
cortisol concentrations are  <80 nmol/l, the diagnosis of  hypocortisolism is evident 
and dynamic testing will also not be necessary. When dynamic endocrine testing is 
indicated, the timing of  the test in relation to the time of  radiation should be taken 
into account since this may affect the outcome of  the tests. Tests like stimulation 
with ACTH, and the combined GHRH +Arginine test will reveal normal results in 
the first years after radiation and will become more reliable after a longer period of  
time, approximately 5 years. Therefore, one of  the most reliable tests reflecting the 
integrity of  the hypothalamus-pituitary- end organ axes, is the insulin tolerance test 
(ITT). However, the use of  an insulin tolerance test may not be appropriate in all cases 
because this is an intensive test in a fragile patient group.  In addition, GH deficiency 
might not be clinically relevant for patients treated for a malignant tumour, because 
malignancy is generally considered a contraindication for GH replacement in adults 
after anecdotal reports of  tumour growth in craniopharyngeomas, and of  increased 
risk for bone tumours in children treated with rGH, and the association between IGF-1 
and cancer risk. However, the documentation of  the presence of  GHD will be useful 
to identify patients at risk for radiation induced hypothalamic/pituitary damage and 
therefore we still recommend testing of  the pituitary- GH-IGF-1 axis. When patients 
are treated with dexamethasone, the HPA-axis cannot be evaluated, and GHD can 
be tested using the combined GHRH+ARg-test . Nevertheless, it might be decided 
that diagnosing GHD is not relevant in a specific patient and than no test should be 
performed. In all other patients we would advice to perform the best available test, taken 
into account the patients WHO performance classification and life expectancy. It is not 
possible to only rely on the patients’ symptoms with respect to hypopituitarism for 
the decision to whether or not to perform endocrine function tests. Such an approach 
would underestimate the presence of  hypopituitarism since patients may have various 
complaints that could also be attributable to cranial radiation/chemotherapy or to the 
impact of  the diagnosis of  cancer itself. Therefore, how to proceed within the first years 
after radiation has to be tailored individually in each patient, since this is a very complex 

















































Proposed follow up 
The incidence of  multiple pituitary deficiencies increases both in time and with higher 
doses. See also figure 2 in the Introduction of  this thesis.  Considering these and our findings that 
90% of  patients will be diagnosed with hypopituitarism after 15 years we recommend 
periodical screening for this entire period. Whether this should be done annually or with 
greater intervals is at the discretion of  the physician.
The protocoled follow-up algorithms needs to be validated prospectively, and should 
also include periodical evaluation of  quality of  life. 
SECTION II
Chapters 4-8 describe the effects of  long-term recombinant human growth hormone 
replacement in adult patients with proven severe growth hormone deficiency (GHD). 
In Chapter 4 we performed a systematic review of  the literature of  studies that have 
evaluated the effects of  growth hormone replacement beyond 5 years of  treatment. 
In the short term, several studies have shown beneficial effects of  growth hormone 
replacement therapy on lipid metabolism, muscle mass and strength, bone mass density 
and quality of  life. The systematic review identified a total of  23 studies. We encountered 
several problems in this search. Generally, most reports lacked a representative control 
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group (of  non-treated GHD patients) not allowing adjustment for potential subjective 
changes or changes due to ageing. Secondly, only a limited number of  centers have 
reported their data, resulting in a limited number of  evaluable patients with a follow-up 
duration beyond 5 years of  rGH replacement. This means that long-term follow-up 
results of  rGH replacement are reported only by a very limited number of  centers, 
and consequently extending follow-up results derive by the same centers. Thus, most 
studies describe (part of) the same patient cohort. With respect to the metabolic profile, 
rGH therapy has shown prolonged, beneficial effects on the long-term for body 
composition, lipid profile, carotid IMT and BMD. However, overall cardiovascular 
risk, as assessed by the prevalence of  the metabolic syndrome, glucose levels, and BMI 
appeared not to be influenced or were even negatively affected. The course of  changes 
in QoL during ongoing therapy is not established. Therefore, the benefit of  prolonged 
rGH treatment should be a matter of  ongoing research to enable adequate risk-benefit 
analyses. Consequently, the benefits of  rGH in clinical daily practice in the long-term 
should be critically re-evaluated in each patient.
Chapter 5 describes the evaluation of  the 10 and 15 years results of  rGH replacement 
therapy on the metabolic syndrome in our own Leiden adult GHD patient cohort. 
For this study, a total of  98 adult patients with GHD with extended follow up were 
prospectively followed at the outpatient clinic of  the Leiden University Medical Centre. 
Cardiovascular risk factors, such as lipids, glucose, blood pressure, and anthropometric 
parameters (waist-hip ratio and BMI) were checked annually in these patients. Even after 
more than 10 years of  treatment, we demonstrated ongoing beneficial effects on lipid 
profile, with a significantly decrease in LDL and increase in HDL compared to baseline. 
However, when we attempted to extrapolate these individual changes in cardiovascular 
risk factors into the commonly used risk profile of  the metabolic syndrome (MS), 
the net result did not appear to have any beneficial effects at all. On the contrary, the 
MS prevalence increased significantly, especially in males, to 57,1% after 10 years of  
replacement (from 32.7 % at baseline). Since in the Netherlands rGH replacement is 
widely available and all eligible patients will be treated with rGH, no control group of  
untreated GHD patients is available and the use of  historical cohorts is not completely 
representative for present optimal care due to improvements in hormonal replacement, 
and consequently, the prevalence of  adverse metabolic profile.  Therefore, we selected 
a control group of  the Netherlands Epidemiology of  Obesity (NEO) study. In the 
NEO-study, a contemporary cohort of  healthy middle-aged controls was sampled from 
the Leiderdorp area, which is in the vicinity of  Leiden.  In Chapter 6 we report the 
results of  the comparison of  the metabolic phenotype of  the patients from the GHD 
cohort treated with growth hormone for at least 5 years with these healthy controls 
from the NEO cohort. A total of  161 middle-aged patients were included in the study. 
When adjusted for age, sex and BMI, GHD patients were classified significantly more 







vs 30.3%). Most importantly, it was shown that starting rGH replacement affects the 
different components of  the MS, resulting in more hypertriglyceridemia and lower HDL. 
Despite hormonal treatment in concurrence with modern guidelines, their metabolic 
profile does not seem to differ much from non-treated GHD at the expense of  marked 
increases in BMI/weight. Although the study was not designed to detect differences in 
cardiovascular events, these results indicate that it still has to be established that rGH 
replacement is more effective than commonly advised lipid lowering treatment with 
statins in the prevention of  cardiovascular events in this specific patient group. 
In Chapter 7, the effects on bone were investigated in 230 GHD patients. We assessed 
bone mineral density at baseline, and annually thereafter during follow-up while on rGH 
replacement. In addition, we reported the incidence of  clinical fractures. Intriguingly, 
no clear beneficial changes were seen in female patients, whereas in male patients, we 
observed a sustained increase in lumbar spine BMD during the entire period of  15 
years of  treatment. Bisphosphonate use did not alter the net outcomes on BMD in 
these patients. Clinical fracture incidence was 20,1/1000 patients per year and was not 
higher when compared to literature controls. Long-term rGH replacement does seem 
to be beneficial for the bone mass of  males suffering from GHD. In females the effect 
of  rGH may be blunted due to estrogen deficiency and due to sex specific geometrical 
differences since women tend to have more trabecular loss due to aging. Furthermore if  
rGH also decreases the risk of  fractures is yet to be debated since all studies performed, 
including ours, were not powered to detect fracture difference. It might very well be 
that the additional calcium/d3 medication already is responsible for a drop in fracture 
incidence. 
In Chapter 8 we evaluated the effects of  discontinuation of  rGH therapy within 
the Leiden GHD cohort and additionally performed a systematic literature search 
on the topic. In a sub-analysis, we also specifically aimed to evaluate the effects of  
discontinuation of  rGH replacement in elderly patients. We found that discontinuation 
of  rGH replacement therapy was associated with an increase in body fat. However, in 
clinical practice this did not negatively affect lipid profile, and we also did not observe 
any changes in glucose metabolism, in the presence of  a decrease in BMI. In patients 
older than 60 yrs, rGH withdrawal did not affect the metabolic profile at all. It thus 
appears that the net metabolic effects of  discontinuing rGH replacement after long-
term use is not by definition disadvantious. This may reflect ongoing beneficial effects 
of  the rGH treatment, a lack of  significant effects (especially at advanced age), or 
possibly a combination of  both. 
In adult patients with growth hormone deficiency data from long-term studies indicate 
that recombinant growth hormone replacement has beneficial effects on cardiovascular 
risk factors and quality of  life in a pre-selected group of  patients with hypopituitarism. 
However, one of  the main indications, amelioration of  the adverse cardiometabolic 
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risk, as profiled in the general population with the metabolic syndrome phenotype, is 
not achieved by this treatment. Conversely, in our cohort, we even observed an increase 
in the prevalence of  the metabolic syndrome during long-term therapy. In addition, 
the effects of  rGH replacement therapy on bone seem gender dependent. However, 
as stated before, ideally long-term comparisons should be made with a comparable 
untreated GHD cohort and a longitudinal study for the control population, which 
were not available. Unfortunately, there are no longitudinal population control data 
available to assess the expected trend for weight gain in the period of  assessment for 
the study described in chapter 5. In addition, there are no large-scale longitudinal data 
in representative GH deficient patients not treated with rGH. However, the Dutch 
Ministry of  Health conducted two large population-based studies: the ‘MORGEN 
Study’, which was conducted during the period 1993-1997, and ‘Nederland de Maat 
genomen’ in 2009-2010, both reporting control data for BMI. In 1993-1997, mean BMI 
was 25.8 kg/m2 and 25.0 kg/m2 in males and females, respectively, and fifteen years 
later 26.0 kg/m2 in males and 24.9 kg/m2 in females in 2009-2010, aged 30-59 years. 
In the absence of  ongoing RCTs of  rGH treatment we have to deal with a heterogenous 
group of  GH patients and findings are likely a resultant of  the imperfections of  
hormone replacement in those with abnormal function. All the patients in our GHD 
cohort have failure of  multiple pituitary axes, and this results in important interactions 
between the hormones used for replacement. It is of  importance that awareness and 
proper monitoring of  these interactions are important in order to reach an optimal 
replacement therapy. Isolated GHD (IGHD) provides the ideal model to characterize 
GHD without interference from other pituitary deficiencies or their treatment. It is 
reported that baseline clinical characteristics and rGH treatment response in patients 
with IGHD in comparison to patients with multiple axis failure show a generally similar 
pattern and rGH treatment response in IGHD patients as well as in patients with 
multiple deficiencies, especially in AO-GHD. These findings support the concept that 
GH per se is responsible for at least part of  the metabolic aspects of  patient that receive 
hormone replacement for multiple pituitary hormone deficiencies.  Furthermore, it 
has been shown in a recent meta-analysis that both very low and high IGF-1 levels 
increase mortality in general population (hazard ratio (HR) 1.18, 95%CI 1.04-1.34). 
This U-shape relationship was present for both cancer and cardiovascular mortality. In 
addition, several other reports show an association of  both low and high IGF-1 levels 
with DM2, sarcopenia, fracture risk and cardiovascular diseases. However there are also 
human studies linking reduced IGF-1 levels/signaling to a reduced cancer risk as well 
as improved longevity. For example, in an Ecuadorian family with severe GHD due to 
GHR gene mutations, type 2 diabetes and cancer risk were strongly reduced. In addition, 
functional mutations of  the IGF-1R gene resulting in altered IGF-1 signaling are more 
common in centenarians than in younger controls. The GH/IGF-1 axis declines 







(including ponies and small dogs). Life span was also expanded in mice lacking GHR, 
resulting in lower IGF-1 levels. Although these mutant mice lack other hormones, their 
extended longevity is thought to be primarily due to GHD, as restoration of  GH levels 
reverted their longevity to that of  non-mutants. Collectively, these results suggest that 
optimizing the GH/IGF-1 axis to promote healthy ageing in humans is more complex 
than originally appreciated, and will require a greater understanding of  its array of  
interactions and tissue specificity.  
Thus, one can conclude that rGH replacement can be safely initiated in adult patients 
with severe GHD and has to be monitored throughout the years, enabling to make 
individual adaptations based upon alteration in e.g. MS and bone mass for each patient 
every year. It has also to be noted that the long-term effects on quality of  life should be 
more carefully addressed in future research, a topic that has not been investigated in the 
studies presented in this thesis. In view of  an aging population the question if  growth 
hormone replacement should be continued lifelong should also be an important topic 
for future research. Growth hormone secretion declines during life and therefore it is 
logical to withdraw growth hormone replacement, or at least to decrease the dosage to a 
minimum when reaching advanced age, especially since some of  the effects maybe long-
lasting or could be treated at least equally effective with other drugs, like for instance 
with statins. Finally, we advocate that future studies on growth hormone replacement 
should also focus on value based outcomes and that centers that treat adult patients 






De hypofyse en hypothalamus
De hypofyse is een klein orgaan dat zich onderaan de hersenen bevindt en in een benige 
holte ligt, de sella turcica genoemd. De hypofysesteel verbindt de hypofyse met een 
andere hersenkern, de hypothalamus. Gezamenlijk zorgen de hypofyse en hypothalamus 
voor de juiste ‘vertaalslag’ van externe signalen door afgifte van hormonen. De hypofyse 
is, ondanks zijn kleine afmeting (ongeveer de grootte van een doperwt), één van de 
belangrijkste klieren van het lichaam. Onder de invloed van hypothalame hormonen 
maakt de hypofysevoorkwab groeihormoon (GH), prolactine, adreno-corticotroop 
hormoon (ACTH), thyroid stimulerend hormoon (TSH) en de gonadotrofines LH en 
FSH. Deze hormonen sturen weer hun eigen doelorganen aan zoals de bijnierschors, 
schildklier en eierstokken/zaadballen. De hypofyseachterkwab bestaat uit axonale 
uitlopers van hypothalame neuronen die het hormoon vasopressine (ADH) maken. 
Uitval van de hypofysefunctie kan ontstaan als gevolg van een tumor in de (buurt van 
de) sella turcica, of  als gevolg van schade aan de hypofyse en/of  hypothalamus door 
operatie of  bestraling.  Uitval van de hypofysefunctie gaat gepaard met aspecifieke 
klachten zoals vermoeidheid en algeheel onwel bevinden, maar kan ook leiden tot 
gevaarlijke situaties zoals een Addisonse crise met lage bloeddrukken als gevolg van 
ernstig cortisoltekort. Hypofyse uitval kan enkel vastgesteld worden door het meten 
van de betreffende hypofysehormonen, als ook de hormonen van de doelorganen, zoals 
bijvoorbeeld testosteron en oestradiol als maat voor LH/FSH activiteit. Gezien het 
sterk pulsatiele karakter van de secretie van hypofysehormonen en de sterke circadiane 
variatie is het meten van enkel ochtendwaarden voor met name groeihormoon en 
ACTH/cortisol niet voldoende. Om te kunnen bepalen of  de hypofyse voldoende 
reservecapaciteit heeft om tijdens situaties met een sterk verhoogde behoefte (zoals 
stress en koorts) genoeg hormonen te kunnen maken, is het noodzakelijk om een 
zogenaamde functietest of  dynamische test uit te voeren. Hierbij wordt de ACTH en 
GH secretie gestimuleerd door het inspuiten van de hypothalame hormonen (CRH 
en GHRH) of  door middel van insuline, wat de meest natuurlijke prikkel is voor het 
opwekken van een stressrespons, namelijk een lage bloedsuiker.
 
DEEL I: HYPOFYSE UITVAL NA BESTRALING VAN HET HOOFD VOOR HERSEN- 
OF KNO-TUMOREN
In de hoofdstukken 2, 3 en de bijlage (appendix) worden de effecten van bestraling 
op de hypofysefunctie beschreven zoals deze kunnen ontstaan na bestraling van het 
hoofd als behandeling van hersen-/Keel-Neus en Oor(KNO) tumoren. Bij deze 
behandeling ligt de hypofyse vaak midden in het bestralingsveld, waardoor deze ook 
veel straling krijgt. Hierdoor wordt de hypofyse blootgesteld aan een stralingsdosis die 








hypofysetumoren. Hierdoor is het een reële kans  dat enkele jaren na de bestraling 
verlies van de hypofysefunctie kan ontstaan. De levensverwachting van patiënten met 
hersentumoren en met KNO-tumoren is in de loop der jaren toegenomen, hierdoor kan 
hypofyse uitval, voor de patiënt  een relevant probleem worden. Hypofyse uitval kan de 
kwaliteit van leven nadelig beïnvloeden, maar ook medische problemen geven variërend 
van vermoeidheid tot een Addisonse crise bij cortisoltekort of  seksuele dysfunctie 
bij vermindering van het geslachtshormoon. Omdat deze klachten vaak moeilijk te 
herkennen zijn bij mensen die behandeld zijn voor kanker, kan dit gemist worden 
indien er niet specifiek naar gezocht wordt. Met name cortisoltekort kan tot potentiële 
levensbedreigende problemen leiden zoals lage bloeddruk. In Hoofdstuk 2 worden 
de resultaten van een meta-analyse beschreven over het voorkomen van hypofyse 
uitval na bestraling van de hersenen. In deze studie laten wij zien dat de prevalentie 
van hypofyse uitval erg hoog is bij patiënten na behandeling voor KNO tumoren en 
hersentumoren. In totaal zijn in deze analyse 813 patiënten geïncludeerd in 18 studies. 
Er is een prevalentie van hypofyse uitval van 0,66 (95% betrouwbaarheidsinterval 0,55-
0,76) gevonden. Zowel bij hersentumoren, als ook bij KNO tumoren is de prevalentie 
verhoogd en de getallen ontlopen elkaar niet veel. Verder valt in deze meta-analyse op 
dat er veel verschillen bestaan in de methodologie tussen de diverse studies. Zo verschilt 
de wijze van testen van hypofysefuncties en de definitie van hypofyse uitval tussen de 
studies. Voor de diagnose groeihormoon deficiëntie en cortisol deficiëntie zijn meer 
dan 6 verschillende testen gebruikt met ook nog verschillende afkapwaarden. Vanwege 
het grote verschil in kwaliteit tussen de studies is ook een sensitiviteitsanalyse gedaan 
waarbij de 4 ‘beste’ studies qua methodologie zijn vergeleken met de resultaten van de 
hele groep. Deze sensitiviteitsanalyse toont dezelfde resultaten als voor de gehele groep. 
Gezien de hoge prevalentie van hypofyse uitval in deze meta-analyse is besloten de stand 
van zaken te onderzoeken m.b.t (de evaluatie van) de hypofysefuncties van patiënten die 
in het LUMC bekend zijn bij de afdelingen Radiotherapie of  Endocrinologie over een 
periode van 20 jaar. De resultaten van dit onderzoek staan beschreven in hoofdstuk 
3. Uit dit onderzoek is gebleken dat in de eerste plaats een groot gedeelte van de 
patiënten binnen het LUMC niet gescreend zijn op hypofyse uitval. Van deze groep 
niet-gescreende patiënten was de meerderheid reeds overleden of  had een dermate 
slechte gezondheid dat zij niet opgeroepen konden worden voor hormonale evaluatie. 
De overige patiënten zijn uitgenodigd voor evaluatie van de hypofysefunctie. Van alle 
onderzochte patiënten in het LUMC is gebleken dat 62% van hen enige vorm van 
hypofyse uitval had ontwikkeld na bestraling. Na de bestraling was in de helft van de 
gevallen na 5 jaar functieverlies van de hypofyse opgetreden. Na 10 jaar en na 15 jaar 
was dit respectievelijk 75% en 90%. 
Op dit moment zijn erg geen landelijke richtlijnen voor het vervolgen van de 
hypofysefuncties na bestraling. Voor een juiste risicoschatting van de kans op het 
ontwikkelen van hypofysefunctie uitval is het van belang dat de radiotherapeut 
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bij de planning van de bestraling aangeeft wat de geschatte dosis op de hypofyse is. 
Patiënten met een dosis van 20 Gy of  meer op de hypofyse kunnen verwezen worden 
voor follow up. Gezien het frequent voorkomen van hypofyse uitval en de met de 
uitval gepaard gaande problemen op het gebied van kwaliteit van leven en andere 
gezondheidsproblemen, adviseren wij periodieke hormonale evaluatie na behandeling 
voor deze aandoeningen mee te nemen in de richtlijn ontwikkeling. De combinatie 
van de geschatte bestralingsdosis op de hypofyse met de verwachtte levensverwachting 
zal uit moeten wijzen of   jaarlijkse/tweejaarlijkse follow-up wenselijk is. Daarnaast 
zal gekeken moeten worden bij welke arts dit moet gebeuren, bijvoorbeeld een 
endocrinoloog of  via de behandelend radiotherapeut- of  internist-oncoloog. Indien 
besloten wordt tot follow-up adviseren we dit in ieder geval tot 15 jaar na afronden 
van de radiotherapie te doen. De belasting van het vervolgen van patiënten en het 
herhalen van hypofysefunctie-testen moet voor elke patiënt individueel afgewogen 
worden. In ieder geval wordt geadviseerd de endocrinologische tractus na te vragen 
en dient bij alle patiënten een eenvoudig bloedonderzoek in de ochtend tussen plaats 
te vinden voor cortisolbepaling en bepaling van de schildklierfunctie (TSH en FT4). 
Aanvullend kunnen tevens IGF-1, prolactine, geslachtshormonen in combinatie met 
een hypofysefunctie-test gedaan worden bij patiënten met benigne ziekte of  een 
levensverwachting van meer dan 12 maanden. Hiervoor kunnen verschillende testen 
gebruikt worden, maar de Insuline Tolerantie Test (ITT, de gouden standaard) heeft de 
voorkeur. Bij contra-indicaties voor deze test kan gekozen worden voor de CRH- of  
ACTH stimulatietest. In  ons cohort hebben wij geen bijwerkingen of  complicaties 
gezien van de ITT, behalve de obligate passagere klachten van hypoglykemie tijdens de 
test zelf. Bij patiënten die corticosteroïden gebruiken moet duidelijk genoteerd worden 
dat deze medicatie niet zomaar gestopt mag worden, aangezien men zeker moet zijn dat 
de Hypofyse-Bijnier-as nog intact is. 
Bij patiënten die met een cumulatieve dosis van minder dan 20 Gy bestraald zijn op de 
hypofyse is de kans op hypofyse uitval zo klein dat een standaard controle hierop niet 
zinvol wordt geacht. 
CONCLUSIE
Hypofyse uitval na bestraling komt frequent voor, sterker nog, meer dan 60% van 
de behandelde volwassen patiënten heeft enige vorm van hypofyse uitval. Daarom 
adviseren wij bij mensen met een levensverwachting van meer dan 12 maanden om de 
hypofysefuncties regelmatig te controleren voor een periode van 15 jaar. Dit kan gedaan 
worden door een internist-endocrinoloog of  door de behandelende internist-oncoloog 
of  radiotherapeut-oncoloog. Voor elke patiënt zal individueel gekeken moeten worden 
wat de belasting is van bloedonderzoek en hypofysefunctie-testen. Dit voorstel voor 








geëvalueerd moeten worden. Geadviseerd wordt om metingen naar de kwaliteit van 
leven hierbij mee te nemen. 
DEEL II: GROEIHORMOON
Hoofdstukken 4-8  beschrijven het effect van langdurig groeihormoongebruik 
bij volwassen patiënten met groeihormoon deficiëntie (GHD). Hoofdstuk 4 is een 
systematische review van de literatuur over de effecten van recombinant humaan 
groeihormoontherapie (rGH) na een gebruik van meer dan 5 jaar. In deze review werden 
in totaal 23 studies geanalyseerd. We zagen dat langdurige suppletie met rGH gunstige 
effecten had op de lichaamssamenstelling, lipidenprofiel, op intima media dikte en op de 
botmassa. Andere uitkomstmaten, zoals het metabool syndroom, de bloedsuikerwaarden 
en BMI werden niet beïnvloed of  verslechterden juist. Dit zijn juist factoren zijn die 
alom beschouwd worden als factoren die het cardiovasculaire risicoprofiel beïnvloeden. 
Veranderingen in kwaliteit van leven na meer dan 5 jaar groeihormoon gebruik zijn 
niet beschreven. Vrijwel geen enkele studie had een goede controlegroep van niet 
behandelde GHD-patiënten omdat in de meeste landen groeihormoon standaard 
wordt voorgeschreven aan geschikte patiënten. Hierdoor kan niet aangetoond worden 
welke veranderingen bij patiënten met hypofyse uitval nu door (natuurlijke) veroudering 
komen en welke door de effecten van rGH. Daarnaast is er maar een beperkt aantal 
centra die hun lange-termijn resultaten hebben gerapporteerd (2) waardoor de patiënten 
aantallen laag zijn en dezelfde patiënten cohorten vaak opnieuw worden beschreven. 
De winst van rGH therapie op de lange termijn bij volwassen zal daarom een punt van 
aandacht moeten blijven voor verder onderzoek. 
In Hoofdstuk 5 beschrijven wij de resultaten van ons eigen cohort dat minimaal 10 jaar 
tot 15 jaar behandeld werd met rGH. In deze studie hebben we specifiek gekeken naar 
het voorkomen van het metabool syndroom bij 98 patiënten met GHD die vanaf  starten 
van de behandeling met rGH in het LUMC onder controle zijn geweest. Cardiovasculaire 
risicofactoren, zoals cholesterol en lipidenspectrum, glucose, bloeddruk en lengte/
gewicht/middel- en heupomtrek werden jaarlijks vervolgd op de polikliniek. We zagen 
een duidelijk gunstig effect op het cholesterol en lipidenspectrum, zelfs na 10 en 15 
jaar behandeling, met een significante reductie in het LDL en verhoging van het HDL 
in vergelijking met het cholesterolspectrum voor aanvang van behandeling. Echter het 
voorkomen van het metabool syndroom van deze patiënten veranderde niet, integendeel, 
dit percentage steeg bij mannen verder door naar 57.1% na tien jaar behandeling. Dit 
was een zeer forse stijging ten opzichte van de 32.7% bij aanvang van therapie. Omdat 
rGH in Nederland algemeen verkrijgbaar is en alle geschikte patiënten behandeld 
worden met rGH is er geen controlegroep in de studie geïncludeerd. Doordat er in de 
jaren veel veranderd is op het gebied van statinegebruik, verbetering van hormonale 
suppletie en veranderde prevalentie van het metabool syndroom kan er dan ook geen 
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vergelijking plaatsvinden met historische patiënt cohorten. Om toch een betere indruk 
te krijgen van de geobserveerde veranderingen in de tijd is er een studie verricht met 
een controlegroep vanuit de  Nederlandse Epidemiologie van Obesitas (NEO) studie. 
In deze studie werden gegevens verzameld van onder andere een cohort van gezonde 
controles van middelbare leeftijd (45-65 jaar) uit de omgeving van Leiderdorp, een 
plaats zeer dicht bij Leiden. Hoofdstuk 6 geeft de resultaten weer van deze vergelijking 
tussen het metabole profiel van onze patiënten op stabiele rGH therapie voor 
minimaal 5 jaar en de bevolkingscontroles vanuit de NEO-studie. 161 GHD patiënten 
werden geïncludeerd in de studie, na correctie voor leeftijd, sekse en BMI bleek dat 
het metabool syndroom significant vaker voorkwam in de GHD populatie, 53,4% vs 
30,3%. Daarnaast was duidelijk te zien dat 5 jaar na rGH behandeling de prevalentie 
van het metabool syndroom was gestegen van 41% naar 53.4% (p=0.007). Ook was 
het risico op het metabool syndroom na 5 jaar behandeling nog steeds 1.3 maal hoger 
dan in de gezonde controle groep, onafhankelijk van leeftijd, geslacht en BMI (95% 
betrouwbaarheidsinterval 1.1-1.5, p=0.008). De patiënten met GHD hadden daarnaast 
een duidelijk ander metabool profiel dan de controle groep; Ze hadden een verhoogde 
kans op hypertriglyceridemie PR 2.0, (95% betrouwbaarheidsinterval 1.7-2.3) en een 
verlaagd HDL-cholesterol PR 1.8 (95% betrouwbaarheidsinterval 1.5-2.2), maar minder 
hyperglykemie PR 0.5 (95% betrouwbaarheidsinterval 0.4-0.7). Ondanks modernisering 
van hormonale suppletie en suppletie technieken veranderde het metabole profiel van 
patiënten niet heel veel ten opzichte van hun metabool profiel bij aanvang van rGH 
therapie terwijl het gewicht en dus de BMI wel fors toenam. De studie was echter niet 
ontworpen om verschillen in cardiovasculaire events te detecteren, maar het valt nog 
maar te bezien of  het starten van rGH ten behoeve van een gunstiger lipidenprofiel 
en reductie van cardiovasculaire events effectiever is dan de reguliere behandeling met 
statines. Aan de andere kant werd er minder hyperglycemie gezien in GHD patienten, 
ondanks  een hogere BMI, wat mogelijk wel mede aan rGH therapie te danken is. 
In Hoofdstuk 7, werden de effecten van langdurig rGH gebruik op het bot onderzocht. 
Voor deze studie werden 230 GHD patiënten geïncludeerd. De botdichtheid 
verminderde in vrouwelijke patiënten in de loop der jaren zowel in de wervelkolom 
als in de heup, na een aanvankelijke stijging. In mannen werd echter een duidelijke 
toename van de botdichtheid van met name de wervelkolom gezien die gedurende 15 
jaar behandeling persisteerde alsook een stabilisatie van de BMD van de heupen, dit in 
het licht van een verwachtte natuurlijke afname in de loop der jaren. Het toevoegen van 
een bisfosfonaat liet geen extra verandering zien. De klinische fractuur incidentie was 
20,1/1000 patiënt jaren en was niet duidelijk verhoogd als vergeleken werd met controle 
data uit de literatuur. De resultaten bij de vrouwen kunnen vertekend zijn doordat de 
vrouwen in de perimenopauze fase waren en oestrogeen deficiëntie in deze periode een 
bepalende rol speelt in het beloop van de veranderingen in BMD. Of  therapie met rGH 








de studies die gedaan zijn niet ontworpen zijn om hier een verschil in te ontdekken en 
ook geen controle groep geïncludeerd kon worden. Omdat in onze studie bijna iedereen 
calcium en vitamine D3 kreeg kan dit al een goede verklaring zijn voor het relatief  lage 
fractuur risico in vergelijk met veel hogere getallen van oudere, niet behandelde, GHD 
cohorten. 
In Hoofdstuk 8 tot slot worden de resultaten beschreven van een observationele studie 
naar het staken van GH vanwege uiteenlopende redenen bij patiënten na behandeling. 
Daarnaast is er ook een systematisch literatuuronderzoek gedaan naar dit onderwerp. We 
constateerden dat het stoppen van rGH therapie geassocieerd was met een stijging van 
het vetpercentage. Deze stijging bleek echter niet samen te gaan met een verslechtering 
van het cholesterolspectrum of  verandering in nuchtere glucose concentraties. Patiënten 
die stoppen met groeihormoon vallen af, resulterend in een lagere BMI. Een subanalyse 
in patiënten ouder dan 60 jaar laat zelfs helemaal geen veranderingen zien behalve een 
iets lagere BMI. Mogelijk zou dit kunnen betekenen dat het stoppen van de behandeling 
met rGH niet per definitie nadelige effecten heeft op het cardiometabole profiel vooral 
op gevorderde leeftijd, echter dit dient nog zeker beter uitgezocht te worden.
CONCLUSIE
Behandeling met rGH heeft in een geselecteerde groep patiënten gunstige effecten. 
De studies hier beschreven betreffen relatief  gezonde GHD patiënten, dus zonder 
maligniteit of  diabetes. Echter een van de voornaamste indicaties waarvoor behandeling 
met rGH wordt geadviseerd bij volwassen patiënten met GHD, namelijk verbetering 
van het cardiovasculaire risicoprofiel, wordt door onze studies niet ondersteund. Het 
lipidenprofiel verbetert wel, maar het overgewicht en metabool syndroom verslechteren 
onder langdurige therapie. De gunstige effecten op het bot zijn enkel terug te vinden bij 
mannen en betreffen voornamelijk een toename van de botdichtheid van de wervelkolom. 
Informatie over reductie van het fractuurrisico ontbreekt tot op heden. Idealiter zullen 
prospectieve onderzoeken met een langdurige follow-up duur moeten plaatsvinden 
met een representatieve controle groep van onbehandelde patiënten met GHD. Een 
dergelijke studieopzet is echter niet haalbaar daar deze groep niet beschikbaar is in 
Europa. In deze studies werden geen bijzondere bijwerkingen gezien van langdurige 
rGH suppletie, dus het lijkt er op dat langdurige behandeling met rGH veilig gestart kan 
worden, zeker bij jongvolwassenen. Of  rGH behandeling ook extra waarde heeft voor 
volwassenen van middelbare of  gevorderde leeftijd valt nog te bezien. Nieuwe studies 
waarbij ook evaluatie van de kwaliteit van leven meegenomen worden moeten dit in de 
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Systematische evaluatie van de gerapporteerde prevalentie van hypopituïtarisme na 
bestraling van het hoofd-halsgebied in verband met cerebrale of  nasofaryngeale 
tumoren en na totale lichaamsbestraling.
OPZET
Systematische review en meta-analyse.
METHODEN
In PubMed, Embase, Web of  Science en de Cochrane Library werd gezocht naar 
artikelen over de prevalentie van hypopituïtarisme bij volwassenen na hersenbestraling. 
In de referenties van belangrijke artikelen werd gezocht naar andere relevante artikelen. 
De meta-analyse werd verricht met behulp van een exacte ‘likelihood’-methode met 
gebruik van een logistische regressie met ‘random effects’-model op studieniveau.
RESULTATEN
Er werden 18 studies met in totaal 873 patiënten geïncludeerd. Dit waren 608 patiënten 
met een nasofarynxcarcinoom en 265 met 1 of  meer hersentumoren. De totale dosis 
aan bestraling varieerde van 14-83 Gy en 40-97 Gy voor respectievelijk nasofarynx- en 
hersentumoren. De prevalentie van enige vorm van hypopituïtarisme was 0,66 (95%-BI: 
0,48-0,76). De prevalentie van groeihormoondeficiëntie was 0,45 (95%-BI: 0,27-0,55), 
0,30 voor LH-FSH-deficiëntie (95%-BI: 0,16-0,29), 0,25 voor TSH-deficiëntie (95%-
BI: 0,13-0,35) en 0,22 voor ACTH-deficiëntie (95%-BI: 0,13-0,29). De prevalentie van 
hyperprolactinemie was 0,34 (95%-BI: 0,11-0,38). Er waren geen verschillen in het 
effect van bestraling tussen de beide tumorgroepen. Er was geen verschil in prevalentie 
tussen studies met meer of  minder risico op bias.
CONCLUSIE
Hypopituïtarisme komt veel voor na hoofd-halsbestraling in verband met 
nasofarynxcarcinomen en hersentumoren. Daarom dienen alle patiënten die bestraald 
zijn op dit gebied langdurig vervolgd te worden met regelmatige controles van de 
hypofysefuncties.
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Introductie
Patiënten met hersentumoren of  tumoren in het neus- of  keelgebied worden vaak 
behandeld met uitwendige radiotherapie. Dit kan na de behandeling op langere termijn 
resulteren in hypofyse-uitval, doordat de hypofyse vaak volledig in het bestralingsgebied 
ligt. Op de kinderleeftijd is hypofyse-insufficiëntie een bekende complicatie: 43% van de 
bestraalde kinderen ontwikkelt hypofyse-uitval.1 Patiënten die kanker op de kinderleeftijd 
hebben overleefd, worden in de follow-up uitgebreid gescreend op hypofyse-uitval. Op 
volwassen leeftijd verloopt deze uitval echter vaak sluimerend met aspecifieke klachten, 
waardoor de disfunctie van de hypofyse gemakkelijk onopgemerkt kan blijven als er niet 
op gescreend wordt. Voor volwassenen is routinematige periodieke beoordeling van de 
hypofysefunctie niet opgenomen in richtlijnen voor de follow-up. In de laatste jaren 
zijn de meeste overlevingspercentages van de patiënten met maligniteiten verbeterd 
door introductie van nieuwe chirurgische, radiotherapeutische of  chemotherapeutische 
behandelingen, waardoor meer patiënten risico lopen op hypofyse-uitval.
Bestraling van de hypothalamus- en hypofyseregio veroorzaakt een in de tijd 
karakteristiek patroon van hormonale uitval; hierbij valt de groeihormoonsecretie 
als eerste uit, gevolgd door uitval van de gonadotrofines, de hypofyse-bijnieras en de 
hypofyse-schildklieras.2-4 De mate van uitval is afhankelijk van de stralingsdosis. De 
incidentie van meerdere deficiënties na bestraling neemt toe in de tijd en naarmate de 
toegepaste stralingsdosis hoger is.5
De diagnostiek van hypofyse-uitval kan lastig zijn. In ieder geval moeten de basale 
ochtendwaarden van alle hypofysehormonen gemeten worden, aangevuld met 
functietesten van de hypothalamus-hypofyse-bijnieras en de groeihormoonas. De 
keuze van de functietest hangt ook af  van de fysieke conditie van de patiënt. Zo zal 
een insulinetolerantietest (ITT) niet kunnen worden uitgevoerd bij patiënten met 
epilepsie of  cardiale problemen. Omdat de evaluatie van endocriene functies varieert 
in verschillende studies, verschilt de prevalentie van hypofyse-uitval sterk in de diverse 
studies.1,6
Het doel van deze review was een systematische evaluatie van de gerapporteerde 
prevalentie van hypofyse-uitval bij volwassenen na bestraling van de hersenen in 
verband met cerebrale of  nasofaryngeale tumoren of  na totale lichaamsbestraling bij 
een hematologische maligniteit.
MATERIAAL EN METHODEN
Het systematisch literatuuronderzoek betrof  artikelen verschenen tot 14 augustus 2010. 
Er werd gezocht in de volgende databases: PubMed, Cochrane Library, Web of  Science, 
Embase, ‘Cumulative index to nursing and allied health literature’ (CINAHL), Academic 
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Search Premier en Science Direct. De zoekstrategie was toegespitst op radiotherapie, 
hypofysefunctie, hersentumoren en nasofaryngeale tumoren. De complete strategie is 
terug te lezen in tabel 1.
Daarnaast werden de referenties van geïncludeerde artikelen gecontroleerd op additionele 
artikelen. Inclusiecriteria waren: (a) bestraling van de hersenen voor een andere 
aandoening dan een hypofysetumor of  totale lichaamsbestraling; (b) leeftijd van 18 jaar 
of  ouder op het tijdstip van bestraling en (c) rapportage over de endocriene evaluatie. In 
geval van gemengde cohorten, zoals een cohort van kinderen en volwassenen, werden 
alleen data geëxtraheerd van patiënten ≥ 18 jaar. Indien verschillende artikelen over 
dezelfde patiëntengroep berichtten, bijvoorbeeld aparte artikelen over de functie van de 
schildklier- en de groeihormoonas, werden de resultaten gecombineerd in de analyse. Bij 
rapportage over hypofyse-uitval door de jaren heen werd het stuk met de langste follow-
up meegenomen in de analyse. Alleen Engelstalige artikelen werden geïncludeerd.
Het literatuuronderzoek resulteerde in 849 artikelen (301 in PubMed, 4 in Cochrane 
Library, 131 in Web of  Science, 353 in Embase, 16 in CINAHL-database, 27 in 
Academic Search Premier, en 17 in Science Direct). Hiervan waren 616 artikelen uniek. 
Op basis van titel en abstract werden 378 publicaties werden geëxcludeerd: 157 artikelen 
vielen af  omdat kinderen waren onderzocht en 7 artikelen waren niet beschikbaar. Van 
de overgebleven 74 artikelen voldeden 51 niet aan 1 of  meer van de inclusiecriteria. 
Uiteindelijk waren 23 studies geschikt voor evaluatie. Enkele publicaties hadden overlap 
in het patiëntencohort; de resultaten van deze publicaties werden gecombineerd tot 1 
studie.7-15 Zo bleven er 18 onderzoeken over voor meta-analyse (figuur 1).
Datareview en -analyse
De selectie van de studies op basis van titel en abstract werd gedaan door 2 onafhankelijke 
reviewers (N.M.A. en N.E.K.). De definitie van hypopituïtarisme moest duidelijk in het 
artikel omschreven zijn, evenals de testen met bijbehorende afkapwaarden, de gebruikte 
assays en lokale referentiewaarden.
Inschatting van het risico op bias
Voor de inschatting van het risico op bias werden per studie verschillende onderdelen 
beoordeeld. Ten eerste werd gekeken naar bestraling. Als vermeld werd dat de hersenen 
bestraald waren, kreeg de studie 1 punt. Als er een bestralingsdosis op de hypofyse werd 
genoemd, kreeg de studie 2 punten. Ten tweede werd het inclusieproces van patiënten 
beoordeeld. Indien er opeenvolgende, niet geselecteerde patiënten geïncludeerd waren, 
werd 1 punt gegeven. Als derde werd geëvalueerd hoe de diagnose ‘hypofyse-uitval’ 
was gesteld en of  er stimulatietesten waren gebruikt. Er werd 1 punt gegeven als de 
hormonale evaluatie gedaan was door middel van dynamische functietesten en 1 punt 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































als alle patiënten in de studie getest waren. Elke studie kon zo maximaal 5 punten 
scoren. Studies die 0 of  1 punt scoorden, werden beschouwd als studies met een hoog 
risico op bias, studies met 2 of  3 punten als middelmatig risico en studies met 4 of  5 
punten als laag risico op bias.
Statistiek
De belangrijkste uitkomstmaat bij deze meta-analyse was de gepoolde proportie van 
patiënten met hypofyse-uitval. Voor alle studies werd de proportie berekend als het 
aantal patiënten met hypofyse-uitval gedeeld door het aantal geteste patiënten. De 
meta-analyse werd uitgevoerd met een exacte ‘likelihood’benadering en er werd gebruik 
gemaakt van een logistische regressie met een ‘random effect’-model op studieniveau 
(dat wil zeggen dat de variantie zowel binnen als tussen de studies werd meegenomen 
in de analyse).16 Ook een meta-regressieanalyses werd uitgevoerd met behulp van een 
exacte likelihoodbenadering. Deze metaregressie werd verricht om het antwoord op de 
vraag te geven of  de tumorlokalisatie (nasofaryngeaal versus hersenen) samenhing met 
de prevalentie van hypofyse-uitval. Alle analyses werden gedaan met STATA 10.0 (Stata 
Corp, Texas, USA).
616	  relevante	  studies	  
74	  ar1kelen	  voor	  totale	  beoordeling	  
25	  studies	  geïncludeerd	  
24	  ar1kelen	  gebruikt	  voor	  de	  analyse	  
378	  ar1kelen	  exclusie	  op	  1tel	  en	  abstract	  
157	  ar1kelen	  betroffen	  kinderen	  
7	  ar1kelen	  niet	  verkrijgbaar	  
49	  ar1kelen	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  niet	  aan	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1	  studie	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  door	  overlap	  met	  
ander	  ar1kel	  
FIGUUR 1.
stroomdiagram van de studieselectie
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RESULTATEN
De geanalyseerde studies werden gepubliceerd in de periode 1975-2009. Er werden in 
totaal 813 patiënten geïncludeerd. Van deze patiënten was 75% (608/813) behandeld 
voor een nasofarynxcarcinoom (tabel 2a en 2b). De overige 25% was behandeld 
voor hersentumoren (tabel 3a en 3b). De totale prevalentie van enige vorm van 
hypopituïtarisme verschilde sterk tussen de studies en varieerde van 25-100%.9,12 Geen 
van de artikelen beschreef  de evaluatie van patiënten die totale lichaamsbestraling 
hadden ondergaan in het kader van behandeling voor een hematologische maligniteit.
De meeste studies waren dwarsdoorsnede-onderzoeken waarbij de tijd tussen de 
bestraling en het testen varieerde van 4 maanden tot 30 jaar; ook binnen de diverse 
studies bestond een grote spreiding. In 2 studies werd de tijd tussen de bestraling en de 
endocriene evaluatie niet vermeld.17,18
In 3 studies werden geen selectiecriteria genoemd.8,17,18 In 4 studies waren symptomatische 
patiënten geselecteerd door te rekruteren op een polikliniek voor complicaties na 
radiotherapie of  door inclusie van patiënten bij wie op voorhand een vermoeden 
bestond op hypopituïtarisme.9,19-21
Inschatting van het risico op bias
Er werd 1 studie geclassificeerd als studie met een hoog risico op bias,17 8 studies met 
een gemiddeld risico,8,9,18-20,22-24 en 9 studies met een laag risico.10-12,14,21,25-27
Groeihormoon-insulineachtige-groeifactor 1-as
De groeihormoon-insulineachtige-groeifactor 1-as (GH-IGF-1-as) werd in 14 studies 
geëvalueerd; daarin waren in totaal 724 patiënten geïncludeerd. Bij 61% van de patiënten 
(440/724) werd deze hormoonas geëvalueerd met de bepaling van basale serumspiegels 
van IGF-1 of  GH en een stimulatietest (een glucagonstimulatietest, een ITT, een 
argininetest of  een gecombineerde groeihormoon-‘releasing’-hormoon(GHRH)-argin
inetest).8,9,11,12,15,18,20,21,24-26,28,29 De prevalentie van groeihormoondeficiëntie varieerde van 
24-100%. De prevalentie van 100% werd gevonden in een onderzoek met 6 patiënten 
van wie er slechts 2 getest waren met een dynamische test, de ITT.24
Hypothalamus-hypofyse-bijnieras
De hypothalamus-hypofyse-bijnieras werd geëvalueerd in 14 studies; er waren in totaal 
751 patiënten geïncludeerd. Bij 61% van de patiënten (460/751) werd de as beoordeeld 
door bepaling van een basale cortisolconcentratie in het serum of  een stimulatietest 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































adrenocorticotroop-hormoon(ACTH)-test). Bijnierinsufficiëntie werd gediagnosticeerd 
bij 0-63% van de patiënten.
Hypothalamus-hypofyse-schildklieras
De schildklierfunctie werd in 16 studies geëvalueerd bij in totaal 488 patiënten. Deze 
functie werd bepaald door meting van de basale concentratie thyreoïdstimulerend 
hormoon (TSH) en vrij thyroxine (T4) in het serum, zo nodig aangevuld met een 
thyreotropine-‘releasing’-hormoon(TRH)-stimulatietest. TSH-deficiëntie werd 
vastgesteld bij 26% van de patiënten (126/488). De prevalentie was 0-67%.
Hypothalamus-hypofyse-gonade-as
De gonadotrope as werd getest door meting van de basale concentratie LH en FSH en 
testosteron of  oestrogeen in 14 studies met in totaal 469 patiënten. Hypogonadotroop 
hypogonadisme was aanwezig bij 30% van de patiënten (143/469), variërend van 30-
82% in de verschillende studies.
Hyperprolactinemie
Prolactinespiegels werden gemeten in 15 studies met 502 patiënten, met 
hyperprolactinemie bij 144 van de 502 patiënten. In 1 studie waren geen basale 
prolactinespiegels bepaald.29 Deze studie werd niet meegenomen in de analyse.
Meta-analyse
De gezamenlijke prevalentie van enige vorm van hypopituïtarisme was 0,66 (95%-
BI: 0,55-0,76). Zoals verwacht, was groeihormoondeficiëntie de meest voorkomende 
deficiëntie met een prevalentie van 0,45 (95%-BI: 0,33-0,57), gevolgd door luteïniserend 
hormoon(LH)-follikelstimulerend-hormoon(FSH)-deficiëntie (0,3; 95%-BI: 0,23-0,37) 
en TSH-deficiëntie (0,22; 95%-BI: 0,16-0,37). adrenocorticotroop-hormoon(ACTH)-
deficiëntie had de laagste prevalentie, namelijk 0,22 (95%-BI: 0,15-0,3). De prevalentie 
van hyperprolactinemie was 0,34 (95%-BI: 0,15-0,6) (tabel 4). Volgens de meta-
regressieanalyse had de tumorlocatie en het soort tumor geen samenhang met de 
prevalentie. Wij vonden geen statistisch significante associatie met de tumorlocatie 
en enige vorm van hypopituïtarisme (p = 0,14), groeihormoondeficiëntie (p = 0,36), 
ACTH-deficiëntie (p = 0,75), TSH-deficiëntie (p=0,11), LH-FSH-deficiëntie (p = 0,21) 
of  hyperprolactinemie (p = 0,44) (tabel 5).
Gezien de wisselende kwaliteit van de studies werd een sensitiviteitsanalyse gedaan op 
studies waarin het risico op bias laag/intermediate was én waarin opeenvolgende, niet-
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geselecteerde patiënten waren geïncludeerd.11,23,25 De prevalentie voor enige vorm van 
hypopituïtarisme was in deze 4 studies 0,62 (95%-BI: 0,45-0,77), wat overeenkwam met 
de resultaten van de totale analyse.
Hypofyse-uitval gerelateerd aan het tijdsinterval tussen radiotherapie en 
evaluatie
Bij 2 studies werd gerapporteerd over de tijdsbestek tussen bestraling en het ontstaan 
van hypofyse-uitval; in beide studies ging het om patiënten die behandeld waren voor 
nasofarynxcarcinomen.16,27 De prevalentie van uitval was 6% na 1 jaar, 35% na 2 jaar, 56% 
na 3 jaar en 62% na 4 en na 5 jaar.11 Over de klassieke volgorde van uitval rapporteerde 1 
studie. Groeihormoondeficiëntie trad gemiddeld op na 2,6 jaar, gevolgd door uitval van 
de gonadotrope as en hyperprolactinemie na ongeveer 3,8 jaar, ACTH-insufficiëntie na 
6,0 jaar en als laatste TSH-insufficiëntie gemiddeld na 11,0 jaar.14
BESCHOUWING
Volgens onze meta-analyse was de prevalentie van enige vorm van hypopituïtarisme na 
craniële radiotherapie 0,66 (95% -BI: 0,55-0,76); er waren geen significantie verschillen 
tussen patiënten met verschillende tumoren. Beoordeling van de hypofysefunctie zou 
daarom geïncludeerd moeten worden in de protocollen voor evaluatie van patiënten die 
langere tijd overleven na bestraling van het hoofd-halsgebied.
Hypopituïtarisme kan al vóórkomen binnen het eerste jaar na behandeling; sommige 
hypofyse-assen zullen echter pas veel later uitvallen, soms zelfs pas 11 jaar na 
behandeling.11,14 Gezien de vergaande psychische en lichamelijke gevolgen voor patiënten 
bepleiten we dat alle bestraalde patiënten met regelmatige intervallen, bijvoorbeeld 
jaarlijks, gecontroleerd worden op hypofysaire uitval.
De prevalentie van hypofyse-uitval varieerde tussen de verschillende studies, van bijna 
geen uitval tot volledige uitval. Deze variaties waren met name geassocieerd met het 
aantal geïncludeerde patiënten en de wijze van evaluatie van hypofyse-uitval.24 Ook 
speelde het wel of  niet gebruiken van dynamische testen een rol. De verschillende 
radiotherapeutische technieken zullen een bijdrage aan de variatie geleverd hebben, 
aangezien hogere cumulatieve doseringen geassocieerd zijn met een hogere incidentie 
van hypofyse-uitval.2,4
De meta-regressie-analyse liet geen verschillen in effect van bestraling zien tussen 
hersen- en nasofarynxtumoren. De totale dosis van straling verschilde niet veel tussen 
beide groepen: 40-83 Gy voor patiënten met nasofarynxcarcinoom en 40-97 Gy voor 
patiënten met niet-hypofysaire hersentumoren. In 9 studies was het risico op bias 
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volgens onze inschatting laag. De verrichte sensitiviteitsanalyse op deze studies liet geen 
verschil zien met de overige studies.11,23,25,29
De meerderheid van de studies betrof  dwarsdoorsnede-onderzoek met grote verschillen 
in de tijdsduur tussen bestraling en evaluatie. Ook de patiëntenselectie varieerde 
sterk. Selectiecriteria werden soms niet vermeld.8,17,21 In andere studies hanteerden de 
onderzoekers een selectieprocedure die erg gevoelig was voor preselectie, bijvoorbeeld 
door rekrutering van patiënten vanuit een polikliniek voor complicaties van radiotherapie 
of  door alleen patiënten met symptomen passend bij hypofyse-uitval te testen.9,19-21 Er 
waren slechts 2 prospectieve studies met in totaal 186 patiënten; de redenen voor verlies 
in de follow-up werden niet genoemd.11,14
Verschillen in de evaluatie van de endocriene functie kunnen ook de vastgestelde 
prevalentie beïnvloeden. De meerderheid van de patiënten was niet geëvalueerd met 
stimulatietesten die hier optimaal voor zijn. Daardoor is het goed mogelijk dat deze 
uitkomsten eerder aan de lage kant zijn en dat de echte prevalentie veel hoger ligt. 
Daarnaast werden in de studies die wel stimulatietesten gebruikten verschillende 
testen en afkapwaarden gebruikt. In slechts 10 van de 18 onderzoeken werden alle 
hypofyseassen getest, maar binnen die studies werden niet bij alle patiënten alle assen 
getest. Bovendien kunnen de hypofyse-schildklieras en de hypofyse-gonade-as ook 
sterk beïnvloed worden door lokale bestraling van de schildklier en de gonaden zelf  en 
door blootstelling aan chemotherapie.7,30,31
Een andere uiting van hypothalame en hypofysaire schade is hyperprolactinemie. 
Door verstoorde hypothalame dopaminesecretie is de mate van hyperprolactinemie 
vaak erg wisselend en subklinisch. Ook kan de prolactineconcentratie na verloop van 
tijd normaliseren doordat de lactotrofe cellen atrofiëren bij gebrek aan hypothalame 
stimulering. In geen van de studies vermeldden de onderzoekers het tijdsinterval tussen 
de bestraling en het ontstaan van hyperprolactinemie; er werd ook geen melding gedaan 
over het verdwijnen van de hyperprolactinemie.
Aanbevolen follow-up Deze resultaten en de verbeterde overleving bij de diverse 
ziektebeelden in acht nemend, vinden wij dat patiënten gedurende minstens 10 jaar 
jaarlijks gecontroleerd moeten worden op mogelijke hypofyse-uitval. Na deze 10 
jaar zou ervoor gekozen kunnen worden om de intervallen te vergroten. Uiteraard 
dient rekening gehouden te worden met de aard van de tumor (maligne of  benigne), 
de conditie van patiënt en medicatie bij andere morbiditeit, zoals het gebruik van 
dexamethason. De follow-up dient te bestaan uit een geprotocolleerde evaluatie van 
basale laboratoriumwaarden van de hypofyse- en eindorgaanhormonen vóór bestraling. 
Dit moet gevolgd worden door jaarlijks bloedonderzoek al dan niet aangevuld met 
stimulatietesten, tot in ieder geval 12 jaar na de initiële behandeling. Hierna zouden de 
intervallen verlengd kunnen worden naar 2 jaar (figuur 2). De te kiezen stimulatietesten 
zijn afhankelijk van de conditie van de patiënt en de klinische relevantie. Zo zal een 

































































Hypofyse-uitval na hoofd-halsbestraling: een systematische review en meta-analyse.
211
groeihormoondeficiëntie bij een patiënt die in het verleden behandeld is voor een 
maligniteit, meestal niet tot behandeling met recombinant groeihormoon leiden. Deze 
deficiëntie is wel een symptoom van hypothalame en hypofysaire schade; daarom kan er 
bij een vitale patiënt wel gekozen worden daarop te testen als indicator van schade om 
al dan niet te starten met recombinant groeihormoontherapie.
CONCLUSIE
Onze meta-analyse onderstreept dat alle patiënten die bestraald zijn op de hersenen, 
gestructureerd gevolgd moeten worden. Omdat deze patiëntengroep zeer divers is, 
zal de follow-up op het individu gericht moeten zijn, waarbij de te testen assen en 
het soort stimulatietesten moeten worden afgewogen tegen de levensverwachting en 
de comorbiditeit. De follow-up kan bij de radiotherapeut of  de behandelaar van de 
oorspronkelijke ziekte plaatsvinden, dus bij diverse specialisten. Patiënten zullen indien 
noodzakelijk overgedragen worden aan de endocrinoloog, die zich bewust moet zijn 
van de lange-termijncomplicaties van bestraling. Adviezen hierover zouden moeten 
worden opgenomen in de richtlijnen voor de follow-up van deze patiëntencategorieën.
LEERPUNTEN
i. Hypofyse-uitval is een late complicatie na hoofd-halsbestraling.
ii. Bij kinderen wordt hierop regelmatig gecontroleerd, bij volwassenen bestaan 
hiervoor geen richtlijnen.
iii. De beschikbare literatuur geeft zeer uiteenlopende getallen voor de prevalentie van 
hypofyse-uitval.
iv. Hypofyse-uitval na bestraling van het hoofd-halsgebied begint over het algemeen 
met uitval van de groeihormoonsecretie na gemiddeld 2,5 jaar, gevolgd door uitval 
van de gonadotrofines na bijna 4 jaar, ACTH-uitval na 6,0 jaar en TSH-uitval na 
gemiddeld 11,0 jaar.
v. De prevalentie van hypofyse-uitval is 60% na bestraling van hersentumoren en 
nasofarynxtumoren.
vi. Gezien de hoge prevalentie van hypofyse-uitval zijn richtlijnen nodig om de evaluatie 
van de hypofysefuncties van volwassen patiënten na bestraling van de hersenen 
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